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ABSTRACT 
Intracoronary injection is a frequently used clinical protocol for stem / progenitor cell 
therapy to the heart. Initial donor cell retention in the heart is the key to the success of this 
approach; however, this process has been poorly investigated. I established an original 
model to quantitatively assess initial donor cell retention after intracoronary cell injection in 
rats using an ex-vivo heart perfusion system and investigated factors that could affect 
retention.  
The initial retention efficiency of bone marrow mononuclear cells (BMMNC) was 
20% after injection into normal hearts. The majority (>90%) of BMMNC loss into the 
coronary effluent occurred within the first minute of injection. Increased BMMNC dose 
increased absolute retention with a linear dose-effect relationship, while retention efficiency 
was unaltered. Retention efficiency increased to 30% in hearts with ischaemia-reperfusion, 
while flow cytometric studies showed that surface marker expression was unchanged 
between the pre-injection donor cell population and the population in the coronary effluent 
in both normal and ischemia-reperfused hearts. This suggests that active interactions 
between donor cells and coronary endothelium were not critical for donor cell retention 
using these experimental conditions. Instead, cell size assessment revealed that larger 
subpopulations of BMMNC were preferentially retained compared to smaller BMMNC in 
both normal and ischemia-reperfused hearts. Furthermore, a larger cell type, bone-marrow 
derived mesenchymal stem cells (MSC; median cell size=10.1 µm), had a markedly 
increased retention efficiency (80%) compared to BMMNC (median cell size=7.0 µm). A 
greater proportion of MSC with a larger diameter were retained compared to smaller 
diameter MSC; this enhanced retention plateaued with MSC ≥ 9 µm. 
Immunohistochemical analysis using fluorescently labeled donor cells demonstrated 
that all BMMNC retained in normal and ischaemia-reperfusion hearts were located within 
the coronary vasculature, without extravasation, up to 60 minutes after injection. Heart 
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perfusion parameters and histological features exhibited evidence of coronary embolism 
after intracoronary injection of MSC, but not BMMNC (up to 40x106). 
 These data collectively suggest that passive mechanical entrapment, and not active 
endothelial cell-donor cell interactions, is responsible for initial donor cell retention after 
intracoronary injection. This has important implications for future clinical protocols of 
intracoronary injection of stem / progenitor cells to the heart. 
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Chapter 1 - INTRODUCTION 
 
1.1.   Importance of heart failure 
 
The lifetime risk for developing heart failure is approximately 1 in 5 for a person aged 40 
years1 and most frequently occurs as a consequence of myocardial infarction (MI). Heart 
failure is associated with a high morbidity and accounts for 5% of all medical and geriatric 
hospital additions in patients over the age of 65 (a greater proportion than those hospitalized 
for acute MI [AMI])2. This places an enormous burden on health care services and society, 
accounting for 2% of all health-care spending in European and North American studies3. 
Despite enormous efforts by scientists and clinicians utilizing the available treatment 
options, heart failure remains the leading cause of death in the Western World4 and 30-40% 
of patients die within 1 year of diagnosis3. 
A wide range of emerging therapies have been introduced with the aim of improving 
survival and quality of life in heart failure patients, including pharmaceutical agents5, 
percutaneous coronary intervention6,  coronary artery bypass grafting7, biventricular pacing8, 
implantable cardioverter defibrillators9 and the use of left ventricular assist devices10. None 
of these approaches, however, overcomes the irreversible loss of cardiomyocytes which 
fundamentally underpins the aetiology of heart failure following MI11. Cardiac 
transplantation is a more aggressive, radical treatment option which does address 
cardiomyocyte loss, although due to a shortage of donors, immunosuppression and financial 
cost, this is not feasible for widespread use12. Research attention more recently has been 
directed towards biological therapies as a potential avenue to explore. Transplantation of 
stem/progenitor cells is one of the most promising approaches. 
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1.2.   Stem/progenitor cell transplantation for acute myocardial 
infarction and heart failure  
 
1.2.1. Stem and progenitor cells 
Stem cells are defined by their  capacity for infinite self-renewal and also  for the ability to 
differentiate into multiple cell types (pluripotency)13-15.  Progenitor cells and precursor cells 
are more committed cells which have the ability to differentiate to a limited lineage. These 
cells are not “stem cells’ according to the strict definition, but, in the field of stem cell 
therapy, these cells are frequently referred to as “stem cells”. 
“Stem cells” can be divided into two broad categories: pluripotent stem cells and 
adult stem cells. Currently available pluripotent stem cells for therapeutic purposes include 
embryonic stem cells (ESC) and induced pluripotent stem cells. Adult stem cells have been 
found in a number of different tissues in adults and are usually tissue-specific progenitor or 
precursor cells, the major types of which include mesenchymal stem cells (MSC), 
endothelial progenitor cells (EPC), haematopoietic stem cells, skeletal myoblasts and cardiac 
progenitor cells (CPC). The potential of these cell types to be used for cell transplantation is 
discussed in more detail in section 1.3. 
 
1.2.2. Stem cell transplantation to the heart 
In the last two decades, experimental research has demonstrated that injection of 
stem/progenitor cells is a promising new approach to treat AMI and heart failure16 and has 
led to a number of clinical studies using this strategy.  
Because of their utility as autografts, adult stem cells do not require 
immunosuppression after transplantation and are free from the risk of teratoma formation 
 20 
and from the ethical issues associated with ESC. For these reasons, adult stem cells have 
been  used preferentially in clinical trials, even though these cells  have much more limited 
differentiation abilities than that of ESC.  This thesis will focus on adult stem cells, which 
are currently more clinically relevant. 
While early clinical trials of transplantation of adult stem/progenitor cells reported 
the feasibility, safety and possible therapeutic effectiveness of this innovative strategy17, 
improvements in outcome measures18-23 observed in more recent, large-scale, randomized, 
controlled studies were not as sizeable as expected. However, pooling of data in meta-
analytical studies has shown that bone marrow mononuclear cell (BMMNC) injection is 
associated with statistical improvements in cardiac function and a tendency towards 
decreased event rates and improved mortality after AMI (without statistical significance)24-
27. Overall, this approach is promising, but improvements in our understanding and a 
refinement of protocols by further laboratory investigation are needed for its future clinical 
success. 
 
1.2.3. Mechanisms of stem/progenitor cell transplantation for heart disease 
The detailed mechanisms underpinning the beneficial effects observed after adult 
stem/progenitor cell transplantation still need to be determined. Cell transplantation does not 
necessarily equal regeneration therapy, and it is now rather doubtful whether 
transdifferentiation and/or cell fusion of donor cells lead to new cardiomyocytes or to 
vascular cells which then contribute to improvements in cardiac function.  In fact, many 
reports have shown that cardiomyogenic differentiation of adult stem cells is extremely 
limited following administration to the heart in vivo28-30. One proposed alternative 
mechanism is a paracrine effect, whereby growth factors, cytokines, chemokines, and other 
signalling molecules released from the transplanted cells lead to neovascular formation, 
fibrosis reduction, activation of endogenous CPC and an increase in viability and function of 
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host cardiomyocytes31. Such changes could have the potential to recover, restore and/or 
regenerate the damaged myocardium, leading to improvement of cardiac function. These 
mechanisms are likely to be cell-type dependent32.  
 
1.3.   Types of adult stem cells for transplantation to the heart  
 
Many types of adult stem/progenitor cells have been tested as donor for cell transplantation 
to the heart. Whether one cell type is superior for heart delivery has not been fully 
elucidated. It is noteworthy that both experimental and clinical studies have had differing 
protocols, with variations in donor cell numbers and cell types, injection routes, the time 
after MI that cells were administered, and outcome measures. Such heterogeneity and 
complexities make a direct comparison between cell types difficult. Previously and currently 
promising sources of adult stem/progenitor injection to the heart include skeletal myoblasts, 
BMMNC, EPC, MSC, and CPC33,34. 
 
1.3.1. Skeletal myoblasts 
Skeletal myoblasts (satellite cells) are undifferentiated precursors for skeletal muscle and 
were the first cell type administered to heart failure patients35. For clinical use, these cells 
were obtained from skeletal muscle biopsies and propagated ex vivo before being 
administered to the heart36. They were initially thought to be an attractive candidate cell type 
for cell transplantation, based on their muscular (thus contractile) phenotype and their 
relative resistance to ischaemia37. After transplantation into the heart, they have been shown 
to form myotubes within the heart but are unable to transdifferentiate to cardiomyocytes38. 
Despite this observation, they still improve cardiac function in animal models, presumably 
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due to their paracrine effects. Subsequent initial clinical studies showed that skeletal 
myoblast injection was feasible and possibly improved cardiac function but led to an 
increase of incidence of critical ventricular arrhythmias39,40. Parallel research has 
demonstrated the inability of skeletal myoblasts to integrate electrically with host 
cardiomyocytes, which would increase arrhythmia risk41.  
The largest clinical study of skeletal myoblast transplantation reported to date is the 
Myoblast Autologous Grafting in Ischaemic Cardiomyopathy (MAGIC) Trial42. In this 
double-blinded study, patients with previous MI, poor left ventricular (LV) function and a 
requirement for coronary artery bypass grafting (CABG) were randomized to receive 
epicardial intramyocardial (IM) injection of autologous skeletal myoblasts (at a cell dose of 
400 or 800×106) or placebo. All patients were required to undergo implantation of an 
implantable cardioverter defibrillator. After 6 months follow-up, no statistically significant 
benefit of myoblast transplantation over CABG alone was observed for measures of LV 
regional or global function. There was a higher incidence of arrhythmic events observed in 
the myoblast-treated patients, although there were no deaths attributable to arrhythmias. 
Since then, the focus of research attention regarding cell transplantation to the heart has been 
mostly directed at other cell types. 
 
1.3.2. Bone marrow mononuclear cells (BMMNC) 
Bone marrow-derived cells are currently the most frequent cell source used in clinical trials. 
In the majority of trials, these cells are used as unfractionated BMMNC. Their 
administration has been shown to be safe and feasible, although long-term follow-up data is 
lacking18-23,43-46. Bone marrow is a complex environment containing heterogeneous 
subpopulations of multipotent cells. BMMNC include haematopoietic stem cells (2%), EPC 
and MSC (<0.05%), all of which could be beneficial for cardiac repair or regeneration.  
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The main advantage of BMMNC in clinical use is that BMMNC fraction can be 
isolated relatively quickly from bone marrow aspirate without need for further ex-vivo 
purification, sorting or expansion. Cells can be injected directly after isolation (at the same 
day). Preclinical studies have suggested that BMMNC have superior survival 6 weeks after 
intramyocardial injection, compared with MSC, skeletal myoblasts and fibroblasts47. To 
date, several large-scale, randomized, controlled studies using BMMNC have reported 
significant therapeutic benefits, however, the degree of the improvement of cardiac function 
has not been as sizeable as previously anticipated (please refer to 1.5.2 and 1.5.3)18-23.  
BMMNC are a heterogeneous cell population and have been sub-classified by 
cluster of differentiation (CD) surface marker expression48. Some of these markers appear to 
be functionally important in leukocyte – endothelial cell interactions, and may therefore 
contribute to donor cell – coronary endothelium interactions after intracoronary (IC) 
injection into the heart  (please refer to 1.8.2). 
CD11b and CD18: Integrins are transmembrane proteins which mediate interactions 
between adhesion molecules and adjacent cells and/or the extracellular matrix. They are 
heterodimers consisting of two distinct alpha and beta subunits. CD11b, otherwise known as 
macrophage antigen-1 (MAC-1), complement receptor-3 or integrin alpha M is one chain of 
the M2 integrin, the other being the common 2 subunit, CD18. The M2 integrin is 
expressed on monocytes, granulocytes, macrophages and natural killer cells49. The CD11b 
subunit is involved in the adhesion and spreading of cells, but cell migration also requires 
the presence of CD18. Its central role is the regulation of leukocyte adhesion and chemotaxis 
as well as phagocytosis and cell mediated cytotoxicity49.  The role of M2 is dependent on 
its ability to recognise intercellular adhesion molecule-1 (ICAM-1), fibrinogen and 
complements.50  
CD29: Integrin alpha-4-beta-1 (very late antigen 4, VLA-4) is an integrin dimer composed 
of CD29 (beta) and CD49a (alpha). Vascular cell adhesion molecule-1 (VCAM-1) binds to 
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VLA-4 which is constitutively expressed on leukocyte plasma membranes (predominantly 
lymphocytes, monocytes and eosinophils51), but this adherence does not occur until the 
leukocytes are stimulated by chemotactic agents. Once this occurs, the integrins undergo the 
necessary conformational change to confer a high binding affinity. In mice, depletion of 
VLA-4 in adult haematopoietic stem cells impaired homing to the bone marrow in 
haematopoietic stem cell transplantation studies52. It is also used as an identification marker 
in MSC. 
CD31: CD31, also known as platelet endothelial adhesion molecule-1 (PECAM-1), is found 
on most leukocyte subtypes, platelets and at the intercellular junctions of endothelial cells. 
34% of mouse BMMNC have been shown to express CD31 and flow cytometry study has 
shown that all >99% of CD31+ cells also express CD4553 indicating that they are 
haematopoietic cells. Transendothelial migration of leukocytes is partly regulated by 
PECAM-1. Blocking antibodies to PECAM-1 attenuate leukocyte transmigration and reduce 
injury to myocardium and coronary endothelium following ischaemia-reperfusion injury. It 
is thought that the major ligand for PECAM-1 is PECAM-154.  
CD34: CD34 is a primitive marker for early haematopoietic and so-called endothelial 
progenitor cells. The biological functions of CD34 are largely unknown. CD34+ cells are 
mobilized into the blood following AMI and it has been postulated that these cells contribute 
to endothelial and myocardial repair post MI. However, in patients with cardiovascular 
disease, the number of circulating CD34+ cells are reduced55.  
CD44: CD44 is a ligand of E-selectin (CD62E)56,57 and cooperates with PSGL-1 and E-
selectin ligand 1 (ESL-1) to control rolling velocities of leukocytes on the walls of inflamed 
venules58. Intravital microscopy demonstrated that CD44 knock-out mice had dramatically 
reduced neutrophil recruitment to the cremater muscle following TNF-α administration58. In 
a mouse model of stroke, when CD44 deficiency mice were used, attenuated post-ischaemia 
recruitment of bone marrow MSC to an ischaemic hemisphere occurred, suggesting CD44 
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may be a critical ligand for MSC recruitment59. 47.7% of unselected isolated BMMNC 
expressed CD44 in murine samples60. 
CD45: CD45 (previously known as the leukocyte-common antigen) is a transmembrane 
tyrosine phosphatatase. It is expressed at high levels (>95%) on all nucleated haematopoietic 
cells and their precursors61,62.  Red blood cells and plasma cells do not express CD45. The 
extracellular domain of CD45 is large with a number of alternatively spliced isoforms which 
are both specific to haematopoietic cell type and differentiation63. Despite extensive research 
effort, target ligands for the different ligands of CD45 have not been conclusively found64,65.   
CD90: CD90 is otherwise known as Thy1 and there are two alleleic forms; Th1.1 and Th1.2. 
Mice express both forms but rats only express Th1.166. Its expression in rat bone marrow 
cells has been reported to be 47%67 and in human bone marrow cells has been reported to be 
1-4%68. This is also used as an identification marker of MSC. CD90 expressed on 
endothelial cells mediates adhesion of inflammatory cells via interactions with 
CD11b/CD1869. 
CD162 (P-selectin glycoprotein ligand -1): PSGL-1 is expressed on myeloid cells and a 
subset of lymphocytes. This has been shown to contribute to different rates of recruitment 
from various cell types to atherosclerotic lesions70,71. It binds to P-, E- and L-selectin and 
mediates the interactions of leukocytes with endothelial cells, platelets and other leukocytes. 
PSGL-1 and its interaction with P-selectin mediates the initial steps of rolling and tethering 
in the leukocyte recruitment cascade. PSGL-1 therefore contributes to vascular damage after 
ischaemia-reperfusion injury.   
 
1.3.3. Mesenchymal stem cells 
MSC, otherwise known as mesenchymal stromal cells, are isolated by their adherence to 
plastic and can be extensively expanded in culture72. They can be isolated from bone marrow 
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or adipose tissue, and have been shown to differentiate into adipocytes, osteocytes and 
chondrocytes (mesenchymal lineages)73 as well as into cardiomyocytes74 and endothelial 
cells75. They should be positive for CD90, CD73, CD27, CD29 and CD105, while negative 
for haematopoietic and endothelial markers (CD45, CD34, CD14, CD11b) as usually 
measured by flow cytometry76. Injection of MSC have been shown to improve cardiac 
function in animal heart failure models and it has been speculated this is predominantly due 
to paracrine mechanisms77. Clinical feasibility studies have reported that MSC 
transplantation (with or without78 co-administration of EPC79) is feasible, safe and improves 
cardiac function. In contrast to BMMNC, this cell type requires ex vivo expansion (for 
usually 3-4 weeks) to obtain the sufficient number of cells for transplantation. On the basis 
of these results, as of June 2012, there are currently 12 phase I and II active registered 
ongoing clinical trials being undertaken to assess MSC transplantation for heart disease80. 
Interestingly, experimental evidence suggests that allogenic MSC in vitro do not 
stimulate a T-cell immune response81,82.  The mechanisms of this immune tolerance remain 
controversial, but such a phenomenon has encouraged clinicians to transplant allogenic MSC 
in human subjects with non-cardiac pathology including polymyositis and inflammatory 
bowel disease83,84. There are several registered clinical trials utilizing allogenic MSC for the 
treatment of heart disease, but these have not yet been reported. 
However, concerns remain regarding the observations that late-passage MSC exhibit 
chromosomal abnormalities85 and reports regarding heterotopic differentiation such as 
ossification or tumour formation86-88. MSC are also larger in size than BMMNC and have a 
larger diameter than that of capillaries in average. IC injection of MSC may therefore result 
in a greater number of cells persisting in the heart by physical entrapment within the 
vasculature89-91 although such entrapment could lead to decreased perfusion in the feeding 
arterial system (coronary embolism)89 and lead to myocardial injury.  
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1.3.4. Endothelial progenitor cells (EPC) 
The term “EPC” describes a subgroup of multipotent cells incorporating a heterogeneous 
group of circulating and culture-derived cells92 which overlap with cells from a 
haematopoietic lineage in terms of surface markers93,94.  These cells originate from the bone 
marrow, and together with mature endothelial cells, are thought to contribute to endothelial 
regeneration and neovascularization via differentiation as well as paracrine ability95,96. In 
addition, endogenous EPC have been reported to play a role in pathogenesis of various types 
of cardiovascular disease97. They can be isolated from the bone marrow or from the 
peripheral blood, but the identification and characterization of EPC and their contribution to 
vascular biology in vivo remains controversial92,98,99. The main disadvantage with the 
concept of EPC as a source for cell transplantation is that their numbers and function are 
reduced in patients with cardiovascular disease, limiting the potential effects of autologous 
EPC transplantation55.  
In clinical settings, so-called EPC have been isolated using particular cell surface 
markers (such as CD34 or CD133). Clinical studies administering CD133+ cells have shown 
that this is a feasible approach to improve cardiac function, although this may lead to an 
increased rate of atherosclerosis in the treated vessel100-103.  No clinical trial has been 
performed to date that compares outcomes in EPC against BMMNC although the 
“Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial 
Infarction Study” (TOPCARE-AMI) demonstrated that both BMMNC and circulating 
progenitor cells (presumed to be similar to circulating EPC) improved cardiac function to a 
similar degree.  
 
1.3.5. Cardiac progenitor cells (CPC) 
Several groups have recently reported that adult hearts contain resident CPC that are able to 
form functional cardiomyocytes, endothelial cells and vascular smooth muscle cells in vivo 
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and in vitro104,105. These are thought to contribute to a slow turn-over of cardiomyocytes in 
normal hearts, but cannot overcome the high degree of cardiomyocyte loss in AMI106. It is 
reportedly possible to isolate, expand ex vivo, and inject CPC into the heart, resulting in 
cardiac functional improvement via cardiomyogenic differentiation and/or paracrine 
mechanisms in animal studies107,108.  
These cells are now undergoing clinical investigation. Preliminary results of a trial 
using c-kit positive, lineage-negative CPC have been reported using small patient 
numbers109. In the Stem Cell Infusion in Patients with Ischaemic Cardiomyopathy (SCIPIO) 
trial, patients with left ventricular (LV) impairment post-MI who were undergoing CABG 
were randomized to receive autologous culture-expanded CPC via IC injection at a mean of 
113 days post CABG. The CPC were isolated using the atrial tissue obtained during surgery 
and approximately 2×106 cells could be obtained per patient. Compared to a control group 
who did not receive cells, LVEF was improved at 4 months post cell transplantation; an 
effect that was enhanced 1 year post cell injection. Additionally, a phase 1 clinical study 
using cardiosphere-derived CPC has suggested that IC injection of these cells is safe and 
may reduce infarct size compared with controls, although no improvement was seen in 
LVEF110.  
This cell type requires further investigation and validation in both laboratory and 
clinical studies. One of the main factors limiting the widespread clinical use of CPC is 
various overlapping CPC types have been reported including c-kit, Sca-1, islet-1, and 
Cardiosphere-derived cells, the superior type of which has not been clarified111. In addition, 
the reproducibility and reliability of some reported data regarding cardiomyogenic 
differentiation of CPC remains controversial112.  
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1.4.   Routes for administering cells into the heart  
 
For the success of cell transplantation to the heart, the choice of the cell delivery route is 
critically important; this will affect the retention, survival, distribution, integration and 
functionality of donor cells and will therefore influence the subsequent outcomes of the 
treatment.  
The ideal cell-delivery method would meet a number of criteria113: (a) donor cells 
would be reproducibly and efficiently delivered to the target area(s) of the heart without 
leakage to other organs; (b) grafted donor cells would persist and survive in the heart, 
maintaining their important cellular functions; (c) the procedure would not cause damage to 
the host heart; (d) the procedure would be well tolerated by patients (even in those with 
severe heart failure) and have a low complication rate; (e) the method could be made 
available in most hospitals without the need for substantial additional facilities; (f) the 
method would be technically straightforward and able to be performed by most 
interventional cardiologists/surgeons after training; (g) the procedure would not be too 
costly; and (h) cells administered by this route would result in benefits to clinical outcome 
measures, such as patient mortality and morbidity. In addition, it would be advantageous if 
the technique were applicable to many types of donor cells and useful in a number of clinical 
situations, ranging from patients with AMI to chronic heart failure. Different routes for 
administering cells to the heart are currently available, including intravenous (IV), 
intramyocardial (IM), and intracoronary (IC) routes, as shown in Figure 1-1. 
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Figure 1-1: Current major routes of delivering stem cells to the heart. LV: left ventricle. RV: right 
ventricle. LA: left atrium. RA: right atrium. CS: coronary sinus. Ao: aorta. SVC: superior vena cava. 
IVC: inferior vena cava. IC: intracoronary. IV: intravenous. IM: intramyocardial. 
 
 
1.4.1. Intravenous (IV) injection 
This systemic route is simpler, less invasive and less expensive than other current cell 
delivery routes. However, injected donor cells' accumulation in the heart (‘homing’) and 
retention in the heart using this route are extremely limited. Given that only 4-5% of cardiac 
output is dedicated to supplying coronary artery flow (with even less through an 
occluded/stenosed artery)114,115 and that many cells are entrapped in the lung, it is likely that 
a very low proportion of IV administered cells actually even pass through the coronary 
circulation.  
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In fact, after IV injection of radioactively labelled, ex vivo expanded, human 
circulating EPC into athymic, nude rats following MI, only a small amount of radioactivity 
(a proportion of about 2 %) was detected in the heart after 24–96 hours116. Most of the 
radioactivity was found in the lungs, spleen and liver116,117.  This finding has been replicated 
using BMMNC118, peripheral blood mononuclear cells117 and purified CD34+ cells119. A 
Positron Emission Tomography (PET) study in three human subjects failed to detect any cell 
uptake in the heart following IV injection of 18F-FDG-labelled cells120. Therefore, the IV 
route is less frequently used in clinical trials using these cell types. However, this method 
may be useful for MSC injection121, based on the data that homing of this particular cell type 
to the damaged heart appears to be higher than other cells122,123.  
 
1.4.2. Intramyocardial (IM) injection 
IM injection is by far the most frequently used cell injection method in small animal studies 
due to its technical feasibility, since reliable in-vivo models for IC injection in small rodents 
have not been established. The IM injection method can deliver cells into a specific target 
area, irrespective of the patency of its vascular supply, and results in a higher initial 
retention of cells within the heart compared with IC or IV injection117,124,125. The two most 
frequent approaches of IM injection in the clinical setting are performed (1) epicardially by 
direct injection after thoracotomy and (2) endocardially via a percutaneous catheter inserted 
into the LV cavity (targeted using electromechanical mapping)126.  
IM cell injection is associated with mechanical injury and a subsequent acute 
inflammatory response, which damages the host myocardium as well as the injected donor 
cells127. In addition, cells injected by this method are known to form islet-like cell clusters 
within the myocardium, resulting in limited interaction with host cells and therefore limited 
integration into the host myocardium. Formation of such intramyocardial heterogeneity has 
been postulated to lead to the development of reentrant ventricular arrhythmias observed in 
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previous experimental and clinical studies of IM injection of skeletal myoblasts41. Our group 
has also reported that IM injection of BMMNC, but not IC injection, was associated with an 
increased rate of ventricular arrhythmias following transplantation in a rat model of 
ischaemic cardiomyopathy128. 
The feasibility, safety and efficiency of IM injection of BMMNC have been 
investigated in clinical settings. A meta-analysis has been undertaken of six reported studies 
(with a total of 179 patients) examining epicardial IM injection of autologous BMMNC 
performed at the same time as CABG129. Patients who received cells in addition to CABG 
exhibited greater improvement in LV function and a greater reduction in cardiac dimensions, 
compared with those who underwent CABG only. There were no major complications 
detected in these studies. 
 Epicardial IM injection is usually carried out in conjunction with other open-heart 
procedures, such as CABG130 or left ventricular assist device (LVAD) implantation131, 
because using this approach in isolation may be too invasive and associated with a higher 
financial cost. Endocardial IM injection requires specialized electromechanical mapping 
equipment and is both a time consuming and technically challenging procedure.  
To reduce the invasiveness of epicardial IM injection (along with the requirement 
for open chest procedures), several attempts to utilize trans-coronary IM injection have been 
made in small animals, large animals and patients132-134. Trans-coronary IM injection can be 
achieved via a percutaneous catheter introduced into the coronary sinus or the coronary 
artery; injection of donor cells into the myocardium is performed using a specific needle 
catheter penetrating through the vessel wall into the target territory135-137. These methods, 
however, require further investigations to establish their safety and efficacy  in the delivery 
of stem cells into the heart. 
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1.4.3. Intracoronary (IC) injection 
IC injection is a method  of injecting donor cells into coronary circulation and can be 
achieved by two routes; injection into the coronary artery (antegrade IC injection) and 
injection into the cardiac vein (retrograde IC injection). With both methods, donor cells are 
administered into the vessel cavity using an over-the-wire balloon catheter. In clinical trials, 
antegrade IC injection is the most commonly used technique138. This procedure is thought to 
be a physiological method of delivering cells to the heart which enables cells to be more 
homogenously disseminated into target areas (without forming cell-clusters and with less 
myocardial damage) than is the case with the  IM approach128. One reason for the popularity 
of this method is that most interventional cardiologists are familiar with the percutaneous 
technique to access the coronary arteries. IC injection is less invasive to patients compared 
to the epicardial IM approach and requires only standard equipment in the cardiac 
catheterization laboratory. Although this technique cannot deliver cells to an area  in which 
the arterial supply is occluded, IC cell transplantation can be applied once the artery is 
reopened by intervention. A disadvantage of IC cell injection is a risk of coronary 
embolism139 and this risk may be particularly important when larger cell types, such as 
MSC91, are injected into the coronary arteries.  
This approach was first reported in humans in 2001 in a feasibility study of 
BMMNC transplantation after primary PCI for AMI140. Since then, the majority of clinical 
studies have been performed using this approach, particularly when injecting smaller cells 
such as BMMNC, and a sizable evidence base has been built up. However, there is a lack of 
appropriate small rodent models for this cell delivery approach, which partly explains why 
there is only a limited understanding of donor cell physiology and dynamics after IC 
injection.  
The retrograde IC approach has been reported to be a successful technique to 
administer stem/progenitor cells to the heart in both animals and human. This method is 
theoretically associated with a lower risk of coronary embolism and can deliver cells to 
 34 
avascular areas. Suzuki and colleagues have developed an original model of retrograde IC 
cell injection in rat and shown that BMMNC128 and skeletal myoblasts128 could be 
satisfactorily administered to the heart via this method. The rates of donor cell survival, 
improvements in LV function, increased neovascular formation, and reduction in cardiac 
hypertrophy / fibrosis obtained by this treatment were similar after epicardial IM injection of 
the same number of cells. Small clinical studies have suggested that this approach is feasible 
and safe for delivery of BMMNC141. 
 
1.4.4. Other approaches 
There are several other emerging technologies for cell delivery to the heart using novel 
biomedical engineering. These include the transplantation of stem cells or stem cell-derived 
cardiomyocytes as tissue-engineered constructs142. The cell sheet technique is one of the 
most promising new approaches. Okano and colleagues have developed a novel 
bioengineering technology to generate scaffold-free cell-sheets using unique culture 
dishes143 where cells are detached from the dish as a free cell-sheet, in response to 
temperature changes. These sheets can then be layered onto the epicardial surface of the 
heart under direct visualisation. Following successful preclinical studies in small and large 
animals144, a hospital-led clinical trial of skeletal myoblast sheet therapy for treating heart 
failure has started in Japan, which has provided positive preliminary results. Further 
investigation is needed to confirm the safety and efficacy of these methods, if they are to 
become clinically established. 
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1.5.   Clinical studies of intracoronary (IC) injection of adult stem 
cells 
 
IC injection is technically feasible by most interventional cardiologists in a standard cardiac 
catheter laboratory and is less invasive compared to the other major injection method; 
epicardial IM injection. The IC method is applicable to a range of clinical settings including 
AMI, post-MI heart failure, and dilated cardiomyopathy. Donor cells injected by this method 
do not form isolated cell-clusters, which may cause critical ventricular arrhythmias that can 
occur following IM injection. In fact, the vast majority of previous large-scale clinical trials 
have utilised IC injection, particularly antegrade IC route, and these clinical studies have 
proven the feasibility and safety of this method. For all these reasons, and especially because 
antegrade IC injection is the most widely used protocol in clinical trials, this project will 
focus on the investigation of antegrade IC injection. When described in this thesis 
henceforth,  ‘IC injection’ will refer to antegrade IC injection. 
 
1.5.1. Therapeutic outcomes of clinical trials of IC cell transplantation 
There are an increasing number of randomized, blinded, multi-centre clinical trials using the 
IC route for cell therapy for heart disease (summarized in Table 1-1). The majority of these 
studies have administered autologous BMMNC shortly following cell isolation, utilizing the 
antegrade IC approach. Typically, 1-100 ×106 BMMNC were injected, with the procedure 
proven to be feasible and safe. There is no evidence that rates of atherosclerotic disease, in-
stent restenosis, ventricular arrhythmias or neoplasia increase following cell administration. 
The majority of studies have been performed delivering cells early after MI (0-7 days), but 
some reports have investigated cell administration in chronic cardiomyopathy.  
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A recent Cochrane database meta-analysis has examined the effects of IC 
administration of BMMNC after MI27. 33 randomized controlled trials with 1765 subjects 
were included. After short-term follow-up, cell treatment in addition to standard care was 
shown to significantly improve LVEF, an effect that was maintained after follow-up of up to 
61 months. The weighed mean difference of LVEF% after long-term follow-up was 3.75. 
This is comparable to the LVEF improvement observed when ACE-inhibitors in isolation 
are given to patients with LV impairment145. There were also beneficial effects on cardiac 
dimensions and a correlation was observed between the donor cell dose and improvements 
in LVEF, suggesting that cell therapy exhibits a dose-response effect. However, these 
improvements did not translate into a reduction in mortality. 
To date, the largest multi-centre, double blind, randomized controlled trial with the 
longest reported follow-up time was the Reinfusion of Enriched Progenitor Cells and Infarct 
Remodelling in Acute Myocardial Infarction (REPAIR-AMI) trial46,146. 204 patients with 
AMI treated with primary PCI were randomized to receive antegrade IC injection of  
>230×106 autologous BMMNC or placebo into the infarct artery, 3-7 days post MI and PCI. 
After 2 years, the cumulative end-point of death, MI, or revascularization was significantly 
reduced in the BMMNC group compared to the placebo group. This was also associated 
with a significant improvement in LV function, cardiac dimensions and infarct size.  
Although most of the clinical trials using antegrade IC injection have investigated 
acute or subacute MI, there are also an increasing number of studies of IC cell injection for 
chronic heart failure, (in both post-MI ischaemic cardiomyopathy and dilated 
cardiomyopathy). The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) 
trial randomized 44 dilated cardiomyopathy patients with normal coronary arteries to receive 
either autologous BMMNC by antegrade IC injection, or medical treatment only147. Two 
thirds of the cells were administered into the left coronary artery and one third were 
administered into the right coronary artery. After a 3 year follow-up period, there was a 
significant improvement in LV function in the treatment group.  
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The majority of clinical trials of antegrade IC injection have utilized BMMNC, 
although other cell types have also been studied. Chen and colleagues78 performed a study 
whereby patients with AMI after coronary angiography ± PCI underwent bone marrow 
harvesting, and bone marrow-derived MSC were expanded for 10 days148. The patients were 
randomized to either receive antegrade IC injection of 8-10×109 MSC or placebo. It was 
reported that LV dimensions and perfusion defects decreased in the MSC group after 3 
months follow-up and LV function improved after 6 months follow-up. No deaths occurred 
in the 6 month follow-up78. More recently, CPC - either c-kit+/Lin- cardiac cells or 
cardiosphere-derived cells - have been transplanted into human hearts via the antegrade IC 
route109,110, but these approaches require further validation in larger scale studies and 
comparison with other established cell types. 
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1.5.2. Poor donor cell retention/presence after IC injection observed in clinical 
studies 
In parallel to studying the safety and therapeutic effect of IC cell transplantation, some 
clinical studies have attempted to quantify the donor cell persistence/survival in the heart 
after IC injection (Table 1-2). Although these studies have only used small numbers of 
patients and different approaches of quantification, the results collectively suggest that very 
few donor cells are retained and survive in the heart after IC injection.  
Goussetis et al. assessed donor cell numbers persisting in the heart in patients with chronic 
ischaemic cardiomyopathy175.  CD133+ and CD133-/CD34+ cells were immunomagnetically 
isolated from the bone marrow of the patients, labelled with 99mTc-
hexamethylpropylenamineoxime (99mTc-HMPAO) and infused into the infarct coronary 
artery after PCI.  Scintigraphic images obtained at 24 hours in 4 patients demonstrated a 
mean 6.8% donor cell uptake in the heart. Images obtained in a single patient at 1 hour 
showed an uptake of 9.2%.   
Hofmann et al. examined transplanted cells retained in the heart of AMI patients treated with 
stenting of the infarct artery115. Unselected BMMNC (n=3) or CD34+ BMMNC (n=3) were 
labelled with [18F]-fluoro-2-deoxy-D-glucose (18F-FDG) and injected into the infarct artery. 
Fifty to seventy-five minutes after cell administration, the patients underwent PET imaging 
and only 1.3-2.6% of labelled BMMNC were found in the heart, a proportion that increased 
to 14-39% in patients receiving CD34+ BMMNC. The remaining radioactivity was found 
mainly in the liver and spleen. This study suggests that there may be subpopulations of 
BMMNC which are preferentially retained in the heart.  
Kurpisz and colleagues, using a similar approach, examined donor cell retention in 3 patients 
with a recent MI treated with stenting176. Autologous CD34+ BMMNC were radiolabelled 
with Indium and the labelled cells were injected into the infarct artery. Twenty-four hours 
after injection, SPECT imaging showed that 2.6-11.0% of donor cells persisted in the heart. 
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As was observed in the other reports, the majority of donor cells were found in the liver and 
the spleen. 
Schachinger and colleagues studied donor cell retention in 17 patients with MI treated with 
either stenting or CABG177. Mononuclear cells were isolated from peripheral blood and then 
subjected to ex-vivo culture. These cells (described as circulating progenitor cells by the 
authors) were then radiolabelled with 18F-FDG and administered via IC injection. When 
assessed by PET, a mean of 7% of the injected donor cells persisted in the heart 1 hour after 
cell injection, which further declined to 2% after 3-4 days. 
Kang and colleagues examined retention in 17 post MI patients undergoing planned PCI,     
5 of whom had chronic ischaemic cardiomyopathy120. Isolated peripheral mononuclear cells 
were mobilized with granulocyte colony-stimulating factor (G-CSF). These cells (described 
by the authors as peripheral haematopoietic stem cells) were labelled with 18F-FDG and       
2 hours post IC injection, the patients were assessed with PET. A mean of 1.5% of injected 
cells were found in the myocardium. A single patient underwent 2 PET studies that 
demonstrated myocardial activity of 3.3% at 2 hours and 1.5% at 20 hours.  
Penicka et al. investigated donor cell retention in 5 patients with AMI and 5 patients with 
chronic MI178. Unselected BMMNC radiolabelled with 99mTc-HMPAO were injected into 
the left anterior descending artery after PCI. At 2 hours after injection, radioactivity was 
detected in the hearts of all patients with AMI though only 1-5% of the total radioactivity. 
This further decreased by 20 hours post injection. In the chronic MI patients, activity was 
detected (1-3%) in 4 of 5 patients after 2 hours, but no activity was detected after 20 hours.  
Schots et al. assessed cell retention in 8 patients with chronic MI (>12 months)179. Selected 
CD133+ cells were radiolabelled with 111-Iridium and administered via IC injection. In each 
patient, serial nuclear imaging was obtained at 2, 12, 36 and 60 hours post-injection. This 
demonstrated a mean retention efficiency in the heart of 7.4, 2.8, 1.6 and 1.2%, at each time 
point respectively. 
 
43
 
Ta
bl
e 
1-
2:
 C
lin
ic
al
 st
ud
ie
s w
hi
ch
 h
av
e 
as
se
ss
ed
 d
on
or
 c
el
l r
et
en
tio
n 
an
d 
pr
es
en
ce
 a
fte
r I
C
 in
je
ct
io
n 
of
 a
du
lt 
st
em
 c
el
ls
  
 
Sp
ec
ie
s 
C
el
l T
yp
e 
C
el
l  
N
um
be
r 
In
je
ct
ed
 
Ti
m
in
g 
of
 C
el
l 
D
el
iv
er
y 
po
st
 M
I 
Ti
m
in
g 
of
 
m
ea
su
re
m
en
t  
po
st
 d
el
iv
er
y 
M
ea
su
re
m
en
t m
et
ho
d 
 
C
el
l r
et
en
tio
n 
re
su
lts
 
 
 
K
an
g 
(2
00
6)
12
0  
H
um
an
 
(n
=1
7)
 
C
irc
ul
at
in
g 
m
on
on
uc
le
ar
 
ce
lls
 
N
ot
 st
at
ed
 
3-
30
0 
da
ys
 
2 
ho
ur
s 
FD
G
 la
be
lle
d 
ce
lls
 
PE
T/
C
T 
of
 h
ea
rt 
1.
5%
 re
te
nt
io
n 
B
lo
ck
et
 
(2
00
6)
18
0  
H
um
an
 
(n
=6
) 
C
irc
ul
at
in
g 
C
D
34
+  
m
on
on
uc
le
ar
 c
el
ls
 
4x
10
6  
7-
21
 d
ay
s 
1 
ho
ur
 
FD
G
-la
be
lle
d 
ce
lls
 
PE
T 
of
 h
ea
rt 
5.
5%
 re
te
nt
io
n 
Sc
ha
ch
in
ge
r 
(2
00
8)
17
7  
H
um
an
 
(n
=1
7)
 
C
irc
ul
at
in
g 
m
on
on
uc
le
ar
 
ce
lls
, e
xp
an
de
d 
ex
-v
iv
o 
1x
10
6  
5 
da
ys
  
– 
17
 y
ea
rs
 
1 
ho
ur
 &
 
2-
3 
da
ys
 
FD
G
 la
be
lle
d 
ce
lls
 
PE
T 
of
 h
ea
rt 
6.
9%
 re
te
nt
io
n 
at
 1
 h
ou
r  
2%
 re
te
nt
io
n 
at
 2
-3
 d
ay
s. 
 
G
ou
ss
et
is
 
(2
00
6)
17
5  
H
um
an
 
(n
=1
) 
B
on
e 
M
ar
ro
w
 C
D
13
3+
 
&
 C
D
13
3-
 C
D
34
+  
1.
5x
10
7  
>9
 m
on
th
s 
1 
ho
ur
 
99
m
Tc
 la
be
lle
d 
ce
lls
 
Sc
in
tig
ra
ph
ic
 im
ag
in
g 
9.
2%
 re
te
nt
io
n 
at
 1
 h
ou
r (
n=
1)
 
H
of
m
an
n 
(2
00
5)
11
5  
H
um
an
 
(n
=6
) 
U
ns
el
ec
te
d 
B
M
M
N
C
  
&
 B
M
 C
D
34
+  
2.
5x
10
8  
5-
10
 d
ay
s 
50
-7
5 
m
in
s 
FD
G
 la
be
lle
d 
ce
lls
 
PE
T 
of
 h
ea
rt 
1.
3-
2.
6%
 re
te
nt
io
n 
un
se
le
ct
ed
 B
M
M
N
C
  
14
-3
9%
 re
te
nt
io
n 
 
B
M
 C
D
34
+ 
ce
lls
  
Sc
ho
ts
 
(2
00
7)
17
9  
H
um
an
 
(n
=8
) 
Pe
rip
he
ra
l b
lo
od
 C
D
13
3+
  
5 
- 5
0 
x1
06
 
>1
2 
m
on
th
s 
2 
an
d 
12
 h
ou
rs
  
11
1-
In
-o
xi
ne
 c
el
l l
ab
el
lin
g 
Sc
in
tig
ra
ph
ic
 im
ag
in
g 
6.
9-
8.
0%
 re
te
nt
io
n 
at
 2
 h
ou
rs
 
2.
3-
3.
2%
 a
t 1
2 
ho
ur
s 
Pe
ni
ck
a 
(2
00
7)
17
8  
H
um
an
 
(n
=1
0)
 
B
M
M
N
C
 
2.
4 
- 5
.7
 
x1
09
 
N
ot
 sp
ec
ifi
ed
 
2 
an
d 
20
 h
ou
rs
 
99
m
Tc
 la
be
lle
d 
ce
lls
 
Sc
in
tig
ra
ph
ic
 im
ag
in
g 
1.
3-
5.
1%
 re
te
nt
io
n 
at
 2
 h
ou
rs
. 
1.
0-
1.
3%
 re
te
nt
io
n 
at
 2
0 
ho
ur
s 
Pe
ni
ck
a 
(2
00
5)
18
1  
H
um
an
 
(n
=1
) 
B
M
M
N
C
 
2.
7x
10
9  
9 
da
ys
 
2 
an
d 
18
 h
ou
rs
 
99
m
Tc
 la
be
lle
d 
ce
lls
 
Sc
in
tig
ra
ph
ic
 im
ag
in
g 
5%
 re
te
nt
io
n 
at
 2
 h
ou
rs
  
1%
 re
te
nt
io
n 
at
 1
8 
ho
ur
s 
K
ur
pi
sz
 
(2
00
7)
17
6  
H
um
an
 
(n
=3
) 
C
D
34
+  B
M
M
N
C
 
2-
4x
10
6  
4-
7 
da
ys
 
24
 h
ou
rs
 
In
di
um
-la
be
lle
d 
ce
lls
 
SP
EC
T 
2.
6-
11
.0
%
 re
te
nt
io
n 
 44 
1.5.3. Poor donor cell retention with IC injection observed in animal studies 
Clinical studies have suggested that there is a poor presence of donor stem/progenitor cells 
in the heart after IC injection (please refer to 1.5.2). However, these results were based on 
studies utilizing a small number of heterogeneous patients with varying injection protocols. 
Several groups have provided further supporting evidence regarding the low retention rate of 
donor cells after IC injection by using large animal models. This approach enabled 
standardized procedures to be applied to more homogeneous subjects in a more reproducible 
manner. 
Forest et al. assessed retention of autologous BMMNC labelled with either a 
fluorescent marker or a radioactive tracer in a day 7 porcine MI model118. Cells were 
injected either via the IC or IV routes. Radioactivity analysis measurements demonstrated 
that only 6.0 ± 1.7% of cells were still retained in the heart after 24 hours of IC injection. 
After IV injection, no donor cells were detected in the heart and the majority of donor cells 
were found in the lungs. 
Doyle et al. dynamically tracked the fate of 18F-FDG labelled circulating EPC 
following IC injection in a porcine AMI model182. The location of labelled cells was 
determined every minute for 1 hour using PET. A balloon was placed in the infarct artery 
and cells were injected using cycles of balloon occlusion / reperfusion. Peripheral blood was 
drawn at 1-minute intervals and 18F-FDG activity was also recorded from these samples. 
After each balloon deflation following injection, there was a loss of 80% of peak myocardial 
activity, which mostly occurred in the first 2 minutes following deflation. This abrupt drop in 
myocardial radioactivity with each balloon deflation was associated with a transient spike of 
peripheral cell-bound (>90%) activity, indicating that the administered cells rapidly pass into 
the systemic circulation.  
Tossios and colleagues also tracked the retention of BMMNC utilizing a pig AMI 
model and compared cell retention between two IC injection protocols; in group 1, BMMNC 
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were delivered during balloon inflation, followed by subsequent balloon deflation whereas 
in group 2, the same number of cells were delivered without an intracoronary balloon.183 
Group 1 injections resulted in a higher immediate retention of cells than group 2, but in 
group 1, the cells were rapidly lost during balloon deflation (reflow). In group 2, there was a 
more steady loss of cells. As a result, there was no difference between the retained cell 
number at 1 hour or 24 hours between the groups, leading the authors to conclude that 
balloon inflation is not necessary for IC cell injection. Dynamic scintigraphic imaging 
showed that donor cell loss from the heart occurred within minutes following IC injection.  
Freyman et al. utilized a pig model of AMI to compare the number of donor MSC  
(a larger cell type than BMMNC) remaining in the heart, after delivery either via the IC, IM 
and IV routes89. Iridium-labelled cells were delivered 75 minutes after the initiation of AMI 
and the organs were harvested following cell delivery for quantification of iridium-particle 
number. 14-days following IC and IM injection, 6% and 3% of the administered cells were 
still located in the heart respectively (p<0.01). No detectable cells were found after IV 
administration and a high proportion were located in the lungs 
These results of large animal and human studies have consistently shown that donor 
cell retention, survival, and/or engraftment are extremely poor after IC injection. In 
particular, following antegrade IC injection of BMMNC (the most frequently used clinical 
protocol), only 1-5% of injected donor cells are still found in the heart around 24 hours after 
transplantation. Furthermore, it is suggested that such poor donor cell presence at 24 hours is 
the consequence of poor donor cell presence (as poor as 1-10%) at much earlier time points 
(1-2 hours) after IC injection. A high proportion of injected cells are found in extra-cardiac 
organs, such as the lungs, liver or spleen. Such poor donor cell presence in the heart is a 
critical weakness of IC injection of stem/progenitor cells, which limits the therapeutic effects 
of this approach. 
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1.6.   Initial donor cell Retention following IC injection 
 
When a new pharmaceutical agent is developed for market, rigorous preclinical testing and 
understanding of the underlying mechanisms mostly occur prior to clinical studies. In the 
field of stem cell therapy to the heart, however, I believe that these normal translational 
processes have not properly occurred. In the rush to introduce stem cell therapy into clinical 
studies, these fundamental preclinical investigations have not occurred to any great degree. 
As a result, there is still a poor understanding of many of the critical processes that occur 
following IC cell injection. 
Given the consistent results from clinical and large animal studies (see 1.5.1 and 
1.5.2), it is clear that initial retention of donor cells in the heart is poor after IC cell injection. 
This results in limited mid/long-term donor cell engraftment and consequently in limited 
therapeutic effects of the treatment. There remains little understanding of the mechanisms 
that affect donor cell retention after IC injection. Further understanding and enhancement of 
retention of donor cells is key to the future clinical success of IC cell injection. 
 
1.6.1. Definition of “initial retention” of donor cells after IC injection 
The words that describe the state of transplanted donor cells within the heart after IC 
injection need to be carefully defined. In the literature, the word ‘engraftment’ is often used 
to describe donor cells within the heart at any time point184, although this is linguistically 
erroneous. In general, successful ‘engraftment’ of organs or tissues is understood to mean 
that the donor organ/tissue has formed functional connections with adjacent structures185. 
The word ‘engraftment’ when applied to cell transplantation, should be used similarly –
functional integration of surviving donor cells with the host myocardium.  
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At least three major factors influence “engraftment” of IC injected cells: “initial 
retention” within the heart, subsequent “survival”, and functional “integration” into the host 
myocardium. Intramyocardial migration and proliferation may also influence “engraftment” 
in some cases. Initial retention encompasses the processes of adhesion of donor cells to the 
endothelium or physical entrapment in the intravascular lumen. Initial retention may also 
include subsequent transendothelial migration into the myocardial interstitium, and/or 
migration into the vascular wall. Importantly, as discussed above, poor longer term “survival 
or presence” and “engraftment” following IC cell injection is predominantly due to poor 
“initial retention”, which should occur within minutes after injection.  
 
1.6.2. Importance of “initial retention” of donor cells after IC injection 
As discussed in section 1.5, clinical studies have suggested that the retention rate after IC 
injection is below 10% after 1-2 hours. Such a poor retention rate at 1-2 hours is likely to be 
determined by low retention rates at an even earlier time point: within minutes after injection 
(“initial retention”). However, the quantitative time-course of initial retention of adult 
stem/progenitor cells in the heart following IC transplantation and its underlying 
mechanisms remain largely unknown. Elucidation of these and improvement of these low 
initial retention rates are required if this cell administration route is to enter standard clinical 
practice. 
This thesis aims to characterise the retention in the heart, with a particular focus on 
the “initial retention”, of adult stem/progenitor cells after IC injection, in a quantitative and 
systemic manner. 
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1.6.3.  Current experimental models to assess initial retention of donor cells after IC 
injection 
To elucidate the detailed time course of retention of different stem/progenitor cells in a 
range of conditions, a reproducible, cost-effective small rodent model is required. However, 
there is currently a lack of established small animal models to mimic IC injection and to 
evaluate donor cell retention. To date, the majority of quantitative analyses of donor cell 
presence/retention in the heart after IC injection have utilized large animal models or clinical 
subjects, in which IC injection protocols are well-established. However, due to the extensive 
resources required, large animal models  were not suitable for my study. Possible methods of 
quantitative measurement of initial donor cell retention in small and large animals are 
discussed below: 
Histological detection of donor cells: Histological techniques offer the potential to track 
injected cells in the heart, to examine their numerical frequency and location in relation to 
blood vessels, and to determine their fate. Various methods to label donor cells are available 
including labelling with fluorescent dyes186,187 or quantum dots188. Alternatively, the use of 
genetically-modified cells to express markers such as GFP, and immune-detection of donor 
cell specific antigen (such as species-specific or sex-specific antigens) can be used189. 
However, histological techniques that involve the counting of cells in the host heart only 
provide a semi-quantitative assessment of the number of cells in the heart unless the whole 
heart is fully investigated. Other limitations are that animals need to be euthanized for the 
heart to be examined and longitudinal cell fate cannot be assessed in the same animal. 
Additionally, fluorescent markers are also subject to decay in the heart, dye leakage into 
adjacent cells/tissues and fusion events. These may all interfere with histological 
interpretation.  
Donor cell detection in digested hearts: One of the methods to quantitatively measure donor 
cell retention is chemical/molecular assessment of marker molecules contained in the heart 
after injection of cells labelled with these markers. Here, after IC injection of pre-labelled 
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donor cells, the heart is digested, and quantity/activation of marker molecules contained in 
the heart homogenate is measured. Possible markers include radioactive substrates (assessed 
by nuclear assessments89,119,127, ß-galactosidase (by enzymatic activity)139,190, firefly 
luciferase (by chemiluminescence), and male specific genes (quantitative Polymerase Chain 
Reaction after transplantation of male cells into female hearts)127. This method is applicable 
in small animals; however, it requires euthanasia of the animals at each study point and does 
not enable longitudinal cell fate tracking in the same sample. The method is prone to 
overestimating the cell retention, because signals from particles after cell death that persist 
in the cardiac tissue or which are taken up by tissue macrophages will be misinterpreted as 
representing cell presence.191 Also, some marker molecules may affect the cellular integrity 
of donor cells192. 
Detection of living donor cells: Radiolabelling of donor cells in large animals and patients is 
one approach to assess the persistence of cells in the heart. Radioactivity measurements 
using Single Photon Emission Tomography (SPECT) or Positron Emission Tomography 
(PET) are used to estimate the donor cell number retained in the 
heart89,116,117,120,175,177,180,182,193. One major advantage of these techniques are that the 
quantification of donor cell presence can be determined at several different time points in the 
same subject. Long-term presence can only be utilized when the half-life of tracers is 
sufficiently long (for examples in the cases of 111In which is used with SPECT or 64Cu-
PTSM which is used with PET)194. However, unfortunately, these methods are not easy to 
apply to small animals, resulting in insufficient sensitivity and resolution. In addition, 
several reports have shown that radiolabelling is toxic to blood cells, haematopoietic stem 
cells or MSC, and it is possible that radioactivity could damage functions of donor 
cells119,123,195. Furthermore, this method is associated with a risk of release of tracer from 
dead cells, which may be retained in cardiac tissue and therefore lead to misleading 
conclusions regarding cell presence. Recently an approach using a reporter gene coupled to a 
systemically injected radiotracer with nuclear assessment by PET has been utilized to 
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quantify cells196. This technique could avoid some of these problems with direct 
radiolabelling of cells but quantification is not straightforward and the need for systemic 
injection of tracer increases background signal and decreases the contrast. 
Donor cell labelling with iron particles for magnetic resonance imaging (MRI) 
visualization is another approach that has been used to assess donor cell presence in vivo. 
Aspects of this technique which are appealing include the fact that MRI provides high 
quality anatomical localization of tissues, does not require ionizing radiation and that iron 
has been reported to be non-toxic for cells197,198. However, iron nano-particles released by 
dead cells may be taken up by tissue macrophages and persist in the heart for 5 weeks199-201. 
In addition, this method will have insufficient sensitivity and resolution to detect low 
numbers of donor cells when applied to small animals. 
1.7.   New models to assess retention following IC injection in small 
animals 
 
Clinical studies and large animal experiments have provided proof-of-concept that poor 
initial retention of donor stem/progenitor cells occurs after IC injection. Small animal 
models are required for a large-scale mechanistic study to assess initial retention of donor 
cells quantitatively in a number of experimental conditions at multiple time points. 
However, there are two hurdles that must be overcome; lack of a model of IC injection and 
lack of a method to assess early retention in small animals serially (please refer to 1.6). 
Previously, injection of cells into the aortic root (with simultaneous snaring of the ascending 
aorta and pulmonary artery)108, injection into the LV cavity186 or IV injection122 have all 
been used in small rodents as a model of IC injection. However, these approaches cannot 
deliver cells into the coronary artery in a reproducible manner and therefore are unsuitable 
for a quantitative study of donor cell retention. Possible methods to overcome these issues in 
small animals are described as follows; 
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1.7.1. Intravital microscope model 
Intravital microscopy is a widely used technique for studying the microvasculature in 
animals in situ. It utilizes thin tissues that can be trans-illuminated including bat wing, 
tadpole tail, and externalized mesentery of the bowel and externalized cremaster muscle in 
small rodents. This sophisticated method has been used to characterize the complex multi-
step processes which occur during leukocyte adhesion and migration by real-time and time-
lapse observation, monitoring, and recording of leukocyte-endothelial interactions202. Target 
cells (either endogenous cells or injected cells from the responsive artery) can be tracked to 
determine their location in relation to the vasculature (intra-luminal, trans-luminal or 
transendothelial migration) under pulsatile blood flow in a semi-quantitative manner203. It 
can also help elucidate the effects of cell surface molecules on either the cells to be injected 
or the recipient endothelium, with or without the use of genetically-modified animals. Using 
the externalized cremaster muscle, it is also possible to inject cells selectively204 and to 
induce localized ischaemia-reperfusion  injury205.  
Toma et al. have recently utilized intravital microscopy to track the fate of 
intraarterially-delivered, fluorescently labelled-MSC in rat cremaster muscle204. They found 
that 92% of MSC arrested within the vasculatures and interrupted flow during the first pass 
at the pre-capillary level, resulting in decreased flow in the feeding arteriole. At 3 days post 
MSC injection, the donor cell number decreased to 14% of its initial peak, mainly due to cell 
death. Labelling of the basement membrane confirmed that at day 1, MSC were sited on the 
luminal side of the basement membrane but by day 3, they had integrated into the 
microvascular wall.  
Using this approach, intravital microscopy could potentially provide a technique of 
obtaining a semi-quantitative assessment of retention202 in small animal models. However, it 
would not provide a fully quantitative assessment of retention. In addition, an important 
limitation of this method is that it investigates non-cardiac tissue, which may exhibit 
different endothelial properties or different mechanisms of donor cell retention. 
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1.7.2. Bioluminescence imaging 
Bioluminescence imaging may be useful to measure donor cell retention in small 
animals47,201,206-208, once a reproducible IC injection model is established. Genetically 
engineered cells overexpressing firefly luciferase are administered, and the animals are then 
injected with the substrate of luciferase D-luciferin. Anaesthetized animals are imaged and 
light is detected using a highly sensitive camera. Only viable cells generate a signal, which is 
advantageous, but this is totally dependent on the sensitivity of the chemiluminescence 
analyser. Furthermore, only surface images can be obtained and results are sensitive to the 
depth of cardiac imaging (cells in the anterior wall will generate a higher signal than those in 
the posterior wall). Additionally, because it can be difficult to obtain a baseline signal 
intensity, there may be a wider variation between sample measurements compared to other 
techniques.  
 
1.7.3. The use of a Langendorff isolated heart perfusion model 
The Langendorff -perfused mammalian heart model was established by Oscar Langendorff 
in 1897209.  The general principle of this method is that crystalloid perfusate is delivered to 
the heart through a cannula secured in the ascending aorta. Retrograde flow in the aorta, 
driven by pressure and volume load, closes the leaflets of the aortic valve and as a result, all 
the perfusate enters the coronary arteries via the coronary ostia at the aortic root, enabling 
the heart to be continuously perfused and beat. The perfusion pressure of the coronary 
arteries is kept constant by maintaining a constant perfusate hydrostatic pressure or 
regulating the flow by a pump210. Most studies use a physiological crystalloid solution     
(e.g. Krebs and Henseleit buffer) to mimic the ionic constituents of plasma211. Although a 
small number of groups have reported the utility of a blood-perfusion model in rodents212, 
this has not become a widely-used model because of technical and practical difficulties 
maintaining heart stability. 
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The main overall advantage of using the Langendorff crystalloid-perfused heart is 
that we can easily and reproducibly achieve IC cell injection in small rodents. It is possible 
to inject a target number of cells into the coronary arteries via the aorta from a side port of 
the aortic cannula while the heart beats normally. Using this approach, our group has 
proposed a model to measure the quantitative frequency and pattern of donor cells in the 
heart following IC injection in mice213. In this model, a known number of cells are delivered 
by injection into the aorta and the coronary effluent is continuously collected following 
injection. Knowledge of the initial donor cell number and counts of donor cells within the 
coronary effluent enable the calculation of the proportion of donor cells that are retained 
within the heart (see 4.3 for details).  An additional advantage of this model  is that we could 
directly and reproducibly inject antibodies or pharmacological substances to inhibit or 
stimulate adhesion molecules/ligands into the heart via the coronary tree, which would 
enable us to study the molecular mechanisms of retention. It should be noted that 
intravenous or intraperitoneal administration of such agents that affect donor cell retention 
are not guaranteed to reach the heart in a reproducible manner.  A further advantage of this 
model is that it  is also easy to induce ischaemia-reperfusion (I-R) injury, by halting and 
restarting perfusion (global I-R injury), or by ligation of left coronary artery (LCA) followed 
by ligature release for reperfusion (regional I-R injury).  
Limitations of this Langendorff-based model may include the lack of blood 
components (cytokines, growth factors, and blood cells such as neutrophils and platelets) in 
the perfusate. However, I believe that this potential limitation will not be significant for my 
project. It is important to note that donor cell retention in the usual clinical procedure takes 
place under almost complete crystalloid perfusion conditions, where donor cells are 
suspended with non-blood, serum-free solution/buffer and injected into the coronary artery 
while occluding the proximal portion of the coronary artery and thereby preventing pulsatile 
blood flow45,154. Hence, most blood components are flushed out with crystalloid solution, 
and thus the intravascular space of my interest is almost blood-free under a non-pulsatile 
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condition. Although the Langendorff model cannot be used for long-term studies, various 
reports have indicated that the Langendorff-heart perfused with crystalloid buffer confers a 
stable circulation without any damage to the coronary endothelium or myocardium for at 
least 2 hours214-217. It has been reported that 2 hour normoxic crystalloid perfusion does not 
increase the expression of adhesion molecules such as P-selectin217,218. Consistent with this, 
our group have previously confirmed with histological analyses that 1 hour crystalloid 
perfusion did not influence expression of major adhesion molecules including P-selectin, 
ICAM-1 and VCAM-1 on the coronary endothelium213.  
In this thesis, the Langendorff-based model in rat will be used to further investigate 
initial retention of donor adult stem/progenitor cells after IC injection. 
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1.8.   Potential mechanisms responsible for initial donor cell 
retention  
 
To date, the underlying mechanisms of the initial retention of any type of stem/progenitor 
cells following IC injection remain largely unknown. It could be speculated that there are at 
least two different mechanisms.  One could be a physical, mechanical entrapment of injected 
donor cells within the vascular lumen (“passive retention”). The other responsible 
mechanism may be similar to that of leukocyte-endothelial adhesion, with a specific group 
of adhesion molecules and their ligands playing an important role (defined as “active 
retention”). The balance between active and passive cell retention may depend on injection 
conditions (including injection pressure and / or volume), the condition of the donor cells 
and the environment of the recipient coronary vessels. 
 
1.8.1. Passive retention (mechanical entrapment) 
Donor stem/progenitor cells injected into the coronary arteries may settle within the lumen 
of coronary vasculature by mechanical (passive) entrapment. This mechanism of retention 
may dominate when cells are injected into hearts with normal, intact coronary endothelium 
(without significant expression of adhesion molecules). Typical examples for this could 
include injection into chronic ischaemic or dilated cardiomyopathic hearts. For this passive 
retention, it could also be speculated that the size of donor cells may have an impact on the 
initial donor cell retention. In a semi-quantitative study using a porcine AMI model, Ly and 
colleagues used in-vivo open-chest bioluminescence imaging to determine cell retention for 
the first 60 minutes after IC injection of the same number of BMMNC or MSC90. As a 
result, they showed that a greater number of MSC, which have a larger cell size, were found 
in the heart at all time points measured, compared to BMMNC. This difference in retention 
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at 60 minutes after IC injection is likely to be a consequence of enhanced initial retention, 
minutes after injection.  
 
1.8.2. Active retention (adhesion molecule-related mechanism) 
Leukocyte-endothelial interaction is a multistep cascade of sequential molecular processes, 
which have been determined using techniques such as intravital microscopy and in-vitro 
flow models with genetic knock-out/-in transgenic models, with or without antibody 
neutralization203. In the normal condition (i.e. absence of inflammation), leukocytes rarely 
interact with the vessel wall but after an inflammatory stimulus is applied, the leukocyte-
endothelial cascade occurs in the post-capillary venules. Upon the initiation of acute 
inflammation, leukocytes roll along the vessel walls at a reduced velocity; this step is 
mediated by the selectin family of adhesion molecules. A few minutes later, some rolling 
cells arrest and undergo a change in their conformational shape. This step, known as 
adhesion, is influenced by the integrin-family including the β2-integrins, such as 
lymphocyte-function associated-antigen 1 (LFA-1) and MAC-1219,220. Extravasation of cells 
crossing the endothelial barrier and migration into the extravascular tissue then follows, 
requiring activation or upregulation of a specific distinct set of adhesion molecules such as 
Intercellular adhesion molecule-2 (ICAM-2), junctional adhesion molecule – A (JAM-A) 
and PECAM-1 which have a distinct and sequential role in mediating neutrophil 
transmigration202. 
In several types of stem/progenitor cells, it has been shown that selectins are 
involved in the active retention (donor cell-endothelial adhesion) processes221-223. Ryzhov et 
al. showed the importance of the P-selectin/PSGL-1 axis on retention of embryonic EPC 
within the heart. They showed using mouse models that short-term stimulation of adenosine 
receptors rapidly enhanced EPC adhesion to cardiac endothelial cells in vitro, and increased 
retention using DiI-labelled cells injected into a Langendorff perfused heart (assessed only 
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semi-quantitatively using immunohistochemistry of collected heart specimens; a different 
model from our new method). These effects of adenosine on EPC adhesion in vitro could be 
partially attenuated by the application of either a P-selectin inhibitor or a blocking agent 
against PSGL-1223. Oh et al. examined the effects of E-selectin on retention, by investigating 
the homing of EPC to an ischaemic limb in mice after intracardiac injection. EPC obtained 
from GFP+/+ mice underwent intracardiac injection into wild-type mice and showed that 
administration of E-selectin enhanced EPC homing to an ischaemic hindlimb (semi-
quantitatively assessed by immunohistochemistry) and that EPC injection into E-selectin 
knockout mice impaired homing, although this could be rescued by local E-selectin 
treatment221. Vajkoczy and colleagues have reported that blocking P-selectin, E-selectin and 
PSGL-1 impaired donor embryonic EPC arrest in the tumour microcirculation, using a 
murine intravital microscopy model222. It has also been shown that human cells do not 
express E-selectin but that ex-vivo engineering of human MSC, can convert CD44 into a    
E-selectin/L-selectin ligand which enhances the retention of such engineered cells into 
mouse bone marrow224.  
The importance of integrin interactions in stem/progenitor cell retention under 
several specific conditions has been demonstrated. Wu and colleagues used mouse models to 
investigate ICAM-1-integrin interactions on retention. They reported that EPC attachment to 
endothelial cells in vitro was diminished by the blockade of CD18; ICAM-1’s ligand on 
donor cells. After the administration of DiI labelled EPC — with or without a CD18 
antagonist — into the LV cavity of 3-day-post-MI animals, the CD18 antagonist was found 
to almost completely abolish EPC retention in the heart, assessed by whole heart 
digestion/cell counting and immunohistochemistry225. Segers et al. showed that VCAM-1 
which interacts with α4-integrins may have an important role in MSC retention, using rat in 
vivo and in vitro models. They demonstrated that pre-treating donor cells and the 
endothelium with TNF-α and IL1-β enhanced adhesion of DiI labelled MSC to cardiac 
microvascular endothelial cells in both static and dynamic flow conditions and also 
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increased retention in the normal heart after left ventricular cell injection. The increased 
adherence observed in vitro after inflammatory cytokine administration was completely 
abolished by the administration of anti-VCAM-1 antibodies, but not anti-ICAM-1 
antibodies226.  
Although none of these studies are appropriately quantitative and they did not 
examine IC injection directly, taken together they suggest that adhesion molecules may play 
an important role in initial retention of stem/progenitor cells in the heart following IC 
injection. This concept requires further clarification. 
 
1.8.3. Timescale of endothelial adhesion molecule expression during ischaemia-
reperfusion (I-R) 
For studying the role of adhesion-molecules involved in the mechanisms of donor cell 
retention after IC injection, it is essential to understand the timescale and degree of adhesion 
molecule expression on coronary endothelium after I-R. In summary based on the following 
data, after 30 minutes of ischaemia and 30 minutes of reperfusion - the condition that will be 
used in this study - it is expected that P-selectin would be upregulated and detectable, but 
that ICAM1, VCAM1 or E-selectin would not be upregulated/detectable in the coronary 
endothelium. 
P-selectin: P-selectin is synthesized constitutively in endothelial cells and stored 
intracellularly but it is mobilized rapidly to the cell surface after stimulation227. In 
Langendorff I-R studies in guinea pigs218 and rats228, P-selectin was not detected after 30 
minutes ischaemia by immunohistochemistry, but was detectable after 15 minutes 
reperfusion. P-selectin upregulation after 30 minutes reperfusion has also been confirmed in 
a mouse Langendorff model213. The time course of P-selectin upregulation after reperfusion 
was also determined in a rat open-chest model with 45minutes of transient LCA ligation and 
reperfusion up to 6 hours. It was found that immunohistochemical expression of P-selectin 
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occurred at 5 minutes of reperfusion (2-fold expression vs. controls) and increased further at 
30 minutes (3 fold expression vs. controls), tailing off thereafter229. Similar findings were 
reported in a cat LCA ligation model with 90 minutes of myocardial ischaemia followed by 
reperfusion up to 270 minutes; P-selectin was immunohistochemically detected at 20 
minutes post reperfusion and gradually declined thereafter230 with no detectable expression 
after 270 minutes of reperfusion231.   
ICAM-1: Immunohistochemistry in a cat LCA ligation model of 90 minutes ischaemia and 
270 minutes reperfusion demonstrated that ICAM-1 was expressed at a low level in control 
myocardium. The ICAM-1 level slowly progressively increased through 0, 10, 20 and 60 
minutes reperfusion with a significant increase at 150 minutes and a greater increase at 270 
minutes230. Supporting these findings, a Langendorff I-R model with 30 minutes reperfusion 
found that ICAM1 was not upregulated when assessed by immunohistochemistry213 and a rat 
LAD ligation study reported that ICAM-1 was upregulated after 120 minutes reperfusion232. 
Furthermore, a mouse open-chest I-R study found that a low level of ICAM-1 was present in 
sham operated mice but that this was upregulated after 60 minutes ischaemia and 60 minutes 
reperfusion233. However, these timings of ICAM-1 upregulation following reperfusion have 
not been universally repeated.  In a dog I-R study with reperfusion for 1 hour, 3 hours or 24 
hours, no differences in ICAM-1 immunohistolabelling could be observed between normal 
or reperfusion hearts. The authors, however, found that ICAM-1 mRNA increased 10-fold 
from 1 hour to 24 hours post-reperfusion234. Bowden and colleagues also failed to 
demonstrate immunohistochemical ICAM-1 staining at 3 or 24 hours post reperfusion in a 
mouse left coronary artery ligation model235. 
VCAM-1: Upregulation of VCAM-1 occurs at a later time point post-reperfusion, as shown 
in a mouse LCA ligation study in which few VCAM-1 vessel were seen in control animals 
by immunohistochemistry but after 24 hours of reperfusion there was a increase in the 
number of VCAM-1 positive cells. This increase was not observed at 3 hours post 
reperfusion235. In a mouse model, VCAM-1 was not observed by immunohistochemistry 
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after 30 minutes of reperfusion213. Osborn and colleagues found that VCAM-1 mRNA was 
barely detectable in normal HUVEC or HUVEC stimulated by TNF-α. However, the mRNA 
levels greatly increased by 2 hours after stimulation and remained high for 72 hours236. 
PECAM-1: PECAM-1 is found at the intercellular junction of endothelial cells. It is 
generally thought that the major ligand for PECAM-1 is PECAM-1 on leukocytes237. The 
expression of PECAM-1 has been confirmed in normal and I-R hearts in a monkey closed 
LCA balloon occlusion model116.  
E-selectin: E-selectin (CD62E) on endothelial cells is a ligand of CD44 on leukocytes56,57. A 
feline LCA-ligation model with 90 minutes of ischaemia with 0, 10, 20, 60, 150 and 270 
minutes of reperfusion did not demonstrate immunohistochemical E-selectin expression230. 
A study in monkeys also failed to detect E-selectin in normal hearts or in a closed chest 
LCA-balloon occlusion MI model with 30-50 minutes ischaemia and 3-5 hours 
reperfusion238. E-selectin is not expressed in unstimulated endothelial cells; it is observed 
only after de novo synthesis 4-6 hours following cytokine or bacterial endotoxin 
stimulation239.
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Chapter 2 - AIMS AND HYPOTHESES 
 
Transplantation of adult stem/progenitor cells is a promising approach for the treatment of 
heart disease, but there is a need for further understanding and refinement of the protocol if 
it is to enter widespread clinical use. One of the major issues facing this emerging treatment 
is the choice and/or optimization of cell-delivery routes. Antegrade IC injection has 
important advantages in that it leads to physiological dissemination of donor cells, that it 
could be utilized in many hospitals without significant additional investment, and that it is 
less invasive compared to other techniques. In fact, this is the route which has been most 
commonly used in current clinical trials and its safety and feasibility has been proven in a 
wide range of clinical settings.  
However, poor initial retention of donor stem/progenitor cells is an important limitation 
of this method, which will have a significant impact on therapeutic outcomes. The aims of 
this thesis intend to characterise initial donor cell retention in a quantitative, comprehensive 
manner and also to investigate the mechanisms responsible for initial retention, using an 
original rat ex-vivo Langendorff-perfused heart model. I will mainly study BMMNC, which 
are the most frequently used donor cell type in current clinical trials. The clinical effects of 
IC injection of autologous BMMNC, although small, have been proven by recent studies 
including a Cochrane database meta-analysis27. Specific hypotheses/aims in this project 
include: 
1. Our original model using Langendorff-perfused rat beating hearts will provide 
reproducible and quantitative information about initial retention of donor cells after 
IC injection. 
2. Initial donor cell retention will occur as a result of passive physical entrapment 
within the vasculature and/or active adhesion to the vascular endothelium via 
adhesion molecule-mediated cell-cell interactions. Therefore, the frequency, pattern 
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and underlying mechanisms of retention of stem/progenitor cells will vary between 
donor cell-types, which have different cell size and different expression profiles of 
endothelial adhesion-related molecules.  
3. The pattern and frequency of initial retention of donor cells will also be affected by 
the condition of recipient hearts, including the impact of prior I-R injury that will 
alter the expression profile of adhesion molecules on endothelial cells. 
4. The frequency and pattern of initial retention of IC injected donor cells will be 
affected by the cell number injected. Injection of a higher cell number will result in 
superior retention, but administration of too many cells  introduces the risk of 
coronary embolism. The result obtained will suggest the optimal cell number for IC 
injection that achieves the greatest retention without coronary embolization. The 
optimal cell number will be dependent on donor cell-types and the host heart 
condition. 
5. There will be a different frequency of donor cell retention among the different 
anatomical areas of the left ventricular wall (i.e. endocardial vs. epicardial areas).  
6. BMMNC are a heterogeneous cell population containing several distinct stem cell 
populations, including EPC, MSC and haematopoietic stem cells. Within this mixed 
population, certain subpopulations will show a greater ability to be retained in the 
heart than others. Identification of such subpopulations will be important in 
understanding BMMNC transplantation. 
7. Initially retained (adhered or entrapped) donor cells to the vascular endothelium will 
subsequently undergo transendothelial migration into the myocardial interstitium or 
integration into the vascular walls. The time scale and frequency of these events will 
be clarified. 
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The information obtained in this project will be translatable to clinical application of 
stem cell therapy and valuable for refining clinical protocols for IC injection of 
stem/progenitor cells. 
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Chapter 3 - METHODS 
 
3.1.   Introduction to the methods 
 
This chapter describes the materials and methods that were utilized in this project. All 
experiments were performed in the Translational Medicine and Therapeutics Laboratory, the 
Biological Sciences Unit and the Flow Cytometry Laboratory in the John Vane Building, 
Charterhouse Square Campus, Queen Mary University of London.  
All animal procedures were carried out in accordance with the Home Office Licence 
(PPL 70/7254). All animals were housed in the Biological Sciences Unit at Charterhouse 
Square Campus, Queen Mary University of London in identical constant conditions 
(ambient temperature 19oC, humidity 55%, 12 hours light/day). They were fed a standard rat 
pellet diet with water ad libitum. After arrival, animals were allowed to acclimatise for a 
minimum of two days in an appropriate room before any experimental (non-recovery) 
procedure was performed. Animals subjected to recovery surgery were allowed to 
acclimatise for 7 days after arrival, prior to surgery. 
 The experiments described in this thesis were all performed using rats. During the 
initial research for this thesis, a substantial effort was made to utilize mice and to optimize 
the experimental protocols using this species. One of the reasons for initially pursuing 
research in mice was because of the availability of house keeping GFP +/+ transgenic animals 
in our institution, which would have assisted with the immunohistochemistry experiments. 
However, generating the mouse ex-vivo Langendorff model proved extremely challenging 
and it was not possible to reproducibly generate mouse MSC linages. Therefore the decision 
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was made to transfer the research to rat; a species in which consistent reproducible data was 
obtained. 
All the experiments and statistical analyses were performed by me, with the 
exception of animal recovery surgery that was performed by Dr Masahiro Kaneko (see 
3.8.2). Dr Chiho Ikebe provided some assistance with MSC passaging steps, on occasion 
(see 3.4.1). Some assistance for fixation of some hearts in Paraformaldehyde after 
Langendorff perfusion (see 3.8.1) was provided by Dr Kenta Yasahiro, Dr Yasunori 
Shintani, Dr Chiho Ikebe, Dr Takuya Narita and Dr Masahiro Kaneko. All these colleagues 
were members of Professor Ken Suzuki’s laboratory at the William Harvey Research 
Institute. Dr Patrick Campbell provided invaluable assistance with presentation of the 
immunohistochemical analyses. 
 
3.2.   Buffers and solutions 
 
The following solutions were generated and utilized in this project as follows: 
Alizarin red: 
Alizarin red was prepared by adding 2g Alizarin Red (Fluka, Catalogue: 05600)) to 100 ml 
double distilled H2O (ddH2O; machine: Purelab Ulta, Elga). The pH was adjusted to 4.1-4.3 
by the addition of 1M HCl (Sigma-Aldrich, Catalogue 320331), using an Orion 210A meter 
(ThermoFisher Scientific, UK). The solution was then was manually filtered by hand 
injection through a 0.45 µl filter (Minisart, Sartorius Stedim) and was stored at room 
temperature until use. 
 
 
66 
 
Bovine serum albumin (0.5%): 
0.25 g Bovine Serum Albumin (Sigma, A4503) was added to distilled H2O. This was 
allowed to dissolve at room temperature, with the aid of agitation (Roller Mixter, Stuart, 
Catalogue: SRT6). The solution was then filtered by hand under aseptic conditions through a 
0.45 µm filter (Minisart, Sartorius Stedim) and stored at 4oC. 
Flow cytometry (FACS) buffer: 
40 ml of FACS buffer was manufactured by 37.84 ml HBSS (Sigma, catalogue H6648) with 
the addition of 2 ml of 0.5% bovine serum albumin (see above) and 160 µl of 0.5M EDTA 
(final concentration 2 mM; Gibro, catalogue: 15575-038). 
Immunohistochemistry blocking solution: 
10% goat serum (Gibco, Catalogue: 16210-064) was diluted in PBS / 0.025% triton X-100 
(Sigma, Catalogue: T8787).  
Modified Krebs-Henseleit (K-H) buffer:  
1980 ml ddH2O was added to a 2 liter glass bottle. The following ingredients were added: 
NaCl 14.026g, NaHCO3: 3.360g, Glucose: 3.603g (Sigma, Catalogue: G7528). This was 
then stirred with a magnetic stirrer (Bibby Scientific, UK). The following stock solutions 
were then added: 4 ml stock solution of KCl and KHPO4 (see below), 4 ml stock solution of 
MgSO4 (see below) and 2 ml stock solution of CaCl2 (see below). The final concentration of 
the buffer was NaCl 120 mM, KCl 4.5 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, CaCl2 2 
mM, NaHCO3 20 mM, Glucose 10.0 mM in 2L ddH2O)240 . The CaCl2 stock solution was 
added last to avoid precipitation. The solution was then stirred again as above and vacuum 
filtered into another 2 liter glass bottle through a 0.2 µm filter (PALL life sciences Supor 
200, P/N 66236) to remove particulate matter. The buffer was always used within 24 hours. 
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Stock solution of KCl and KHPO4 (×250):  
KCl 41.934g and KHPO4 20.414g were added to 500 ml ddH2O. The solution was vacuum 
filtered through a 0.45 µm filter (Nalge Nunc MF75) into a 500 ml sterile filter bottle (Nunc) 
and stored at room temperature. 
Stock solution of MgSO4 (×250):  
18.056g MgSO4 was added to 500 ml ddH2O. The solution was vacuum filtered through a 
0.45 µm filter (Nalge Nunc MF75) into a 500 ml sterile filter bottle (Nunc) and stored at 
room temperature. 
Stock solution of CaCl2 : 0.625M  
34.684g CaCl2 was dissolved in 500 ml ddH2O. The solution was vacuum filtered through a 
0.45 µm filter (Nalge Nunc MF75) into a 500 ml sterile filter bottle (Nunc) and stored at 
room temperature. 
Oil–red-O stain stock solution: 
The Oil-red-O stain stock solution was prepared by adding 150 mg Oil Red O (Sigma, 
catalogue O0625) to 50 ml 100% Isopropanol (2-propanol) (Sigma, catalogue: I9516), 
agitated for 10 minutes and stored at room temperature This stock solution was then diluted 
with distilled water to form a 60 % solution, subjected to filtration by hand injection through 
a 0.45 µm filter (Minisart, Sartorius Stedim) and used within 2 hours. 
Paraformaldehyde (4%):  
2g of Paraformaldehyde powder (Sigma-Aldrich; catalogue 6148) was added to 50 ml of 
PBS and warmed in a microwave (Mx95tcHinari Lifestyle)  to approximately 60-70oC, 
covered by a paraffin film (Parafilm M, Sigma-Aldrich, Catalogue: P7793-1EA). 200 µl 
aliquots of 1M NaOH (Sigma-Aldrich, Catalogue: S8045) were then added until the powder 
had completely dissolved. The same volume of 1M HCl (Sigma-Aldrich, Catalogue 320331) 
was then added to neutralize the solution. The flask was placed immediately on ice to cool, 
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was manually filtered by hand injection through a 0.45 µl filter (Minisart, Sartorius Stedim) 
and was stored at -20oC until use. 
Phosphate buffered saline (PBS): 
10 PBS tablets (Oxoid, Thermo-fisher scientific, BR0014G) were added to 1L ddH2O. For 
ex-vivo and in-vitro protocols, the PBS solution was filtered and autoclaved at 121oC for     
7 minutes (Boxer Laboratory Equipment, Ware, UK). 
Sodium citrate buffer: 
Sodium citrate buffer was prepared by adding 2.94g sodium citrate trisodium salt dehydrate 
(C6H5Na307•2H2O; from Sigma,-Aldrich, Catalogue: S4641) to 1L dH2O. The pH was 
adjusted to 6.0 by the addition of 1M citric acid (Sigma-Aldrich, Catalogue: C8, 315-5), 
using an Orion 210A meter (ThermoFisher Scientific, UK). 
Sucrose (30%): 
Sucrose 30% solution was prepared by adding 75mg Sucrose (Sigma, Catalogue: 84097) to 
250mls ddH20. The solution was then vacuum filtered through a 0.45 µm filter (Nalge Nunc 
MF75) into a 250 ml sterile filter bottle (Nunc) and stored at -4oC.  
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3.3.   Bone Marrow Mononuclear Cells (BMMNC) 
 
3.3.1. BMMNC isolation 
Male Sprague Dawley rats (aged approximately 6-8 weeks) were purchased from Charles 
River (UK), sacrificed by cervical dislocation following isofluorane anaesthesia (Abbot, 
Catalogue B506) using an inhalation anaesthesia unit (Vet Tech Solutions Ltd with 
Fluorovac Harvard Solutions). The femurs and tibias were dissected, carefully cleaned of 
adherent soft tissue and transported in sterile PBS (without antibiotics) on ice. The epiphyses 
were removed with a rongeur, and the marrow was harvested by inserting a syringe needle 
(19 gauge; BD Microlance 3, Catalogue number 301700) into one end of the bone whilst 
flushing with PBS into a 50 ml tube (Star Lab; catalogue: E1450-0200). Then, the bones 
were cut longitudinally using a rongeur and adherent bone marrow tissue was flushed with 
PBS into the tube. The 50 ml tube was centrifuged at 400 g for 5 minutes (Centrifuge 
machine: Universal 320, Hettich Zentrifugen) and the supernatant was aspirated and 
removed. The bone marrow cell pellet was resuspended, filtered through a 100µm filter (BD 
Falcon, catalogue number 352360) and centrifuged at 400 g for 5 minutes in a 15 ml Falcon 
tube. The supernatant was removed and the bone marrow cells were resuspended in 5 ml 
PBS (without antibiotics). The cell suspension was then carefully layered by pipette onto     
7 ml Ficoll (Sigma) using cut 1000 µl pipette tips (TipOne, Lot number Z107468R) and 
subjected to gradient centrifugation at 1040 g for 30 minutes with no brake.241 Cells at the 
interface were collected as BMMNC and washed three times in PBS. For washing, the cells 
were resuspended in PBS and centrifuged as above, followed by supernatant removal as also 
described above. 
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3.3.2. Efficiency of BMMNC isolation 
The number of BMMNC per animal isolated using the above protocol was determined by 
counting the number of living cells obtained (n=5 animals) using a haemocytometer 
(Hawksky, UK) or a Countess Automated Cell Counter (Invitrogen, UK). The viability of 
isolated BMMNC was determined by quantifying the proportion of unstained cells with 
Trypan Blue solution (Invitrogen, UK, final concentration 0.2%), viewed with light 
microscopy (Nikon TMS) utilizing a haemocytometer (Hawksky, UK). For cell counting 
with the haemocytometer, the number of cells in the four outer quadrants was counted. 
 
3.3.3. Morphology of collected BMMNC 
 The general cell morphology of freshly isolated BMMNC was examined using a cell smear 
under a phase-contrast microscope (BZ8000, Keyence). To generate a cell smear, 10 µl of 
BMMNC suspended in PBS was dropped onto one end of a Polylysine slide glass (Thermo 
Scientific). A coverslip (22×50mm, VWR International) was then placed at a 45o angle 
against the droplet on the opposite side to the slide glass end, until capillary motion spread 
the cell suspension along the coverslip. The coverslip was then pushed along the slide in a 
rapid motion which dragged the cell suspension along the slide glass242.  The slide was then 
allowed to air dry for 30 minutes at room temperature. 
 
3.3.4. Red blood cell contamination of BMMNC samples  
There was a concern that isolated BMMNC might be contaminated with red blood cells 
(RBC). To assess this possibility, isolated cells were dropped onto a Polylysine slide glass 
(Thermoscientific), smeared using a cover slip and allowed to air dry for 30 minutes as 
described in 3.3.3. The slides were fixed with 4% Paraformaldehyde for 15 minutes at room 
temperature and washed with PBS containing 0.025% triton X-100 (Sigma) by adding the 
slides into Coplin Jars for 5 minutes, 3 times. Cells were stained with DAPI (Roche; 1:1000 
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in PBS / 0.025% Triton X-100 (Sigma)) for 5 minutes and washed as above. The slides were 
mounted with fluorescence mounting medium (DAKO, catalogue: S3023) and viewed using 
a phase contrast microscope (BZ8000, Keyence). RBC proportions were determined by the 
ratio of non-nucleated (DAPI negative) cells to the total cell number.  
 
3.3.5. Cell size of BMMNC 
Collected BMMNC were suspended in PBS and analysed for cell size using a Countess 
Automated Cell Counter (Invitrogen, UK). The Countess Automated Cell Counter provides 
a measurement of cell size (diameter) in µm. The BMMNC suspension was added to a slide 
glass specific to the cell counter machine (Countess Cell Counting Chamber Slides / 
Invitrogen, UK, C10228). Cells smaller than 5 µm were not included in the final analysis, as 
they were deemed to be debris and the manufacturers recommend the Automated Cell 
Counter is used for cell analysis in the size range of 5 – 60 µm. The following settings for 
analysis were used (Sensitivity: 85.0, Min Cell Size 5 µm, Max Cell Size: 60µm, Circularity 
80). 
BMMNC from n=11 animals were independently analysed. For each sample, up to 8 
measurements were taken of cell size. Each measurement was imported into the Countess 
Automated Cell Counter software (Invitrogen, UK) and exported using a .csv file a spread-
sheet. This file format provides the total number of cells in each measurement subdivided by 
cell size. The sum of the number of cells per cell size was determined for each sample and 
this enabled the mean distribution of each cell size (%) to be calculated for each sample. The 
cell size distribution (%) was used as a measure of cell size, instead of the absolute cell 
number subdivided by cell size, because the cell numbers were different in each sample. 
Using the mean cell size distributions per sample, the overall mean sample size for the 11 
samples was calculated.  
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3.3.6. Flow cytometric characterisation of BMMNC 
Flow cytometry was performed to determine the expression of relevant cell surface markers 
on isolated BMMNC prior to cell injection. Surface marker characterisation of donor cells in 
the coronary effluent was also performed to determine whether cell populations with 
particular cell surface markers were preferentially retained.  
Based on previous reports (see Introduction), this project examined CD11b, CD18, CD29, 
CD31, CD34, CD44, CD45 and CD90. For each analysis, 1×106 BMMNC were placed in 
separate 1.5 ml eppendorf tubes and suspended in 100 µl of FACS buffer (see 3.2). The 
relevant primary antibody at an optimised concentration was added to each eppendorf tube 
and incubated on ice for 30 minutes. The antibodies used with their relevant controls are also 
described in Table 3-1. The eppendorf tubes were washed three times with FACS buffer; this 
was performed by aspirating the solution down to the pellet, resuspending in 1000 µl FACS 
buffer and resuspended in 100 µl of FACS buffer. When the primary antibodies were not 
conjugated with fluorescent markers, the appropriate secondary antibody was added (see 
Table 3-1), incubated on ice for 30 minutes and the samples were again washed three times 
with FACS buffer prior to analysis. To minimize background signal from secondary 
antibody administration, samples were treated with 5 µg/ml anti rat FAB antibody 
(Polyclonal goat FAB anti rat Ig (H+L), Southern Biotech, USA, Catalogue Number 3000-
01) for 30 minutes, followed by 3 times washing with FACS buffer, before secondary 
antibody administration. The samples were then incubated with 0.5 µg/ml Propidium Iodide 
(BD Pharmingen Catalogue number 55646) at room temperature for 15 minutes243 and 
analysis was then performed on a DAKOcyan using Summit 4.3 software. 
 For data analysis, cells were included in the analysis if they were viable and within 
the main population of cells. Viability was first determined using Propidium Iodide (PI) 
staining using the PE-Cy5 (or FL3) channel. The proportion of dead cells measured by 
Propidium Iodide in all the staining protocols was >90%, a level which is deemed to be 
acceptable for flow cytometry protocols244. Viable cells were then gated and the main 
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population of cells were selected based on observed using histograms using Forward Scatter 
(FS) and Side Scatter (SS) on logarithmic scales (Figure 3-1). 
 
 
Figure 3-1: Example of selection of BMMNC for flow cytometry using viability, cell size and cell 
granularity. Unselected BMMNC were incubated with PI and viability (R1) was determined by flow 
cytometry (DakoCyan flow cytometer and Summit 4.3 software). Viable cells were not stained with 
PI. Viable cells were then gated and the main population of viable cells were then gated again (R2), 
according to cell size (forward scatter: FS) and cell granularity (side scatter: SS). In this analysis, 
92.5% of cells were viable and 90.7% of the total cells were included in the final analysis. 
 
Analyses for FITC- and PKH67-positivity were analysed on the FITC (or FL1) 
channel. Alexa-647 labelled cells were analysed on the APC (or FL4) channel. Voltage 
gating was determined from relevant negative controls. Histograms were generated with the 
channel of interest plotted against SS (refer to Figure 3-2). 
GATING.
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Figure 3-2: Example of quantification of BMMNC surface marker using flow cytometry. A control 
BMMNC sample was stained with IgA primary antibody and Alexa-647 secondary antibody (A). A 
separate BMMNC sample was incubated with anti CD11b primary antibody and Alexa-647 secondary 
antibody (B). Analysis using Dakocyan flow cytometer and Summit 4.3 software. There was a low 
level (4.9%) of non-selective staining in the control sample (lower right quadrant: R6) and the 
proportion of this staining was the same (4.3%) in the CD11b sample. Cells in the upper right 
quadrant (R4) were therefore deemed to represent positivity for CD11b. The proportion of positive 
cells after CD11b incubation was 16.0% and 0.7% in the control sample. For this sample therefore, 
CD11b positivity was deemed to be 15.3%.  
 
      A          B 
IgA control CD11b
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3.4.   Mesenchymal Stem Cells (MSC) 
 
3.4.1. Isolation, culture and passaging of MSC 
MSC were isolated from bone marrow of adult Sprague Dawley rats (6-8 week old males; 
purchased from Charles River, UK) as previously described73 with modifications. Whole 
bone marrow cells were isolated as described for BMMNC above (refer to 3.3.1), excluding 
the gradient centrifugation steps. Collected whole bone marrow cells were placed in 25cm2 
flasks (Nunc) with an initial plating concentration of approximately 1×106 cells/cm2, 
cultured in αMEM (Gibco) with 20% inactivated fetal bovine serum (FBS) containing        
L-glutamine (200 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml); (Sigma, 
catalogue T3924), at 37°C in a humidified atmosphere containing 95% air / 5% CO2. 
(incubator: Binder, Germany).The culture medium was aspirated and changed every         
48-72 hours without additional washing. When cell confluency reached 80-90%, cells were 
passaged by detachment using 0.25% Trypsin / 0.2% EDTA (Sigma, catalogue T3924). 
Plating concentrations for subsequent passages were approximately 2.5×104 cells/cm2. 
 
3.4.2. Morphology of MSC 
The morphology of cultured MSC was assessed using phase contrast light microscopy 
(Nikon TMS) over progressive passaging. Images were acquired with a Nikon Coolpix 2500 
x4 magnification at passage 0, passage 1, passage 2 and passage 3. 
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3.4.3 Cell size of collected MSC 
Collected MSC were suspended in PBS and analysed for cell size using a Countess 
Automated Cell Counter (Invitrogen, UK) as described (refer to 3.3.5). Cells smaller than    
5 µm were not included in the final analysis, as they were deemed to be debris and the 
Automated Cell Counter is recommended by the manufacturers for cell analysis in the size 
range of 5 – 60 µm. The following settings for analysis were used (Sensitivity: 85.0,        
Min Cell Size 5 µm, Max Cell Size: 60µm, Circularity 80). 
For cell size analysis of passage 2 cells, n=17 separate 175cm2 flasks, in which MSC 
were cultured, were analysed. For passage 3 cells, 7 different 175cm2 flasks were analysed. 
For passage 4 cells, 9 different 175cm2 flasks were analysed. Each measurement was 
imported into the Countess Automated Cell Counter software (Invitrogen, UK) and analysed 
as described (refer to 3.3.5) for each passage.  
 
3.4.3. Cell surface marker expression of MSC  
Expression of CD29, CD34, CD45, and CD90245 (refer to 1.3.3) in collected MSC were 
assessed by flow cytometry246. 3×105 MSC at passage 5 were placed in Protein Lobind      
1.5 ml eppendorf tubes (Sigma, Dorset, England); it was found that this led to a lower rate of 
MSC loss following centrifugation. MSC were subjected to the same antibody staining 
conditions as described for BMMNC (refer to 3.3.6) using the antibodies described in    
Table 3-2. Following staining, all cells were stained with Propidium Iodide for 15 minutes 
prior to analysis (final concentration 0.5µg/ml; BD Pharmingen). Analysis was performed as 
described for BMMNC (refer to 3.3.6).  
78
 
 Ta
bl
e 
3-
2:
 A
nt
ib
od
ie
s u
se
d 
fo
r f
lo
w
 c
yt
om
et
ry
 to
 a
ss
es
s t
he
 su
rf
ac
e 
ex
pr
es
si
on
 o
f p
ro
te
in
s o
n 
cu
ltu
re
d 
M
SC
 
 
Fl
uo
re
sc
en
t-
co
nj
ug
at
ed
 
Is
ot
yp
e 
M
an
uf
ac
tu
re
r 
W
or
ki
ng
 
C
on
ce
nt
ra
tio
n 
C
on
tro
l 
A
nt
ib
od
y 
Se
co
nd
ar
y 
an
tib
od
y 
Pr
im
ar
y 
A
nt
ib
od
ie
s 
C
D
29
 
A
le
xa
 F
lu
or
 6
47
 
co
nj
ug
at
ed
 m
on
oc
lo
na
l A
rm
en
ia
n 
H
am
st
er
 Ig
G
 a
nt
i 
m
ou
se
 a
nd
 ra
t (
C
lo
ne
 H
M
β1
-1
) 
B
io
le
ge
nd
 In
c.
, C
A
, U
SA
, C
at
al
og
ue
 
10
22
15
 
5µ
g/
m
l 
Ig
G
 A
le
xa
 6
47
 
N
/A
 
C
D
34
 
N
o 
pu
rif
ie
d 
m
on
oc
lo
na
l m
ou
se
 Ig
G
1 
 
an
ti 
ra
t a
nd
 h
um
an
 C
D
34
 (I
C
O
11
5)
 
Sa
nt
a 
C
ru
z,
 C
A
, U
SA
,  
C
at
al
og
ue
: s
c7
32
4 
10
µg
/m
l 
Ig
G
k1
 
A
le
xa
 6
47
 
C
D
45
 
FI
TC
 
C
on
ju
ga
te
d 
pu
rif
ie
d 
m
on
oc
lo
na
l m
ou
se
 Ig
G
 a
nt
i-r
at
 
C
D
45
 
ch
em
ic
on
 in
te
rn
at
io
na
l C
at
al
og
ue
: 
cb
15
02
f 
5µ
g/
m
l 
Ig
G
 
N
/A
 
C
D
90
 
FI
TC
 
C
on
ju
ga
te
d 
pu
rif
ie
d 
m
on
oc
lo
na
l m
ou
se
 Ig
G
1 
an
ti-
ra
t 
C
D
90
/th
y1
 (O
C
-7
 c
lo
ne
) 
A
bc
am
, C
at
al
og
ue
: a
b2
26
-1
00
 
1µ
g/
m
l 
Ig
G
 
N
/A
 
Se
co
nd
ar
y 
A
nt
ib
od
ie
s 
A
nt
i-m
ou
se
 Ig
G
 
A
le
xa
-6
47
 
G
oa
t a
nt
i-m
ou
se
 Ig
G
 (H
+L
) 
hi
gh
ly
 c
ro
ss
-a
ds
or
be
d 
In
vi
tro
ge
n 
A
21
23
5 
20
µg
/m
l 
 
 
C
on
tro
l A
nt
ib
od
ie
s 
Ig
G
 
A
le
xa
 F
lu
or
 6
47
 
A
rm
en
ia
n 
H
am
st
er
 Ig
G
 is
ot
yp
e 
co
nt
ro
l  
U
SA
 (c
lo
ne
 e
bi
o2
99
ar
m
) 
eb
io
sc
ie
nc
e 
2µ
g/
m
l 
 
N
/A
 
Ig
G
k1
 
N
o 
pu
rif
ie
d 
m
ou
se
 Ig
G
k1
 is
ot
yp
e 
co
nt
ro
l 
C
lo
ne
 M
O
PC
-3
1C
 
B
D
 P
ha
rm
in
ge
n 
C
at
al
og
ue
 5
57
27
3 
5µ
g/
m
l 
 
A
le
xa
 6
47
 
Ig
G
1 
FI
TC
 
C
on
ju
ga
te
d 
m
ou
se
 Ig
G
1 
ne
ga
tiv
e 
co
nt
ro
l  
A
bd
 se
ro
te
c 
m
ca
92
8a
48
8f
 
5µ
g/
m
l 
 
N
/A
 
  
 
 
79 
3.4.4. Differentiation capacity of MSC  
At passage 3, the differentiation potential of MSC into adipocytes and osteocytes was 
examined to confirm the identity of the cells. Adipogenic differentiation assays were 
performed with cells plated246,247 at 2×104 cells/cm2 in a base medium (α-MEM containing 
with15 % FBS and penicillin (100 U/ml) and streptomycin (100 mg/ml), supplemented with 
100 µM isobutyl methylxanthine (Sigma-Aldrich I7018), 60 µM indomethacin (Sigma-
Aldrich, I7378), 1 µg/ml human insulin (Sigma, catalogue: I9278) and 0.5 µM 
hydrocortisone (Sigma-Aldrich, H0135)73. Osteogenic differentiation assays were performed 
with plated cells246,247 at 3×103 cells/cm2 in a base medium supplemented with 0.1 µM 
dexamethasone (Sigma-Aldrich, D4902), 10 mM B-glycerophosphate (Sigma-Aldrich, 
G9422) and 0.05 mM ascorbic acid (Sigma-Aldrich, A4403)248. Immediately following 
plating of passage 3 cells, cells were incubated with the differentiation media. Controls were 
set up using MSC plated with the same cell concentration in a base medium without 
supplementation. Assays were performed in 6 well plates (Nunc). The medium was changed 
every 48-72 hours and differentiation was analysed by the methods described below on day 
21. The controls were also cultured for 21 days and subjected to the same staining 
procedures. 
Adipogenic differentiation was assessed by Oil-Red-O staining with counterstaining 
using haematoxylin. Oil–red-O staining solution was prepared (see 3.2) and used within       
2 hours. The cells were washed with PBS twice and fixed with 4% PFA for 10 minutes at 
room temperature. They were further washed three times with PBS and the cells were then 
incubated with 60% isopropanol solution for 1 minute. That solution was discarded and the 
cells were then incubated with the Oil-O-Red solution for 10 minutes at room temperature. 
The cells were washed once with 60% isopropanol (Sigma, catalogue: I9516) and then three 
times with double distilled water. The cells were then counterstained with haematoxylin 
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1g/L (Sigma-Aldrich catalogue MHS16) for 5 minutes, rinsed in distilled water and then 
observed by a microscope (BZ7000, Keyence).  
Osteocyte differentiation was confirmed by co-localization of alkaline phosphatase 
staining with Alizarin Red (for calcium deposition). The cells were washed twice with PBS, 
fixed with 4% PFA for 10 minutes and washed with distilled water for a further 3 times. To 
detect alkaline phosphatase, BM Purple (No 11442074001, Roche) was added to the cells 
and incubated at room temperature for 1 hour. The cells were then washed again with double 
distilled water three times. The cells were then incubated in Alizarin Red solution (refer to 
3.2) until the colour became visualized (for 30 seconds – 5 minutes). The cells were further 
washed with double distilled water, counter stained with haematoxylin for 5 minutes and 
then observed by a microscope (BZ7000, Keyence).  
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3.5.   Labelling of donor cells 
 
3.5.1. Choice of PKH67 for donor cell labelling 
Labelling of donor stem/progenitor cells is required for their clear discrimination from 
recipient heart cells after transplantation, particularly in histological studies. PKH67 was 
chosen among various types of commercially available dyes based on its high-efficiency and 
strong labelling of a range of cell types, sufficiently-long half-life (10-12 days), low cell-
toxicity249, utility for fluorescent microscope studies250 and previous reports using it for 
tracking cell fate following IC injection in vivo183,251. 
 
3.5.2. PKH67 staining of BMMNC 
The labelling condition for BMMNC using a PKH67 labelling kit (Sigma; MIDI67) was 
optimized as follows. Freshly isolated BMMNC were washed in PBS and re-suspended in   
1 ml Diluent C (Sigma) at a concentration of 2×107 cells/ml. Then 1 ml of double the final 
required concentration of PKH67 was added to the cell suspension and mixed gently with a 
pipette. Final concentrations of 0 µM (control), 2 µM for 5 minutes and 2 µM for 10 minutes 
were tested (2 µM is the final concentration recommended by the manufacturers). 2 ml FBS 
(Sigma-Aldrich, Dorset, UK) was then added and incubated for 2 minutes to stop the 
staining reaction. The cell-dye mixture was then centrifuged at 400g for 10 minutes and 
resuspended in 10 ml PBS. The solution was transferred to a new tube (to remove residual 
dye bound to the tube walls) and washed in PBS. All reactions were performed at room 
temperature with the cells shielded from light. Then, the viability of the cells was assessed 
with trypan blue staining (Sigma). For this, cells were counted using a haemocytometer 
(Hawksky, UK); the number of cells in the four outer quadrants was counted and the 
percentage of non-blue (viable) cells to total cells was calculated. The efficiency of PKH67 
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staining was determined by fluorescent microscopy and bright field imaging (BZ7000, 
Keyence); the proportion of PKH positive cells to the total number of cells was calculated.  
 
3.5.3. Possible changes in BMMNC surface marker expression by PKH staining  
PKH67 is a cell-membrane labelling dye, and this might affect the surface marker 
expression of BMMNC. To assure that this was not the case, PKH67-stained cells and 
unstained cells were subjected to flow cytometric analysis as described above (refer to 
3.3.6).  
 
3.5.4. PKH staining of MSC 
For optimization of PKH staining of MSC, passage 3 MSC were obtained in a similar 
fashion to cell passaging using trypsinization. The labelling condition for MSC using a 
PKH67 labelling kit (Sigma; MIDI67) was optimized as follows. Cultured MSC were 
washed in PBS and re-suspended in 1 Diluent C (Sigma) at a concentration of 2×107 
cells/ml. Then 1 ml of double the final required concentration of PKH67 was added to the 
cell suspension and mixed gently with a pipette. Final concentrations of 0 µM (control),       
2 µM for 5 minutes and 2 µM for 10 minutes were tested (2 µM is the final concentration 
recommended by the manufacturers). 2 ml FBS (Sigma-Aldrich, Dorset, UK) was then 
added and incubated for 2 minutes to stop the staining reaction. The cell-dye mixture was 
then centrifuged at 400g for 10 minutes and resuspended in 10 ml PBS. The solution was 
transferred to a new tube (to remove residual dye bound to the tube walls) and washed in 
PBS. All reactions were performed at room temperature with the cells shielded from light. 
Then, the viability of the cells was assessed with trypan blue staining (Sigma). For this, cells 
were counted using a haemocytometer (Hawksky, UK); the number of cells in the four outer 
quadrants was counted and the percentage of non-blue (viable) cells to total cells was 
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calculated. The efficiency of PKH67 staining was determined by fluorescent microscopy and 
bright field imaging (BZ7000, Keyence); the proportion of PKH positive cells to the total 
number of cells was calculated.  
 
3.6.   The isolated Langendorff-perfused heart model – normal rat 
heart model 
 
The Langendorff-based, isolated, perfused heart model is a popular, well-established model 
in cardiovascular research, which has been used for several decades209,210,240. Use of an 
isolated ex-vivo heart ensures the absence of confounding effects from other organs and 
circulating factors such as clotting factors and neurohormonal substances. I applied this 
method for quantitative measurement of initial donor cell retention after IC cell injection in 
rats. This section describes the Langendorff perfusion technique using normal rat hearts. 
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3.6.1. Langendorff apparatus assembly 
A photograph of the glassware, thermometer, 3-way tap and clips are shown in Figure 3-3.  
 
Figure 3-3: Langendorff equipment utilized for the project. (A) large warming reservoir for 
warming and oxygenating K-H buffer, (B) example of a clip to secure glassware, (C) small warming 
reservoir for warming K-H buffer, (D) warming jacket around heart, used for I-R protocols (E) 
oxygenator placed within A, (F) Three-way tap, (G) example of large clip to secure glassware.    
 
Water-jacketed glassware was utilized to form the reservoir to warm the buffer; the 
inner lumen contained the buffer for heart perfusion, whereas the outer lumen was subjected 
to a continuous flow of warmed double distilled H2O. Three pieces of glassware were used 
and positioned in series; a 35cm large upper reservoir which contained a volume of buffer of 
approximately 400 ml was sited at the highest point (Figure 3-4). Perfusate in this reservoir 
was supplied with oxygen/CO2 via an oxygenator. This was connected via nylon tubing to a 
30cm lower reservoir with a narrower diameter (with an inner lumen volume of 
approximately 50mls). Below the lower reservoir, a three way tap was connected with 
further tubing. A three-way cannula was attached to this tubing and a 14 gauge ridged 
cannula (Harvard) was connected to the lower aspect of this. Sited below the cannula, a 
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double lumen water jacked was placed which could be raised upwards to the level of the 
cannula. This was used to submerge the heart and maintain its stable temperature during 
ischaemia-reperfusion.  
A waterbath and pump (Techne TE10A tempette) was used to heat and circulate the 
double distilled water continuously. The water circuit and pump were connected to the outer 
lumens of the reservoirs and the water jacket in series. The set-up of the equipment is shown 
in Figure 3-4. A graphical representation of the Langendorff apparatus is shown in Figure   
3-5. 
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Figure 3-4: Photographs of set-up of Langendorff equipment. (A) The upper reservoir is seen at the 
top of the image held by two clamps. The lower reservoir is seen at the bottom aspect of the image 
also supported by one of two clamps. Plastic tubing connects the two reservoirs. (B) The lower 
reservoir, the three way tap and the water jacket were lined up in series. Below the lower reservoir, 
the three way tap (C) was sited. This was used to administer donor cells via the side port. 
A      B 
  
C 
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Figure 3-5: Diagrammatic representation of ex-vivo Langendorff apparatus.
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3.6.2. Krebs-Henseleit buffer 
Under the Langendorff unit, the isolated hearts were perfused with modified Krebs-
Henseleit buffer (refer to 3.2)240. This was utilized within 24 hours after generation. The 
buffer was gassed with continuous 95% O2 /5% CO2 (BOC) and maintained at 37oC. pH 
analysis using pH strips (VWR, Catalogue: 1.09584.1111) confirmed that the buffer pH was 
7.4 at the cannula tip. 
 
3.6.3. Dissection, cannulation and perfusion of the rat heart using a Langendorff unit 
Male Sprague-Dawley rats (200-300g) were purchased from Charles River, UK and weighed 
using a set of high precision scales (KERN PCB 1000-1, Ballingen, Germany). Rats were 
anaesthetized with isoflurane anaesthesia (Isoflo 100%, Abbott, USA) and administered with 
heparin via the intraperitoneal approach (Leo Pharma, FL, USA: 100 iU/kg). After 5 minutes 
(by which time the anticoagulant was macroscopically effective), cervical neck dislocation 
was performed, and a median sternotomy was performed. The heart was excised, placed 
immediately in ice-cold modified Krebs-Henseleit buffer and taken for immediate 
cannulation. A careful incision of the aorta was made at the level of the aortic arch enabling 
the ascending aorta to be cannulated with a blunt ended 14-gauge needle (Harvard) with the 
use of microscopy angled forceps. The aorta was temporarily clipped to the cannula and, 
once appropriate perfusion was confirmed, the aorta was secured to the cannula with a 5-0 
silk suture (Bear, Japan). A small cut was made in the proximal pulmonary artery to ensure 
that coronary effluent could drain freely. The heart was then fully perfused by the warmed, 
gassed modified Krebs-Henseleit Buffer at a constant pressure manually maintained at 95-
105 cmH2O. The perfused heart temperature was measured using a thermometer (Testo 925) 
with a fine wire probe (Testo 0602 0493). The equipment used for this procedure is 
described (Figure 3-6). 
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It was important to minimize the time from heart removal to establishment of ex-
vivo perfusion, because during this time hearts suffers ischemia. Following considerable 
training and practice, I was able to achieve this within 120 seconds of neck dislocation and 
frequently within a shorter time period.  
 
Figure 3-6: Surgical equipment used during the project for Langendorff heart cannulation.                   
(A) DeBakey Dissecting Forceps, FB401R, Aesculap (USA), 2mm wide, 150mm. (B) Joseph Straight 
Scissors, BC156R, Aesculap (USA), 150mm (C) Kocher 14cm Forceps, 914-0370, Gowllands 
Medical Devices Ltd (UK), (D) 100mm Microscopy Angled Forceps (n=2) BD321R, Aesculap 
(USA), (E) 12 cm straight Eye Scissors, 03-320-115, Allgaier instrumente (Germany). Instruments A-
C were used for removal of the heart from the mediastinum. Instruments (D, n=2) and (E) were used 
to hang the heart on the Langendorff apparatus. (A) and (B) were used to perform the median 
sternomy. (C) was used to clip and reflect the sternum superiorly to expose the heart. (A) and (B) 
were then used to careful remove the heart from the mediastinum at the level of the aorta. The heart 
was then placed in ice-cold Krebs-Henseleit buffer. Extraneous heart tissue was used using (E) with 
manipulation by (D) and then the heart was hung on the Langendorff apparatus using two examples of 
(D). 
 
A"
B"
D"
C"
E"
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3.6.4. Confirmation of appropriate heart perfusion 
Stable heart perfusion was confirmed by the consistent and appropriate volume of coronary 
effluent, pH of coronary effluent, stable appropriate heart rate measured by continuous ECG 
monitoring, and appropriate heart beating and contractility. Unlike some Langendorff 
perfusion protocols216,240, we opted not to utilize cardiac pacing to maintain heart rates; 
cardiac pacing might potentially mask imperfect perfusion and the absence of pacing would 
enable physiological heart rates with sinus rhythm and other haemodynamic parameters to 
be monitored. 
 ECG recording was made (BIOPAC System MP35) with electrodes (BIOPAC 
systems, SN410A201) to record the heart surface ECG. Analysis was undertaken using BSL 
Pro 3.7 software (BIOPAC systems). The positive electrode was clipped to the aortic 
cannula and both the negative and neutral electrodes were held gently against opposite walls 
of the LV. Heart rate was determined by measuring the mean R-R interval of 10 consecutive 
beats (see Figure 3-7). 
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Figure 3-7: Surface ECG analysis of Langendorff rat heart. BSL Pro 3.7 software (BIOPAC 
Systems) was used with the aid of a positive electrode clipped to the aortic cannula and two negative 
electrode positioned either side of the LV. The R-R interval - highlighted in black – has been 
computed to represent 333 beats per minute (shown top left). 10 consecutive R-R intervals were 
measured and the mean of these measurements was used to represent heart rate at any particular time.  
 
3.6.5. Coronary effluent collection and counting contaminating cells  
Coronary effluent was collected by holding a 50 ml Falcon tube directly under the perfused 
heart for 60 seconds. Serial collections of coronary effluent were made at specific time 
points. The number of cells passing into the coronary effluent per minute was assessed by 
determining the mean cell concentration (cells/ml) of two measurements, using either a 
haemocytometer (Hawksky, UK) or a Countess Automated Cell Counter (Invitrogen, UK). 
This concentration was then multiplied by the coronary effluent volume.  
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3.6.6. RBC leakage into coronary effluent 
Unexpectedly, a countable number of cells were observed in the coronary effluent without 
donor cell injection. These cells were assessed further. Five minutes after hanging the heart, 
the coronary effluent was collected, smeared on a Polylysine slide glass (Thermo Scientific) 
and air dried for 30 minutes (as described in 3.3.4). They were then fixed by briefly placing 
the slides in a Coplin Jar containing 100% methanol (Fisher Chemical, catalogue 
M/3950/PC17) and further air dried. The cells were then incubated with Haematoxylin 
(Sigma-Aldrich, catalogue: MHS16) for 5 minutes at room temperature. After washing with 
water, the slides were dried and observed by light microscopy (BZ7000, Keyence). The cells 
were found to have the typical morphology of RBC (refer to 3.3.4). Confirmatory evidence 
that the cells were not nucleated was obtained using DAPI staining. As detailed in 3.3.4, 
coronary effluent cells were smeared on a Polylysine slide glass and air dried for 30 minutes. 
The cells were then fixed with PFA 4% for 15 minutes at room temperature. After 3 washing 
steps with PBS, the cells were stained with DAPI (1:1000 in PBS) for 5 minutes followed by 
a further 3 washing steps. The slides were then mounted and viewed using a fluorescent 
microscope (BZ7000, Keyence). Control images were obtained for isolated BMMNC 
(without injection into the heart) which were fixed and stained using the same protocol. We 
serially counted the number of the RBC contained in the coronary effluent and found that the 
number of RBC decreased with time after perfusion. This number was less than 5×104 
cells/min, a figure much lower than the donor cell number in the coronary effluent by the 
time of IC cell injection (refer to 4.3.3). 
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3.6.7. IC cell injection into Langendorff-perfused hearts 
After 20 minutes stabilization of Langendorff perfusion, donor cells were administered into 
the isolated beating heart. At this time, the hearts were usually stably perfused with showing 
stable perfusion parameters such as coronary flow, heart rate, and regular sinus rhythm 
without arrhythmias. In addition, the number of RBC counted in the coronary effluent after 
20 minutes was low enough for the project’s purposes (refer to 4.3.3). That is to say, after 
cell injection, the donor cells would make up the great majority of cells in the coronary 
effluent; RBC would therefore only make a trivial contribution to the total coronary effluent 
cell number.  
 A designated number of donor cells (either BMMNC or MSC) were suspended in    
3 ml PBS and injected into the heart from a side port (3-way tap) of the aortic cannula using 
a 5 ml luer-lock syringe (BD Syringe, Catalogue: 301027). Cell injection was performed 
over 20 seconds. It was opted to use this timing because the mean coronary flow rates 
immediately prior to injection were approximately 9 ml/min (refer to 4.3.1) and injecting     
3 ml PBS cell solution over 20 seconds would therefore not substantially modify the 
coronary effluent flow rate. During injection, the aortic valve remains physiologically closed 
and all cells pass through the coronary circulation. The donor cells therefore enter the right 
and left coronary arteries.  
Donor cell number injected: It was important for the project to utilize a range of cell doses 
which mimic those used in clinical trials; weight adjusted for rat hearts. For clinical studies 
of IC injection of BMMNC, the cell number IC injected typically ranged from ≤1×108 (for 
example, the ASTAMI study154), ≤1×109 (REPAIR-AMI,46 Janssens et al,45 Huang et al252) 
and to ≤1×1010 (Kang et el,156 the BOOST study43,253). In contrast to our model where cells 
were injected into all the major coronary arteries (right, left anterior descending and left 
circumflex), clinical trials usually injected the cells into a single coronary artery. The 
assumption was made that the median cell number used in clinical trials was 1×109 
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BMMNC for a 75kg human and that a rat’s weight is 200g. Therefore the equivalent dose 
for a single rat artery would be 2.7×106 BMMNC, or 8×106 BMMNC injected into all three 
arteries. Based on this calculation, we decided to investigate the 3 BMMNC numbers; 1×106, 
8×106 and 40×106. 
Negligible donor cells retained in the Langendorff apparatus itself: This system was 
designed so that the dead space for cell injection was minimized (<20 µl). To confirm 
whether donor cells were retained in the Langendorff apparatus itself or the injection 
syringe/needle, 8×106 BMMNC suspended in 3 ml PBS were injected into the side port of 
the apparatus as described, without heart cannulation/perfusion (n=3). Subsequently 
warmed, oxygenated Krebs-Henseleit buffer was flushed through. All the flushed effluent 
was collected in a 50 ml Falcon tube and the cell concentration in the effluent was 
determined using a Countess Automated Cell Counter (Invitrogen, UK) to count the donor 
cell number flushed out. As a result, it was confirmed that no donor cells were retained in 
the Langendorff apparatus, injecting syringe or aspiration needle and that no cells ruptured 
during the injection process. (refer to 4.3.4). 
 
3.6.8. Coronary effluent cell counting and calculation of retention efficiency 
Coronary effluent cell concentrations (cells/ml) were assessed using a haemocytometer 
(Hawksky, UK) or a Countess Automated Cell Counter (Invitrogen, UK). The coronary 
effluent flow rate (ml/min) was noted and utilized to calculate the Coronary Effluent Cell 
Count at each minute (cells/min). At the same time, size of cells was measured by using a 
Countess Automated Cell Counter. All measurements were made in duplication.  
 Because it was noted that there was a low level of RBC contamination in the 
coronary effluent at the time of donor cell injection, a formula was developed to remove this 
contaminating factor, for the precise quantification of donor cell loss in the coronary 
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effluent, as below. Given that the RBC counts in the coronary effluent slowly decreased over 
time, it was decided to take a Baseline RBC Count which was the mean of the RBC count in 
the 1 minute immediately preceding cell injection and the count at 5 minutes following cell 
administration. It was confirmed that almost 100% of BMMNC leakage from normal hearts 
occurred within 5 minutes (refer to 4.4.2). Therefore, the Coronary Effluent Donor Cell 
Number in each minute was calculated at each minute after injection by the following 
formula: 
 (Coronary Effluent Cell Count) - (Baseline RBC Count) 
Total Donor Cell Number in the Coronary Effluent within 5 minutes was thus calculated as 
the sum of all included Coronary Effluent Donor Cell Number, for each of the first five 
minutes. If the Coronary Effluent Donor Cell Count value was negative, it was deemed that 
all the donor cells had exited the heart. The value for that minute and subsequent minutes 
were not included in subsequent analyses. Finally, Donor Cell Retention Efficiency (%) 
was calculated as follows: 
 
(Injected Donor Cell Number) – (Total Donor Cell Number in the Coronary Effluent) 
  _______________________________________________________________________ x 100 
                                                   (Injected Donor Cell Number) 
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A simplified version of the model for assessing donor cell retention is shown in Figure 3-8. 
 
Figure 3-8: Simplified version of modified ex-vivo Langendorff model for quantification of cell 
retention.  
 
3.7.   Ischaemia-Reperfusion (I-R) heart model 
 
It was hypothesised that I-R injury would change the expression of adhesion-related 
molecules on the coronary endothelium, or change the status of the microvasculature, and 
that therefore donor cell retention after IC injection would be affected. After stable heart 
perfusion with a Langendorff apparatus was achieved as described (refer to 3.6.3), global 
ischaemia was induced by the total cessation of coronary flow by closing the 3-way tap. 
Normothermia was maintained by submerging the hearts in non-oxygenated Krebs-Henseleit 
buffer in glassware within the Langendorff circuit, which satisfactorily maintained the heart 
temperatures between 36-37oC254,255.  
After 30 minutes, the warmed Krebs-Henseleit buffer was drained and coronary 
flow was re-established by opening the 3 way tap. Hearts were carefully monitored for 
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ventricular fibrillation which was terminated by manual heart compression between forceps. 
Heart rate and coronary effluent data were collected at 10, 20 and 30 minutes of reperfusion. 
The chosen numbers of donor cells were injected into the heart at 30 minutes of reperfusion. 
 
3.8.   Immunohistochemical assessments 
 
3.8.1. Immunohistochemistry of donor cell retention 
The hearts injected with 8×106 PKH67-labelled BMMNC were collected at a set time points 
(5 or 60 minutes) following IC cell injection, and immediately placed in ice-cold modified 
Krebs-Henseleit buffer. Promptly, three transverse segments of equal thickness were cut 
from apex to base and the specimens were incubated in 4% ice-cold PFA for 1 hour, 
followed by overnight incubation in 30% sucrose at 4oC. These segments were then rapidly 
frozen in Optimum Cutting Temperature (OCT) compound (VWR International, 361603E) 
using liquid nitrogen, from which 7.5 µm transverse cryosections were cut using a cryostat 
(OTF5000, Bright). Cryosections were allowed to air dry for 60 minutes at room 
temperature and then stored at -80oC or in liquid nitrogen until analysis.  
For immunohistochemistry, samples were brought up to room temperature and 
incubated in PBS at room temperature for 5 minutes, which was repeated 3 times to remove 
the OCT compound. A DAKO pen (DAKO) was used to mark the boundary of the section. 
Following incubation with blocking solution (10% goat serum [Gibco 16210-064]) in PBS 
for 60 minutes. The sections were incubated with 1/100 Biotinylated Griffonia (Bandeiraea) 
Simplicifolia Lectin I Isolectin B4 antibody (Vector laboratories, 0.5mg/ml, catalogue 
number B1205) in 5% goat serum for 60 minutes. Isolectin-B4 is useful as a marker for 
endothelial cells256 from non-primates such as mouse, rat, rabbit, and goat and has been used 
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to characterize the localization/distribution of retained donor cells. After washing 3 times in 
PBS, this was followed by incubation with 1/400 dilution of Streptavidin - Alexa 594 
(Invitrogen, UK, 2 mg/ml, Catalogue number s32356), together with 1/1000 dilution of 4’6-
Diamidine-2’phenylindole dihydrochloride (DAPI, Roche, Catalogue: 10236276001) for 
nuclear counterstaining, for a further 60 minutes. Washing steps and antibody dilution were 
performed with PBS. All the staining reactions were performed at room temperature. The 
sections were mounted using DAKO fluorescence mounting medium (Catalogue: SC3023) 
and observed using fluorescent microscopy (BZ7000, Keyence) with DAPI-B (blue), GFP 
(green) and TxRed (red) filters (Keyence). 
Each segment (apex, mid section, base) was analysed separately per heart. One 
section of each segment was viewed in detail and each PKH67 positive cell was counted. 
The location within the ventricular wall was noted: endocardium, myocardium or 
epicardium (divided by eye into 3 equal proportions (Figure 3-9).  
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Figure 3-9: Determination of location of fluorescently-labelled donor cells in the ventricular wall. 
The location of PKH67-labelled donor cells in the ventricular wall was determined by dividing the 
wall into three layers by eye: endocardium, myocardium and epicardium. 
 
A number of bright field images of each section on low magnification were taken 
and the images were combined using the Photomerge software function in Photoshop CS2 
(Adobe). The magic wand software feature was then used to remove the background. These 
compound images were then imported into Image J software so that the merged images 
could be analysed (the Keyence Microscope analysis software does not have a capability to 
analyse merged images in this fashion).  
Analysis in ImageJ was undertaken as follows: an image with a known distance scale was 
loaded, a line was drawing to mimic the scale and “Analyse -> set scale” was selected; the 
known distance and units were then entered. The image was converted to an 8-bit image 
(Image->Type->select “8-bit”) and the threshold was adjusted (Image->Adjust->Threshold) 
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until the whole image was red. “Set” and then “OK” were then selected and the threshold 
box was closed. “Analyse->Analyse particles” was selected, the minimum pixel size was 
changed to 50 and OK was clicked. The cross sectional area result was recorded. 
 
3.8.2. Immunohistochemistry of endothelial cell surface molecules in the heart  
Expression of intercellular adhesion-related molecules expressed in the coronary 
endothelium may be a determining factor of donor cell retention, and this would be affected 
by I-R injury prior to cell injection. Based on the previous literature (please refer to 1.8.3), 
we thought that P-selectin and ICAM-1 might have a role in initial retention of donor 
BMMNC after IC injection. Therefore, the expression pattern of these molecules was 
investigated in normal as well as I-R hearts. 
The rat hearts were perfused on the Langendorff apparatus for at least 20 minutes for 
stabilisation and collected with or with additional I-R. No donor cells were injected. These 
perfused hearts were removed, transported in PBS on ice, cut into three segments (apex, mid 
section and base), then fixed with 4% PFA at room temperature, incubated in 30% sucrose at 
4oC overnight, placed in OCT compound and stored at -80oC (as described – refer to 3.8.1). 
7.5 µm thick sections were cut using a Cryostat (OTF5000, Bright), allowed to air dry at 
room temperature for 1 hour and then stored at -80oC prior to analysis.  
For immunohistochemistry, samples were brought up to room temperature and 
incubated in PBS at room temperature for 5 minutes, which was repeated 3 times to remove 
the OCT compound. A DAKO pen (DAKO) was used to mark the boundary of the section. 
For antigen retrieval, the sections were placed in 10 mM sodium citrate buffer (pH: 6.0) 
within Coplin Jars and autoclaved at 121oC for 7 minutes (Boxer Laboratory Equipment, 
Ware, UK). Once cooled, the sections were washed 3 times with PBS for 5 minutes. 
Following incubation with blocking solution (10% goat serum in PBS / 0.025% triton X 100, 
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refer to 3.2) for 60 minutes. The sections were incubated with goat anti-rat P-selectin 
polyclonal antibody (Santa Cruz, sc-6941, 0.2 µg/ µl; 1/10 dilution), mouse anti-rat ICAM-1 
monoclonal antibody (Abcam, Ab33894, 0.1 µg/µl; 1/10 dilution), overnight at 4oC. The 
following day, the sections were washed 3 times with PBS (5 minutes) and incubated with 
PBS containing 5% goat serum for 1 hour at room temperature. After 3 time washing in 
PBS, this was followed by incubation with Alexa Fluor 488-conjugated donkey anti-goat 
IgG (Invitrogen, A11055; for P-selectin detection) or Alexa Fluor 488-conjugated goat anti-
mouse IgG (Invitrogen, A11001; for ICAM-1 detection), respectively, at a concentration of 
1/100 diluted in PBS for 1 hour at room temperature, shielded from the light. The sections 
were washed again and then counterstained for endothelium (Isolectin B4) and nuclei 
(DAPI) as previous described (see 3.8.1.). The concentration of each antibody was 
optimized by pilot experiments (data not shown). The sections were mounted using DAKO 
fluorescence mounting medium and observed using fluorescent microscopy (BZ7000, 
Keyence). 
From previous reports, it was expected that both these molecules would not be 
detected by immunohistochemistry in normal hearts, and that the expression of P-selectin, 
but not ICAM-1, would be detectable after 30 minutes ischaemia and 30 minutes 
reperfusion213,229. It has previously been reported that in a cat LCD ligation model, ICAM-1 
was detected by immunohistochemistry after 270 minutes reperfusion230. Therefore 
appropriate positive control heart samples for ICAM-1 were generated as follows (with the 
kind assistance of Dr Masahiro Kaneko, William Harvey Research Institute) to convincingly 
carry out immunohistochemical studies of ICAM-1.  
Positive control samples for ICAM-1 were generated using male Sprague-Dawley 
rats (220g) purchased from Charles-River. Anaesthesia was induced with 5% isofluorane 
inhalation and subcutaneous injection of 0.1mg/kg Buprenorphine and maintained with 1.5-
2% isofluorane (Abbot, catalogue: B506). The trachea was intubated with an 18G cannula 
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(Bio-Flon, Catalogue: MMK424) to deliver mechanical ventilation (Vet Tech Solutions, Ltd 
with Fluorovac, Harvard Apparatus) with 2% isofluorane. The chest wall was shaved, 
sterilized with ethanol and draped. A small incision was made from the xiphoid sternum 
towards the left axilla and dissection was performed in layers. The muscles within the 3rd or 
4th intercostal space were retracted to gain access to the heart. Using a 6-0 Nylon suture 
(Bear Medic, Japan, Catalogue: VT08V06H-45), a single bite was taken posterior to the mid 
left anterior descending coronary artery. Both ends of the suture were passed through a 22G 
cannula (BioFlon) and the cannula was then slid down the two suture ends, with tension 
applied to occlude coronary flow. Myocardial ischaemia was confirmed by change in 
myocardial colour (became pale). After 30 minutes ischaemia, tension on the cannula was 
released to enable reperfusion. The suture was removed, the intercostal space and skin were 
both closed with a 4-0 Nylon suture (Bear Medic, Japan, Catalogue: S13G04N-75) and 
anaesthesia was ceased. The rat was extubated and returned to its cage. Then two hearts each 
were collected at 270 minutes of reperfusion after cervical dislocation (under isofluorane 
anaesthesia). The heart was explanted from the chest using the same method of removing the 
heart for Langendorff perfusion (refer to 3.6.3) and the heart was transported in ice-cold 
PBS. Then these heart samples were investigated in the same manner as above (refer to 
3.8.1).
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3.9.   Statistical analysis and software utilized 
 
Normally distributed data was expressed as mean ± standard error of the mean (SEM). 
Where the data was not normally distributed, a median value was quoted. Throughout the 
thesis, a p value <0.05 was deemed to represent statistical significance.  
 Data was collated in Microsoft Excel 2007. GraphPad Prism 5.01 and SPSS12.0 
were used for the purposes of statistical analysis. When comparing two sets of quantitative 
data, a paired or unpaired T-test (where appropriate) was utilized. When comparing more 
than two sets of quantitative data, a one-way ANOVA test was utilized with a Bonferroni 
post-hoc test. A comparison of two populations was made using non-linear regression a 
comparison between the two best fitting curves, generated by second-order (quadratic) or 
third order (cubic) polynomial functions where appropriate; an F-test was then used to 
compare the curves.  
The graphs were generated in GraphPad Prism 5.01, Datagraph 3.0 and Microsoft 
Excel 2007. Other images were generated using Adobe Illustrator CS2, Adobe Photoshop 
CS2, Datagraph 3.0, Summit 4.3 and Omnigraffle Professional 5.4. The manuscript was 
written with Microsoft Word 2011 and Scrivener (Beta version). Endnote X2.01 was used to 
import references into the document. 
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Chapter 4 - RESULTS 
 
4.1.   Bone Marrow Mononuclear Cell (BMMNC) collection and 
characterization 
 
4.1.1. Purity, quantity and viability of isolated BMMNC  
Rat BMMNC were isolated as previously described (refer to 3.3.1). Efficiency of cell 
collection, determined by counting the number of isolated BMMNC per animal (n=5) was 
3.57 ± 0.74×108. The viability of isolated BMMNC, determined with Trypan Blue staining 
(separate isolated samples n=5, total cells measured n=3,254), was 99.4 ± 0.2%. 
The nucleation of isolated BMMNC was determined by performing a smear of 
isolated cells, fixing the cells with 4% PFA and then staining the cells with DAPI. The 
proportion of mono-nucleated cells in the isolated BMMNC population was calculated as 
99.5 ± 0.2% (n=3 different animals). There were a small number of DAPI-negative cells, 
which were thought to be red blood cells (RBC) (Figure 4-1).  
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Figure 4-1: DAPI staining of isolated rat BMMNC. Smeared cells were fixed with 4% PFA and 
stained with DAPI. Bright field (A) and DAPI positive cells (B) are shown. 99.5% of cells had one 
round nucleus. Rarely, non-nucleated cells (DAPI negative cells) were seen (marked with a black 
arrow) and thought to be RBC. (Scale bar = 100 µm).  
A      B 
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4.1.2. Morphology  
Cell morphology of collected rat BMMNC was analysed (Figure 4-2). Cells in suspension 
were pipetted into a haemocytometer with phase contrast imaging (Biozero microscope, 
Keyence). To further investigate morphology, cytospin was used to adhere the isolated 
BMMNC to a slide glass. The cells were then stained with haematoxylin. The majority of 
the cells were round although there was some heterogeneity. To the eye, the cells were          
< 10μm in diameter. 
 
 
 
 
 
 
Figure 4-2: BMMNC morphology. BMMNC suspended in PBS were viewed using phase contrast  
imaging (A). Haematoxylin was used to stain isolated cells subjected to cytospin (B). The majority of 
the cells were round although there was some heterogeneity in shape. The cells were < 10 µm in size. 
Scale bar = 50 µm  
 
A          B 
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The size distribution of BMMNC was measured using a Countess Automated Cell 
Counter (Invitrogen) and calculated from n=11 individual bone marrow samples acquired on 
different days. Particles < 5 µm were not included in the analysis because they were deemed 
to be debris. The distribution of cells is shown in Figure 4-3. The mean cell size was 7.0 µm, 
the median cell size was 7.0 µm and the population had a parabolic distribution with a 
leftwards skew. Cells ≥14 µm accounted for only 0.8% of the total population. The 
distribution of cell sizes were grouped into the ranges 5-6 µm, 7 µm and 8 µm. Using this 
categorization, the 3 categories were each approximately of equal size, which suggests that 
this subdivision broadly classifies cell sizes into tertiles, or cells below the median size, the 
median size and above the median size. 
 
 
Figure 4-3. Cell size distribution of isolated BMMNC. The distribution of isolated BMMNC was 
plotted according to individual cell size, expressed as a percentage of all the cells (A). When the cells 
were grouped into the categories 5-6 μm (below the median), 7 μm (the median) and ≥8 µm (above 
the median), the three categories were broadly of equal size (B). 
 
A        B 
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4.1.3.  Surface marker expression of BMMNC 
Surface markers of interest of collected BMMNC were determined by flow cytometric 
analysis, in at least 3 separate experiments for each marker. Representative images are 
shown in Figure 4-4. The proportion of viable cells measured by Propidium Iodide in all 
staining protocols was >92%. The mean expression in collected BMMNC (Figure 4-4) was 
CD11b: 17.8 ± 0.6% (n=5), CD18: 29.5 ± 1.2% (n=5), CD29: 96.7 ± 0.7% (n=7), CD31: 
42.1 ± 4.4% (n=4), CD34: -0.57 ± 0.6% (n=3), CD44: 41.4 ± 2.3% (n=6), CD45: 83.7 ± 
0.9% (n=5) and CD90: 56.6 ± 2.1% (n=5). The expression of CD34 was taken to be 0%. 
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4.1.4.  Labelling of BMMNC with PKH67 
Collected rat BMMNC were labelled with PKH67 to determine their intracardiac location by 
histological assessments after IC injection. The manufacturer’s recommended staining 
concentration of PKH67 is 2 µM for 5 minutes, but the optimal staining condition is likely to 
depend on cell type. To optimize staining conditions, the staining efficiency and effect on 
cell viability was determined using different staining concentrations (0, 0.4, 2.0 and         
10.0 μM) for 5 minutes. Following PKH67 staining of 1x107 BMMNC with each condition, 
the cells were stained with trypan blue and viewed under both bright field imaging (Figure 
4-5, A-D) and fluorescent imaging (Figure 4-5, E-H).  
As a result, it was found that increasing concentration of PKH67 resulted in an 
increased number of trypan blue-stained (non-viable) cells (Figure 4-6). However, this 
increase also resulted in a greater proportion of fluorescent labelled cells that could be 
observed with shorter exposure times (Figure 4-7) The proportions of both measures were 
plotted to determine the optimum staining concentration (Figure 4-6). It was found that the 
optimum staining concentration for BMMNC was 2 μM, which is supportive of the 
manufacturer’s recommendation. This concentration was used for subsequent experiments in 
the project. 
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Figure 4-5: Optimization of PKH67 staining of isolated BMMNC. BMMNC were stained with for  
5 minutes with PKH67 concentrations of 0 µM (A,E), 0.4 µM (B,F), 2 µM (C,G) and 10 µM (D,H). Trypan 
blue and bright field imaging was used to determine viability (A-D). Green fluorescent imaging for the same 
concentrations (E-H) was used to assess staining efficiency with an exposure time of 1, 2, 0.83 and 
0.25 seconds exposure time respectively. An increasing concentration of PKH67 resulted in brighter 
fluorescent intensity. Scale bars = 50 µm.
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Figure 4-6: Viability and staining efficiency of PKH67 staining of BMMNC with different dye 
concentrations. Staining efficiency was calculated as a proportion of viable cells. The optimum dye 
concentration was determined to be approximately 2 μM. 
 
 
In a further pilot optimization experiment, it was assessed whether staining conditions for 
BMMNC could be further improved by increasing the PKH67 staining time from 5 minutes 
to 10 minutes, or whether this would adversely affect viability. Staining with 0 μM PKH67 
was utilized as a control. Data was obtained from 2 separate experiments performed on 
different days. The staining efficiency (positive cell ratio) was not significantly improved by 
staining for 10 minutes (mean 92.0% vs. 97.8%, 5 minutes vs. 10 minutes, n=2). However, it 
was observed that the signal intensity subjectively appeared stronger with a more uniform 
pattern of staining (Figure 4-7). The viability of PKH67 stained BMMNC was assessed 
using trypan blue, in duplicate. Mean viability was not different between the two incubation 
times (97.2% vs. 98.3% for 5 and 10 minutes samples respectively). Collectively, it was 
Concentration  Dead cells     
(% of total cells) 
PKH+ cells 
(% of viable cells) 
Total Cells 
0 μM 13 (4.7) 0 (0) 276 
0.4 μM 10 (3.9) 202 (82.4) 255 
2 μM 8 (6.5) 113 (98.2) 123 
10 μM 90 (51.4) 85 (100) 175 
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decided that the optimum staining condition for injected BMMNC was 2 µM PKH for        
10 minutes and this was used for subsequent experiments.  
 Efficiency of PKH67 staining with the optimized condition (2 µM for 10 minutes) of 
BMMNC was also assessed by flow cytometry. PKH67 negative and positive cells were 
gated for green fluorescence (Figure 4-8). The calculated PKH67 positivity was 99.35 ± 
0.05% (n=35 separate samples measured on 3 separate days).
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Figure 4-8: PKH67 staining efficiency assessed by flow cytometry. Representative images of (A) 
negative control stained with 0 µM PKH67 and (B) PKH67 staining with the optimized condition; 2 
µM for 10 minutes. The proportion of PKH positive cells was >99.5% (R2).  
 
 
4.1.5.  Possible adverse effects of PKH67 staining on BMMNC 
PKH67 staining might affect important cell properties of BMMNC, which could influence 
donor cell retention after IC injection into the heart. Considering previous literature and 
information provided by the manufacturer, this risk was thought to be negligible. However, 
to clarify that this risk did not apply, it was investigated whether PKH67 labelling of 
BMMNC affected their cell size and/or surface protein expression, which are thought 
important in donor cell retention.  
On three separate days, BMMNC were stained with PKH67 (2 µM for 10 minutes), 
and cell size and surface protein expression were determined with an automated cell counter 
and flow cytometry, respectively, and compared with non-stained cells. There was no 
significant difference between the stained and unstained cells in terms of any surface 
proteins examined (Figure 4-9) or cell size (Figure 4-10). This data strongly suggested that 
PKH67 labelling would not affect cellular properties of BMMNC, which are relevant to 
A          B 
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BMMNC retention after IC injection. Therefore, PKH67 was used for the reminder of the 
study below. 
 
 
 
 
 
 
Figure 4-9: Changes in surface proteins of BMMNC by PKH67 labelling. Flow cytometry analysis 
demonstrated that there was no difference in CD proteins studied between PKH67-stained and non-
stained cells. Data are presented as mean ± SEM. Paired T-test: NS. 
 
 
Figure 4-10: Changes in size of BMMNC by PKH67 labelling. There was no difference in cell size 
between PKH67-stained and non-stained cells. Mean percentage distribution of cell sizes from 
PKH67 unstained (total n=3,511) and stained (total n=2,214) cells measured on 3 separate days. Data 
are presented as means ± SEM. Paired T-test: NS.  
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4.2.   Mesenchymal Stem Cell (MSC) collection and characterization 
 
4.2.1.  Efficiency of MSC isolation and expansion 
Whole bone marrow cells were collected for MSC collection from 4 adult Sprague-Dawley 
rats. The mean number of whole bone marrow cells obtained from each animal was 6.5 ± 0.6  
x108 (n=4). The cells from each rat were plated in a separate 25cm2 flasks, at a passage 0 
initial mean plating concentration of 2.6 ± 0.3 x107 cells/cm2 (this included a large number 
of non-adherent, non-MSC). MSC adhered to the culture dish within two days and started 
proliferating. After a mean of 7.4 days, attached cells were found to be approximately 90% 
confluent. At passage 1, the mean number of MSC obtained from each initial animal was 6.6 
± 1.0 x106 and these cells were then passaged into 75cm2 flasks, which equated to a plating 
concentration of 2x104 ± 0.2 cells/cm2.   
After a further mean 3.9 days, 90% confluence was obtained and at passage 2, 
2.1x107 cells were obtained from each initial animal. The doubling time from passages 1 to 2 
was therefore 2.4 days. Cells from each 75cm flask were placed in a 175cm2 flask which 
equated to a plating concentration of 2.9x104 cells/cm2. 
After a further mean 5.8 days, 90% confluence was achieved and at passage 3, mean 
4.9x107 cells per initial animal were obtained. The doubling time from passages 2 to 3 as 
therefore 4.8 days. The cells from each flask were subdivided and placed in two          
175cm2 flasks, which equates to a plating concentration of 6.0x104 cells/cm2. 
After an additional mean 4.0 days, 90% confluence was obtained. 9.8x107 cells were 
obtained from each initial animal, equating to a doubling time from passages 3-4 of 4.0 days. 
Therefore, using this protocol it was demonstrated that approximately 1x108 MSC could be 
collected from each initial donor animal within 17-21 days of commencing culture. 
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4.2.2. MSC morphology and size 
The morphology of MSC was analysed using phase contrast light microscopy over 
progressive passages. Initially after plating, the presence of rounded cells was observed, 
most likely representing RBC and leukocytes. The presence of these cells was abolished 
after passaging and multiple medium changes. A heterogeneous population of cells was then 
seen with some oblong / elongating cells beginning to appear (Figure 4-11, A). By day 10 of 
initial plating, spindle-shaped cells grew rapidly and formed discrete colonies. When 
passaged in a new flask at a lower cell / surface area concentration (Figure 4-11, B) spindle-
shaped cells could be clearly visualized with few examples of the rounder cells. The spindle-
shaped cells grew in a uniform monolayer (Figure 4-11, C). Over time the spindle-shaped 
morphology remained but the cells became wider and began to resemble the morphology of 
fibroblasts (Figure 4-11, D).  
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Figure 4-11: MSC morphology. Cultured MSC were viewed by light microscopy and phase-contrast 
images were acquired with Nikon Coolpix 4500, x4 magnification. (A) Day 5 passage 0, (B) Day 10 
passage 1, (C) Day 15 passage 2 (D) Day 21 passage 3. Scale bar=200 µm. 
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Passage 2-4 MSC were analysed using an automated cell counter to determine cell 
size (Figure 4-12). For passage 2 MSC, a total of n=17 separate 175cm2 flasks (9,091 total 
cells) were analysed. The median and mean cell sizes were 10.5 µm and 12.1 µm, 
respectively. For passage 3 cells, 7 different 175cm2 flasks were analysed with a total of 
5,166 cells assessed. The median cell diameter was 11.5 µm and the mean cell diameter was 
also 11.5 µm. For passage 4 MSC, a total of 9 separate 175cm2 flasks were analysed with a 
total of 5,976 cells assessed. The median and mean cell sizes were 11.5 µm and 12.2 µm 
respectively. 
The cell size of MSC appears to shift to the right with progressive passaging. 
Passage 3 resembles a composite of the populations of passage 2 and passage 4 cells (Figure 
4-12). However, the populations of cell diameters were compared by non-linear regression 
by generating second order polynomial (quadratic) best fit lines; there was no significant 
difference between the distribution of cell diameters between the groups (p=0.99 for all 
comparisons, Sum of Squares F-test). 
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Figure 4-12: Cell size of MSC during culture. The cell size distribution of cultured rat bone marrow 
derived MSC was assessed using an automated cell counter. The numbers of MSC for each cell size 
were calculated and expressed as a fraction of the total number of MSC for each passage.                
(A) Passage 2 MSC, n=9,091 cells (B) passage 3 MSC, n=8,266 cells (C) passage 4 MSC,        
n=5,976 cells.  
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4.2.3. MSC surface markers 
Expression of MSC identification markers (CD29, CD34, CD45 and CD90) on the cultured 
MSC (passage 4) was assessed by flow cytometry. The cultured cells were highly positive 
for CD29 (99.4%) and CD90 (99.4%) and almost exclusively negative for CD34 (0.1%) and 
CD45 (-0.17%, taken to be 0%), as expected (Figure 4-13).  
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Figure 4-13: Surface markers of passage 4 MSC (representative images). The cultured MSC were 
highly positive for CD29 and CD90 and negative for CD34 and CD45. The IgGk control was for 
CD34. The Alexa-649 control was for CD29. The FITC-control was for CD45 and CD90. 
  IgGk control              Alexa-647 control                  FITC-control 
   
CD29                                        CD34                                                      
 
CD45-FITC              CD90-FITC 
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4.2.4. Differentiation capacity of cultured MSC 
Passage 3 MSC were examined for their differentiation capacity to mesenchymal lineages as 
described (refer to 3.4.4). After 21 days of culture with adipogenic differentiation medium, 
Oil-O-Red staining demonstrated multiple lipid vesicles within individual cells which 
stained the cells red, confirming the typical appearances of adipocytes. Similarly, cultured 
cells incubated with osteogenic differentiation medium were stained for alkaline 
phosphatase and alizarin red. Colonies were observed with co-staining of alkaline 
phosphatase and calcium, demonstrating the typical appearances of osteocytes (Figure 4-14). 
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Figure 4-14: Differentiation capacity of passage 3 MSC (representative images). Adipocytes 
differentiated from MSC (a) and Control cells (b) were stained with Oil-O-Red. Osteocytes 
differentiated from MSC (c) and control cells (d) were stained with alkaline phosphatase (ALP) and 
alizarin red for calcium deposition. All assays were counterstained with haematoxylin. Lipid particles 
(red) within the adipocytes were a frequent finding (a). Co-localization of ALP (light blue) and 
calcium (dark red) was detected in the osteogenic assays. These findings were not observed in the 
control assays. Scale bar = 200 μm.
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4.2.5. Labelling with PKH67 
For optimization of labelling of MSC with PKH67,,2x106 passage 3 MSC were stained with 
2 µM PKH67 for either 5 minutes or 10 minutes. Control cells were suspended in Diluent C 
without PKH67. Staining efficiency was assessed using fluorescent microscopy. For both 
time points, PKH67 staining was highly efficient and almost all cells on imaging were 
stained; mean 5 minute staining efficiency was 99.6% (n=3 samples, n=801 cells) and mean 
10 minute staining efficiency was 99.7% (n=3 samples, n=1,320 cells). A representative 
image is shown in Figure 4-15. 
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In addition, the viability of n=380-740 cells were determined for each PKH67 
labelling condition using trypan blue staining. The experiment was performed in duplicate 
on separate days. The mean viability was 97.5% and 94.0% for 2 µM for 5 minutes vs. 2 µM 
for 10 minutes respectively. Viability in the control sample (0 µM) was 97.5%. 
 Given the similar labelling efficiency with a higher viability, it was decided to 
utilize 5 minutes incubation of 2µl PKH67 for the main staining experiments. The effect of 
this PKH67 staining condition on cell size was also analysed. The distribution of cell size 
from pre-stained cells and from post-stained cells were compared (Figure 4-16). There was 
no significant difference in cell size following PKH67 staining (paired T-test: NS). 
 
 
Figure 4-16: Size distribution of MSC before and after staining with PKH67. Cell size was 
measured with automated cell counter. There was no significant impact on cell size after cell staining. 
Error Bars represent SEM.  
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4.3.   Establishment of a rat model to investigate initial retention of 
stem/progenitor cells after intracoronary injection 
 
4.3.1. Langendorff rat heart perfusion - reproducibility without cell injection 
It was first determined whether stable and reproducible perfusion was obtained for normal 
rat hearts during Langendorff ex-vivo perfusion. After multiple practice attempts using     
>20 rat hearts, n=6 hearts were perfused and measurements for heart rate, coronary effluent 
flow rate, and temperature and pH of the coronary effluent, were serially recorded at 10, 20, 
30 and 40 minutes after hanging (Figure 4-17)  
Variations between samples were small enough at each measurement time point, 
judging from the small SEM. This suggested that the perfusion model is reproducible. There 
was no significant difference in any measurements over time (One-way ANOVA). From the 
bar chart appearances, it was concluded that stabilization had occurred 20 minutes after heart 
hanging. Therefore, in the normal heart model, cells were injected at this time point 
(Methods 3.6.7). Similarly, this was the stabilization period used before subjecting the 
perfused hearts to the ischaemia-reperfusion protocol (refer to 3.7). 
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Figure 4-17: Stable perfusion obtained for normal rat hearts using Langendorff apparatus. Heart 
rate (A), temperature of coronary effluent (B), pH of coronary effluent (C) and coronary effluent 
volume (D) were obtained for n=6 hearts following hanging on Langendorff apparatus with normal 
perfusion. Error bars indicate SEM. 
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4.3.2. Langendorff model optimization and RBC contamination in coronary effluent 
Early in the process of optimizing the Langendorff model for normal heart perfusion, it was 
observed that cells were present in the coronary effluent after hanging the heart, without 
donor cell injection. This was an unexpected finding and had the potential to affect the 
ability of the model to quantify donor cells in the coronary effluent. These cells were 
quantified further. 
Five minutes after hanging the heart, the coronary effluent was smeared on a slide 
glass and stained with haematoxylin. It was demonstrated that the cells had the appearances 
of biconcave discs (Figure 4-18). It was concluded that these cells were red blood cells 
(RBC). At later time points, there was a lower visual concentration of RBC under 
microscopic examination (not shown).  
 
Figure 4-18: RBC in the coronary effluent. Coronary effluent leaving the heart 5 minutes after 
hanging was smeared on a slide glass. The cells were fixed and stained with haematoxylin. 
Microscopy demonstrated biconcave discs; the typical appearances consistent with red blood cells. 
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Confirmatory evidence that the cells were not nucleated was obtained using DAPI 
staining. Control images were obtained for isolated BMMNC (Figure 4-19). It was found 
that cells in the coronary effluent were not nucleated, suggesting that they were RBC. The 
BMMNC positive control almost exclusively exhibited DAPI nuclear staining. 
 
Figure 4-19: Staining of coronary effluent cells with DAPI. It was demonstrated that the coronary 
effluent cells were not nucleated. DAPI stain (A) viewed at 0.125 seconds exposure, Bright field 
image (B) shown. Control images were obtained for isolated BMMNC which were fixed, stained and 
viewed using the same protocol and exposure times (C and D). Scale bar represents 50 µm. 
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It was observed that the frequency of RBC leakage was highest immediately after 
hanging and progressively decreased. At each time point, cell number was counted using a 
haemocytometer (Figure 4-20). It was found that the number of RBC at 20 minutes of heart 
hanging was 4.1±1.9x104 cells/min. This was considered to be sufficiently small compared 
to the number of donor cells in coronary effluent. The number continued to gradually 
decrease and at 60 minutes, the mean count was approximately 1x103 cells/min. 
 
 
Figure 4-20: RBC exiting the heart in the coronary effluent after heart hanging. Rat hearts were 
perfused on the Langendorff apparatus (n=7). Immediately after heart hanging, a large amount of 
RBC exited the heart (approximately 9x106 cells / min) that decreased over time. At 20 minutes after 
hanging, the number of cells exiting the heart was approximately 1x105 cells / min. This level 
decreased to approximately 1x103 cells / min by 60 minutes post-hanging. The cell number is 
expressed on a logarithmic scale. Data expressed as mean ± SEM  
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4.3.3. RBC contamination in coronary effluent after cell injection  
To ensure that RBC contamination was at a low enough level compared to the donor cell 
count in coronary effluent, the ratio of RBC in coronary effluent cells was analysed.      
8x106 PKH67-labelled BMMNC were injected into perfused normal Langendorff after       
20 minutes of stabilization on 3 separate days. The cell counts prior to injection (RBC) were 
low on each occasion (<5.0x104). The coronary effluent was observed minute-by-minute to 
determine the proportion of PKH67-positive cells in all coronary effluent cells (Figure 4-21). 
In all experiments, almost 100% of the cells in the coronary effluent within the first 1 minute 
of injection were PKH67 positive. The total number of cells observed per field progressively 
decreased each minute after injection. After 5 minutes when the cell counts in the coronary 
effluent had returned to baseline, very few cells, either PKH67 positive or negative, were 
observed.  
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Figure 4-21: Negligible RBC contamination in coronary effluent after cell injection. After injection 
of 8x106 PKH67-labelled BMMNC into normal Langendorff-perfused hearts, almost all the cells in 
the coronary effluent were PKH67 positive. Representative fluorescent and bright field images are 
shown for the 1 minute prior to injection (-1), the first 2 minutes after injection and the 5th minute post 
injection. Cells - either PKH67 positive or negative - were only very rarely seen in the coronary 
effluent beyond 5 minutes donor cell injection. 
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4.3.4. Negligible numbers of donor cells retained in the Langendorff apparatus 
For assessing the possible retention/attachment of injected cells in the Langendorff apparatus 
and injection syringe/needle, 8x106 BMMNC suspended in 3 ml PBS (n=3) were injected 
into the side port of the Langendorff apparatus, collected in a 50 ml Falcon tube and flushed 
through with warmed, oxygenated Krebs-Henseleit buffer (without heart hanging/perfusion).  
The mean cell counts in the three samples were 7.99x106, 8.03x106 and 8.06x106. 
This demonstrated that no cells injected into the side port were retained in the Langendorff 
apparatus itself (paired T-test versus counts of 8x106, NS) and that there was only a very 
small margin of error (<1% of the total) after counting the same population of cells.
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4.3.5. Ischaemia-reperfusion heart – reproducibility without cell injection 
To determine whether subjecting hearts to 30 minutes ischaemia followed by 30 minutes 
reperfusion during Langendorff perfusion led to a reproducible experimental state, n=5 rat 
hearts were perfused in this fashion and data was collected for coronary effluent flow rate, 
coronary effluent temperature, heart rate and number of RBC exiting the heart without donor 
cell injection (Figure 4-22)  
It was observed that within a couple of minutes of ischaemia, the heart ceased 
contraction although it was not possible to record to record the ECG because the heart was 
submerged in warmed Krebs-Henseleit buffer. During this non-flow, global ischaemia, the 
temperature was maintained at 37oC. Within 2 minutes of reperfusion, the heart was 
observed to contract sporadically, progressively increasing in regularity. The first recording 
of heart rate was made 10 minutes after reperfusion which had a lower heart rate than that 
recorded prior to ischaemia. Heart rate progressively increased during reperfusion. The      
30 minutes reperfusion heart rates were lower than those recorded prior to ischaemia at      
20 minutes stabilization (270 ± 22 bpm vs. 310 ± 16 bpm) although this reduction was not 
statistically significant (p=0.09). Immediately following reperfusion, atrial fibrillation with a 
rapid ventricular rate and ventricular fibrillation were also noted occasionally in the early 
stages. Mechanical cardioversion by flicking the heart with one finger typically cardioverted 
the rhythm but this was not always successful. Hearts with intractable tachyarrhythmias 
following reperfusion were excluded from the analysis as a stable heart condition did not 
occur, though this occurred infrequently.  
In the reperfusion period, temperatures were also observed to be variable, although 
these had stabilized by 30 minutes of reperfusion. There was no significant difference 
between the pre-ischaemia and reperfusion temperatures (p=0.79, One-way ANOVA).         
I-R did not have any effect on the rate of coronary effluent flow rate at the recorded time 
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points. (p=0.99, One-way ANOVA). Immediately following reperfusion within the first      
1-3 minutes, it was noted that coronary effluent flow rates appeared to be increased. 
However these volumes had stabilized by the time the first formal measurement was made at 
10 minutes. 
The number of RBC leaving the heart was measured with an automated cell counter 
(Figure 4-22). The number of RBC within the stabilization period was similar to those 
reported previously (refer to 4.3.2), but this number was consistently even lower after         
30 minutes of reperfusion (≤ 1x104 cells). 
 
 
 
139 
 
Figure 4-22: Langendorff parameters and RBC leakage before and after ischaemia-reperfusion, 
without cell injection. Heart rate (A), temperature of coronary effluent exiting the heart (B) and 
coronary effluent flow rate (C) and RBC loss in the coronary effluent (D) are shown (n-5). Data 
expressed as mean ± SEM. 
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4.3.6. Expression of adhesion molecules in coronary endothelium 
Based on previous reports, it was suggested that P-selectin and ICAM-1 would not be 
expressed in normal intact hearts (refer to 1.8.3). Furthermore, after 30 minutes ischaemia 
and 30 minutes reperfusion in ex-vivo Langendorff hearts, P-selectin would be upregulated 
but that ICAM-1 would not be upregulated. In this project, these molecules were assessed by 
immunohistochemistry in I-R hearts and normal hearts subjected to 30 minutes normal 
perfusion only (n=2 hearts, I-R and controls each). 
As expected, it was found that P-selectin was expressed in hearts subjected to        
30 minutes ischaemia and 30 minutes reperfusion. I-R. It was noted that P-selectin was most 
strongly expressed in larger vessels (representative image Figure 4-23). Using the same 
staining conditions with the same antibody concentrations, P-selectin was not detectable in 
sections from the normal hearts. 
It was expected that ICAM-1 would not be expressed in normal hearts or hearts with 
30 minutes ischaemia and 30 minutes reperfusion. Therefore, positive control hearts were 
generated (n=2 each); hearts with 30 minute ischaemia and 4.5 hour reperfusion hearts for 
ICAM-1 (see Methods 3.8.2.). Using the staining protocol, it was observed that the positive 
controls expressed ICAM-1 staining, particularly in the larger vessels. In contrast, in both 
the normal hearts and hearts with 30 minutes ischaemia and 30 minutes reperfusion, no 
ICAM-1 expression was identified in any of the small or large coronary vasculature 
(representative image Figure 4-24).
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4.4.   Retention of BMMNC after IC injection into normal hearts 
 
4.4.1. Langendorff parameters after BMMNC injection 
IC cell injection carries a risk of coronary embolism, deteriorating cardiac perfusion and 
function. This risk could be dependent on donor cell numbers to be injected. It was therefore 
determined whether cell injection significantly affected coronary perfusion flow rates after 
injection of 1×106, 8×106 and 40×106 BMMNC into normal hearts (Figure 4-25).  
In the first minute during cell injection, there was a slight increase in coronary 
effluent flow rates (but this volume included the 3mls of cell suspension). Post injection in 
the subsequent minutes, there was no change in coronary effluent volume after any injected 
cell dose. Correspondingly, there was no significant change found in the temperature or 
heart rate (Figure 4-26) of the perfused hearts before and after cell injection in any groups. 
This suggests that this range of BMMNC doses do not result in acute damage to the heart or 
coronary embolism. 
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Figure 4-25: Coronary flow before and after BMMNC injection into normal hearts. Data shown for 
different donor cell numbers injected: (A) 1×106, n=5, (B) 8×106, n=10 (C) and 40×106 n=7. The 
coronary effluent volume collected immediately prior to the cell injection is labelled -1. The coronary 
effluent within the 1st minute of cell injection is labelled 1 and includes the 3 ml of Krebs-Henseleit 
buffer in which the cells were suspended. Data expressed as mean ± SEM. 
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Figure 4-26: Temperature and heart rate of Langendorff perfused normal hearts. The temperature 
and heart rate of coronary perfusate exiting the heart was recorded before and after injection of 
different cell numbers (A and B) 1x106, n=5, (C and D) 8x106, n=10 (E and F) and 40x106 n=7. The 
time in the minute prior to injection is labelled “-1”. Data expressed as mean ± SEM.  
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4.4.2. Pattern of BMMNC loss into coronary effluent 
Cell counts in the coronary effluent after injection of 1×106, 8×106 and 40×106 BMMNC 
into normal hearts were serially quantified (Figure 4-27). As described in 3.6.6, there was a 
small (but measurable), number of RBC that continued to leak into the coronary effluent 
prior to cell injection, Within the 1st minute of cell injection, there was a rapid increase in 
donor cells in the coronary effluent which progressively decreased over the subsequent 
minutes. Within 5 minutes, the cell count per minute had returned to the baseline level. This 
pattern of cell loss in the coronary effluent appeared to be the same between the groups. The 
baseline level was deemed to be the background RBC loss.  
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Figure 4-27: Cell numbers in the coronary effluent before and after injection of BMMNC into 
normal hearts. Data is shown for injection of (A) 1×106 BMMNC, n=5, (B) 8×106 BMMNC, n=13 
and (C) 40×106 BMMNC, n=8. -1 represents the minute prior to injection. Error bars represent SEM. 
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To precisely quantify the donor cell retention rate, these cell numbers in the 
coronary effluent were adjusted by subtracting the RBC number in the coronary effluent. As 
discussed in 3.6.8, the mean cell count for the minute prior to injection and the fifth minute 
post injection were used to calculate the baseline RBC level in the coronary effluent. This 
was subtracted from the cell counts obtained during the first 5 minutes of cell injection. The 
justification for this was as follows: the cell count in the coronary effluent at 5 minutes was 
not statistically different from the cell count for the minute immediately preceding BMMNC 
injection. This suggested that all detectable donor cells had been flushed out of the heart 
within the first 5 minutes and that the cell count at 5 minutes had returned to the baseline 
RBC count.  
Using this concept, the pattern of calculated donor cell loss is shown after injection 
of 1×106, 8×106 and 40×106 BMMNC (Figure 4-28). The time course of the pattern of donor 
cell leakage was broadly the same between the groups. Within the first minute, the cell loss 
was at its highest, but this number progressively decreases in a logarithmically decreasing 
pattern. By 5 minutes, the number of donor cells leaving the heart was very small and did 
not make a large contribution to overall cell loss. At the fifth minute, the mean cell count in 
the coronary effluent was undetectable after injection of 1×106 BMMNC, <1.5×104 cells per 
minute after injection of 8×106 BMMNC and <5.0×104 cells per minute after injection of 
40×106 BMMNC.  
 
 
 
 
149 
 
Figure 4-28: Calculated donor cell numbers in the coronary effluent after injection of BMMNC 
into normal hearts. Data is shown for injection of (A) 1×106 BMMNC, n=5, (B) 8×106 BMMNC, 
n=13 and (C) 40×106 BMMNC, n=8. Error bars represent SEM.  
 
To further clarify whether the rate and pattern of cell loss was similar between the 
injected cell numbers, the cell counts for each minute were expressed as a fraction of the 
total coronary effluent BMMNC loss (Figure 4-29). It was determined that within the first 
minute of cell injection, 90.1 ± 5.0% (1x106 group), 94.9 ± 0.8% (8x106 group), and 97.0 ± 
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Figure 4-29: BMMNC loss into coronary effluent after injection into normal hearts. The patterns of 
cell loss between the three BMMNC number groups injected into normal hearts were compared. The 
cell count for each minute was expressed as a fraction of the total cell loss in the coronary effluent up 
until 5 minutes. (n=5, 13, and 8 for injection of 1, 8, and 40x106 BMMNC). Error bars = SEM. 
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4.4.3. BMMNC retention efficiency in normal hearts 
The absolute number of donor BMMNC retained in the heart after IC injection was 
calculated with knowledge of the donor cell number in the coronary effluent (refer to 4.4.2) 
and the total injected cell number and compared between the 3 BMMNC cell doses (1×106, 
8×106 and 40×106). The absolute number of retained donor BMMNC was significantly 
increased following a higher injected cell dose (p<0.0001, One-way ANOVA). The mean 
absolute retention cell numbers for 1×106, 8×106 and 40×106 groups were 0.20 ± 0.04 ×106 
(n=5), 1.70 ± 0.18 ×106 (n=13) and 9.40 ± 0.74 ×106 (n=8) respectively (Figure 4-30, A). 
The proportion of the retained cells at 5 minutes as a fraction of the total injected cell dose 
was then calculated (Figure 4-30, B). It was found that there was no difference between the 
retained proportions of cells between the 3 groups. The retained proportions of injected 
1×106, 8×106 and 40×106 BMMNC were the same (20.0 ± 3.5%, 21.2 ± 2.2 and 23.5 ± 2.2% 
respectively). 
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Figure 4-30: BMMNC retention in normal hearts. Donor cell retention in the heart after IC injection 
of different BMMNC doses is shown for (A) absolute number of cells retained and (B) retained cells 
as a proportion of the injected number. Error bars indicate SEM. (n=5, 13, and 8 for injection of 1, 8, 
and 40x106 BMMNC). #=p<0.05, Bonferroni’s multiple comparison test  
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I further analysed the initial BMMNC retention after IC injection into normal hearts 
with a focus on minute-by-minute changes in the retention efficiency for the first five 
minutes post injection (Figure 4-31). There was a slight decrease in the proportion of 
injected cells in the heart over time, but this pattern did not differ between the injected cell 
numbers (Two-way ANOVA for each time point). Additionally, there was no difference 
between the cell retention over 5 minutes for each cell group. This suggests that BMMNC 
retained at 1 minute after IC injection were mostly retained after 5 minutes, regardless of 
cell numbers injected. 
  
Figure 4-31: Minute-by-minute BMMNC retention efficiency in the normal heart after IC 
injection. The proportion of injected donor cells retained in the heart was calculated for each of the 
first 5 minutes post injection. For each cell number injected, there was a subtle decrease in retained 
cells. Error bars indicate SEM. n=5, 13, and 8 for 1×106, 8×106 and 40×106 BMMNC injection 
groups. 
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4.4.4. Cell surface markers of BMMNC in coronary effluent 
The surface marker expression of BMMNC in the coronary effluent was assessed by flow 
cytometry and compared with BMMNC prior to injection, with a view to determining 
whether cells with a particular surface protein were preferentially retained in the heart after 
IC injection. Three separate experiments were performed using cells obtained from the 
coronary effluent after 40×106 BMMNC injection into normal hearts. It was observed that 
the expression of each surface marker investigated was not altered between pre-injection 
BMMNC and BMMNC in the coronary effluent (Figure 4-32; unpaired T-test: NS for each 
marker). This suggests cell retention using these experimental conditions is not dependent on 
these cell surface markers. 
 
Figure 4-32: Surface marker expression in BMMNC in coronary effluent. CD marker expression of 
donor cells pre-injection (n=5) and donor cells in the coronary effluent (n=3) was not different. Error 
bars indicate SEM.  
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4.4.5. Size of BMMNC in coronary effluent 
To study the hypothesis that cell size is a factor which determines donor cell retention after 
IC injection, the cell size distribution of BMMNC in the coronary effluent was determined 
using an automated cell counter and compared with BMMNC before injection. 
The mean cell size of BMMNC in the coronary effluent was 6.85 µm and the 
median cell size was 7 µm. This compared to the mean and median cell size of 7.0 µm in the 
pre-injection sample (refer to 4.1.1). The coronary effluent cells had a trend towards a 
leftwards shift in cell size, with an increase in the proportion of smaller BMMNC and a 
reduction in the proportion of larger BMMNC (Figure 4-33).  
 
Figure 4-33: Cell size distribution of BMMNC in coronary effluent after injection into normal vs.    
pre-injection hearts. The distribution of BMMNC size of donor cell prior to injection and in the 
coronary effluent were compared with an automated cell counter for n=6 normally perfused hearts. 
The number of BMMNC for each cell size was calculated and expressed as a fraction of all the 
BMMNC in each group. There appeared to be a leftwards shift in the size of coronary effluent cells 
compared to the pre-injection cells. n=23,942 pre-injection cells. Error bars indicate SEM.  
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 Because the total cell number within the coronary effluent and the distribution of 
pre-injection donor cell sizes were known, the proportion of retained cells according to cell 
size could be calculated. For further analysis, the cells were subdivided into three groups; 
cells with size of 5-6 µm (below the median size), 7 µm (the median size) and ≥ 8 µm 
(above the median size). Figure 4-34 demonstrates the relative proportions of cell sizes for 
pre-injection donor cells and donor cells retained in the heart. The proportion of retained 
BMMNC with a below-median pre-injection diameter (5-6 µm) was lower than that of pre-
injection BMMNC. In contrast, the proportion of retained BMMNC with an above-median 
pre-injection diameter (≥ 8 µm) was greater than that of pre-injection BMMNC. The 
proportion of retained BMMNC with a median cell diameter (7 µm) was unchanged 
compared with the pre-injection samples of all the retained cells in the heart.  
 
Figure 4-34: Cell size distribution of donor BMMNC prior to injection and of retained BMMNC 
after IC injection into the normal heart. The proportions of cells below the median (5-6 µm), the 
median (7 µm) and above the median ≥8 µm were calculated. The proportion of smaller BMMNC 
retained in the heart below the median size was lower than that of pre-injection BMMNC. 
Conversely, larger cells were retained with increased efficiency. Error bars indicate SEM, n=11,        
# = p<0.05 (2-tailed unpaired T-test). 
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The relationship between donor BMMNC size and retention efficiency after IC 
injection into the normal heart was further analysed. This result clearly showed that there 
was an increase in cell retention efficiency with greater donor cell size (p<0.05, One-way 
ANOVA). The proportion of injected BMMNC ≥ 8 µm that were retained was 2.41-fold 
larger (48.8% vs. 20.2%, p<0.05) than that for BMMNC with a 5-6 µm cell size (Figure      
4-35). 
 
Figure 4-35: Retention efficiency of BMMNC according to their cell size. The proportions of the 
sizes of donor cells retained in the heart were calculated (n=5). Larger cells were preferentially 
retained (p<0.05, One-way ANOVA). Error bars indicate SEM. 
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4.4.6. Histological distribution of retained BMMNC in the heart 
The anatomical location of PKH67-positive donor BMMNC within the recipient normal 
hearts after IC injection was histologically determined (refer to 3.8.1). In brief, each segment 
(apex, mid section, base) was analysed separately per heart and the anatomical location of 
every PKH67-labelled cell was recorded. The cross-sectional area of each myocardial 
section was calculated using ImageJ software analysis. The results showed that there was a 
trend towards a higher concentration of cells localized in the mid section, but this was not 
statistically significant (Figure 4-36; Mid: 1.4 ± 0.3, n=8 hearts, Apex: 0.9 ± 0.1, n =5 hearts, 
Base: 0.7 ± 0.1 cells/mm2, n=5 hearts, p=0.06, One-way ANOVA).  
Next, the location of donor cells within the ventricular wall was noted - 
endocardium, myocardium or epicardium (divided by eye into 3 equal proportions). There 
was a progressive increase in concentration of donor cells towards the endocardium. There 
was a three times higher concentration of donor cells in the endocardium compared to the 
epicardium (p<0.0001, One-way ANOVA)  
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Figure 4-36: Location of retained donor cells within the normal heart. The number of fluorescently-
labelled cells in the apex (n=8), mid-section (n=6) and base (n=5) were compared after injection of 
8×106 cells into normally perfused Langendorff hearts, corrected for the cross-sectional area (A). 
There was no significant difference between the three sections (p=0.06, One-Way ANOVA). 
Additionally, the depth of cells within the ventricular wall was noted on all the heart sections (B). The 
concentration of cells progressively increased from the epicardium (n=13) to the myocardium (n=19) 
to the endocardium (n=19); p<0.0001, One-way ANOVA.  
 
4.4.7. Anatomical relationship between retained cells and the coronary vasculature 
The location of cells related to the coronary vasculature (inside or outside of the vascular 
cavity; endothelial adhesion or extravasation) was determined by injection of PKH67-
labelled BMMNC injected hearts with isolectin-B4 and DAPI staining. At 5 minutes after 
cell injection, all the observed PKH67-labelled cells were inside the vasculature 
(representative images: Figures 4-37 and 4-38). In further analyses of the hearts obtained for 
sectioning 60 minutes after cell injection, no observed PKH67-labelled cell was observed to 
have extravasated out of the coronary vasculature (representative images: Figures 4-39 and 
40). There were no findings to suggest coronary embolism histologically. 
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4.5.   Retention of BMMNC after IC injection into I-R hearts  
 
4.5.1.  Langendorff parameters of I-R hearts after BMMNC injection 
IC injection after I-R may be more likely to result in coronary embolism, which would lead 
to decreased coronary effluent volumes and derangement of cardiac function compared to 
the normal heart. This could also be dependent on donor cell numbers. It was determined 
whether cell injection affected coronary perfusion after injection of 1x106, 8x106 and   
40x106 BMMNC into I-R hearts. 
There was no decrease in the coronary effluent flow rate after injection after any 
injected cell dose (Figure 4-41). Similarly, there was no significant change found in 
temperature or heart rate (Figure 4-42) of the perfused hearts before and after cell injection 
in any groups. This suggests that this range of BMMNC doses did not result in acute damage 
to the heart or coronary embolism after IC injection in I-R hearts. 
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Figure 4-41: Coronary flow before and after IC BMMNC injection into I-R hearts. Data are shown 
for different cell numbers injected: (A) 1x106 BMMNC (n=4), (B) 8x106 BMMNC (n=4) and           
(C) 40x106 BMMNC (n=6). Stabilization = 1 minute prior to ischaemia. Error bars indicate SEM.  
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Figure 4-42: Heart rate and temperature during stabilization, reperfusion and after injection of 
BMMNC into I-R hearts. Data is shown for (A and B) 1x106 BMMNC, (C and D) 8x106 BMMNC 
and (E and F) 40x106 BMMNC. Stabilization = 1 minute prior to ischaemia. Data is expressed as 
mean ± SEM. 
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4.5.2. Pattern of BMMNC loss into coronary effluent 
Cell counts in the coronary effluent after IC BMMNC injection into I-R hearts were 
quantified. As discussed in 3.6.8, the baseline RBC level in the coronary effluent was 
calculated for each heart sample. This was subtracted from the cell counts obtained during 
the first 5 minutes of cell injection. 
Using this concept, the pattern of donor cell loss into coronary effluent is shown 
after injection of 1x106, 8x106 and 40x106 BMMNC (Figure 4-43). The time course of the 
pattern of donor cell leakage was similar between the groups. Within the first minute, donor 
cell loss rates in the coronary effluent were at their highest, but this loss progressively 
decreased in a logarithmically decreasing pattern. By 5 minutes the number of donor cells 
leaving the heart was very small and did not make a sizable contribution to overall donor 
cell loss. At the fifth minute, the mean cell count in the coronary effluent was 2.1x104 cells 
per minute after injection of 1x106 BMMNC, 3.6x104 cells per minute after injection of 
8x106 BMMNC, and 6.1x104 cells per minute after injection of 40x106 BMMNC. 
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Figure 4-43: Calculated donor cell numbers in the coronary effluent after injection of BMMNC 
into I-R hearts. Data is shown for injection of (A) 1x106 BMMNC (n=4), (B) 8x106 BMMNC (n=11) 
and (C) 40x106 BMMNC (n=6) into IR Langendorff hearts after stabilisation. Error bars represent 
SEM. 
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To further assess if the rate of cell loss was different between the injected cell 
numbers (1x106, 8x106 and 40x106), the cell counts for each minute were expressed as a 
fraction of the total coronary effluent cell loss (Figure 4-44). It was determined that within 
the first minute of cell injection, 95.0 ± 2.1% (1x106 group), 97.2 ± 0.3% (8x106 group), and 
97.5 ± 0.4% (40x106 group) of the original donor cell number were lost into the coronary 
effluent (p=0.12, One-way ANOVA).  
 
Figure 4-44: BMMNC loss into coronary effluent after injection into I-R hearts. The patterns of 
cell loss between the three BMMNC number groups injected into I-R hearts were compared. The cell 
count for each minute was expressed as a fraction of the total cell loss in the coronary effluent up until 
5 minutes. Error bars = SEM. 
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4.5.3. BMMNC retention efficiency in I-R hearts 
The absolute number of donor cells retained in the heart after IC injection was compared 
between the 3 BMMNC cell doses. The absolute number of retained donor BMMNC was 
significantly increased following a higher injected cell dose (Figure 4-45). The mean 
absolute cell number retention for 1x106, 8x106 and 40x106 were 0.32 ± 0.03 x 106 (n=4), 
2.33 ± 0.08 x106 (n=11) and 11.8 ± 0.70 x 106 (n=6), respectively (p<0.0001, One-Way 
ANOVA). The proportion of the retained cells at 5 minutes as a fraction of the total injected 
cell dose was then calculated (Figure 4-45). It was found that there was no difference 
between the retained cell proportions between the 3 groups. The retained proportion of 
injected 1x106, 8x106 and 40x106 BMMNC were the same (31.7 ± 2.8%, 29.2 ± 1.0% and 
29.5 ± 1.7% respectively, p=0.37, One-way ANOVA). 
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Figure 4-45: BMMNC retention after IC injection into I-R hearts. Donor cell retention in the heart 
after IC injection of BMMNC doses is shown for (A) absolute number of cells retained and             
(B) retained cells as a proportion of the injected number. Error bars indicate SEM. #=p<0.05, 
Bonferroni’s Multiple Comparison Test. 
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A further analysis of the initial BMMNC retention after IC injection into I-R hearts 
was undertaken, with a focus on minute-by-minute changes in the retention efficiency for 
the first five minutes post injection (Figure 4-46). The pattern of retention did not differ 
between the injected cell numbers (Two-way ANOVA). Additionally, there was no 
difference between the cell retention after 1 minute and after 5 minutes (Two-way 
ANOVA). This suggests that BMMNC retained at 1 minute after IC injection were mostly 
retained after 5 minutes, regardless of cell number injected. 
 
Figure 4-46: Donor cell retention efficiency in I-R hearts immediately after IC injection of 
BMMNC. The proportion of injected donor cells retained in the heart was calculated for each of the 
first 5 minutes post injection. For each cell number injected, there was a slow decrease in retained 
cells. Error bars indicate SEM. 1x106 (n=5), 8x106 (n=13), 40x106 (n=8). 
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4.5.4. Surface markers of retained BMMNC in I-R hearts 
The surface marker expression of BMMNC in the coronary effluent after IC injection into   
I-R hearts was assessed by flow cytometry and compared with BMMNC prior to injection, 
with a view to determining whether cells with a particular surface protein were preferentially 
retained in I-R hearts after IC injection. The mean surface marker expression for pre-
injection cells was collated from pre-injection cells from both normal and I-R hearts (n=5) 
experiments. Two separate experiments were performed using the cells from the coronary 
effluent after 40x106 BMMNC injection into I-R hearts. It was observed that the expression 
of each surface marker investigated was not altered between pre-injection BMMNC and 
BMMNC in the coronary effluent (Figure 4-47, unpaired T-test). This suggests cell retention 
in these I-R heart protocols is not dependent on these cell surface markers.  
 
Figure 4-47: Surface marker expression in BMMNC in coronary effluent after IC injection into   
I-R hearts. CD marker expression of donor cells pre-injection (n=5) and donor cells in the coronary 
effluent after IC injection to I-R hearts (n=2) was not different. Error bars indicate SEM.  
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4.5.5. Size of retained BMMNC in I-R hearts 
To determine whether cell size is a factor that affects donor cell retention after IC injection 
into I-R hearts (n=6), the cell size distribution of BMMNC in the coronary effluent was 
determined using an automated cell counter and compared with BMMNC before injection 
(Figure 4-48).  
The mean cell size in donor cells in coronary effluent was 6.44 µm and the median 
cell size was 6 µm. This compared to the mean and median cell size of 7.0 µm in the pre-
injection sample (refer to 4.1.1). The coronary effluent cells appeared to have a leftwards 
shift in cell size, with an increase in the proportion of smaller BMMNC and a reduction in 
the proportion of larger BMMNC, but this observation was not statistically significant 
(p=0.94, F-test, Sum of Squares).  
 
Figure 4-48: Cell size distribution of BMMNC in coronary effluent after injection into I-R heart vs. 
pre-injection cells. The distribution of cell sizes were compared with an automated cell counter for   
I-R perfused hearts (n=6). The number of BMMNC for each cell size was calculated and expressed as 
a fraction of all the BMMNC in each group. There appeared to be a leftwards shift in the coronary 
effluent cells compared to the pre-injection cells. n=23,942 pre-injection cells. Error bars indicate 
SEM  
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Because the total cell number within the coronary effluent and the distribution of 
pre-injection donor cell sizes were known, the proportion of retained cells according to cell 
size could be calculated. For further analysis, the cells were subdivided into three groups; 
cells with size of 5-6 µm (below the median size), 7 µm (the median size) and ≥ 8 µm 
(above the median size). Figure 4-49 demonstrates the relative proportions of cell sizes for 
pre-injection donor cells and donor cells retained in the heart. Although cells sized 5-6 µm in 
diameter accounted for 41% of the pre-injection BMMNC, only 12% of the retained cells 
were this size. There was an increase in the proportion the retention of cells with a median 
diameter and an even greater increase in the retention of cells with a diameter above the 
median; the largest BMMNC accounted for 53% of retained cells, whereas this size only 
constituted 30% of the pre-injection cells. 
 
Figure 4-49: Cell size distribution of donor BMMNC prior to injection and of retained BMMNC 
after IC injection into the I-R heart. The proportions of cells below the median (5-6 µm), the median 
(7 µm) and above the median ≥8 µm were calculated. The proportion of smaller cells retained in the 
heart below the median size was lower than expected. Conversely, larger cells were retained with 
increased efficiency. Error bars indicate SEM, n=11 samples for pre-injection samples hearts, n=6 for 
coronary effluent samples, # = p<0.0001, * = p<0.01  
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The relationship between donor BMMNC size and retention efficiency after IC 
injection into the I-R heart was further analysed (Figure 4-50). There was a clear increase in 
cell retention efficiency with greater cell size (One-way ANOVA, p<0.0001). Bonferroni’s 
multiple comparison post-hoc test demonstrated that there was a significantly (6-fold) 
greater proportion of injected ≥ 8 µm cells retained than injected 5-6 µm cells (58.5% vs. 
9.5%, p<0.0001). 
 
Figure 4-50: Retention efficiency of BMMNC after IC injection into I-R hearts and their cell size. 
The proportions of each sized donor cells retained in the heart were calculated (n=6). Larger cells 
were more efficiently retained. Error bars indicate SEM. # = p<0.05, Bonferroni’s multiple 
comparison test. 
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4.5.6. Histological distribution of retained BMMNC in the heart 
The anatomical location of PKH67-positive donor BMMNC within the recipient I-R hearts 
after IC injection was determined using immunohistochemistry (refer to 3.8.1). In brief, the 
apex, mid-section and base were analysed separately per heart and the anatomical location of 
each PKH67 labelled cell was recorded. The apex, mid-section and base were not compared 
because no difference was found in the normal heart samples.The cross-sectional area of 
each myocardial section (epicardium, mid myocardium and endocardium) was calculated 
using ImageJ software analysis. The results showed that there appeared to be a progressive 
increase in the concentration of donor cells towards the epicardium (Figure 4-51). There 
were double the number of cells in the epicardium compared to the endocardium. However, 
this result was not statistically significant (n=6 hearts, p=0.059, One-way ANOVA). 
 
 
 
Figure 4-51: Intramyocardial location of retained donor cells within the I-R heart. The number of 
fluorescent-labelled cells in the apex, mid-section and base were compared after injection of        
8x106 cells into normally perfused Langendorff hearts, corrected for cross-sectional area. There was a 
trend toward a significant increase in the proportion of cells found in the epicardium (n=6 hearts, 
One-Way ANOVA). Error bars indicate SEM. 
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4.5.7. Anatomical relationship between retained cells and the coronary vasculature 
The location of cells related to the coronary vasculature was determined by injecting 
PKH67-labelled BMMNC into I-R hearts with isolectin-B4 and DAPI staining. At 5 minutes 
after cell injection, all the observed PKH67-labelled cells were located inside the vasculature 
(representative images: Figure 4-52 and Figure 4-53). In further analyses of hearts obtained 
for sectioning   60 minutes after cell injection, no observed PKH-labelled cell was observed 
to have extravasated outside of the coronary lumen (representative images: Figure 4-54 and 
Figure 4-55). There were no histological findings suggesting that coronary embolism had 
occurred in any sample.  
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4.6.   Comparison of BMMNC retention in normal and I-R hearts 
 
In order to elucidate further the possible effect of I-R on donor cell retention after IC 
injection, more detailed direct comparisons between normal heart experiments (4.4) and I-R 
heart experiments (4.5) were made. Although there are some duplicated data with previous 
sections, I believe that direct comparisons in this section are useful to highlight similarities 
and differences between the two experimental conditions. 
 
4.6.1. Pattern of BMMNC loss into coronary effluent 
The pattern of calculated cell loss into coronary effluent for the initial 5 minutes was 
compared between BMMNC injected into normal hearts and into hearts subjected to           
30 minutes ishaemia-30 minutes reperfusion. This comparison was made after injection of 
1x106, 8×106 and 40×106 (Figure 4-56). It was found that the number of donor BMMNC in 
the coronary effluent tended to be higher (though not statistically significant) after injection 
into normal hearts than I-R hearts at most time points studied.  
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Figure 4-56: Donor cell loss into the coronary effluent from normal and I-R hearts. The pattern of 
donor cell loss was compared after injection of (A) 1x106 BMMNC, (B) 8x106 BMMNC and          
(C) 40x106 BMMNC into normal and I-R hearts. The number of donor BMMNC loss in the coronary 
effluent tended to be higher (though not statistically significant) after injection into normal hearts than 
I-R hearts at most time points studied. n=4-13 each group. Error bars = SEM. 
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The time course of donor cell loss into the coronary effluent was analysed in a 
different way. The pattern of cell loss was compared by analysing the cells lost in each 
minute into the coronary effluent as a percentage of the total cells lost (Figure 4-57). There 
were no significant differences between the distributions between the normal and I-R groups 
for each cell number (paired T-test). However, in the normal groups, the proportion of cells 
lost within the first minute tended to be lower and higher in the second minute, regardless of 
donor cell number injected, compared to the I-R groups. This suggests that cell loss may be 
more rapid in the I-R groups. 
 
 
 
Figure 4-57: Cells lost each minute in the coronary effluent, expressed as a percentage of the total 
cells lost. The numbers of cells lost within the 1st minute, the 2nd minute and the 3rd-5th minute were 
expressed as a fraction of the total cells lost within the first 5 minutes. It was observed that the 
majority of the cells were lost within the first minute. However, the data suggests that cell loss into 
the coronary effluent from the I-R hearts may have been more rapid than from the normal hearts.   
n=4-13 each group. 
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4.6.2. Absolute and relative BMMNC retention efficiency 
Absolute cell number retained at 5 minutes after IC injection of 1x106, 8x106 and 40x106 
BMMNC were compared between normal and I-R hearts (Figure 4-58, A). For each cell 
number, the absolute number of cells retained in the heart was significantly increased in the 
I-R hearts compared to the normal hearts (p<0.0001, 2-way ANOVA). 
 The cell numbers retained were then expressed as a proportion of the original donor 
cell number injection and compared between the normal and I-R hearts for each cell number 
(Figure 4-58, B). The retention efficiency of BMMNC injected into I-R hearts was higher 
(approximately 30%), compared with a retention efficiency of approximately 20% after 
injection into normal hearts (p<0.0001, 2-way ANOVA).  
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Figure 4-58: Comparison of retention of BMMNC after IC injection in normal and I-R hearts. The 
absolute numbers of retained cells at 5 minutes after IC BMMNC injection into normal and I-R hearts 
(three different cell numbers) were compared (A). There was a significant increase in absolute 
retention in I-R hearts for each cell number injection (p=0.01: Two-Way ANOVA). The retention 
efficiency of cells were also compared, expressed as a fraction of the initial donor cell dose (B). There 
was an increase in efficiency of cell retention after BMMNC were injected into I-R hearts compared 
with normal hearts, at each cell number (p<0.0001, Two-way ANOVA). n=4-13 each group. Data 
expressed as mean ± SEM. 
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4.6.3. Size of retained cells 
The size of donor BMMNC in the coronary effluent was compared after injection into 
normal (n=5) and I-R (n=6) hearts. In the normal group, the mean cell size was 6.85 µm and 
the median cell size was 7 µm. In the I-R group, the mean cell size was 6.44 µm and the 
median cell size was 6 µm. Furthermore, the populations of cell diameters were compared by 
non-linear regression by generating second order polynomial (quadratic) best fit lines 
(Figure 4-59). There was no difference between the distributions of cell diameters between 
the groups (p=0.94: Sum of Squares F-test).  
 
Figure 4-59: Cell diameter distributions of BMMNC in coronary effluent after injection into 
normal and I-R hearts. The cell size distribution of donor BMMNC lost in the coronary effluent after 
IC injection into normal and I-R hearts were compared. The number of BMMNC for each cell size 
was calculated and expressed as a fraction of all the BMMNC in each group. After IC injection into  
I-R hearts, the cell size distribution appears to shift leftwards but there was no statistical difference 
between the groups. n=5 normal hearts coronary effluent samples, n= I-R injury heart coronary 
effluent sample samples. Data expressed as mean ± SEM. 
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For clarifying these observations, the proportions of retained BMMNC were 
subdivided by cell size into three groups; a smaller diameter than the median size (5-6 µm), 
the median size (7 µm) and cells with a greater diameter than the median (≥8 µm), and 
expressed as a fraction of the total retained cells (Figure 4-60). Larger BMMNC accounted 
for a greater proportion of the retained cells in both groups, but the proportions of BMMNC 
of different sizes within the heart were not substantially different after I-R compared with 
injection into normal hearts. 
 
Figure 4-60: Cell size distribution of donor BMMNC retained within the heart, after injection into 
normal and I-R hearts. The cell sizes of donor BMMNC retained in the heart was analysed and 
expressed as a fraction of all the retained cells, after (A) normal and (B) I-R heart injection. The 
proportion of cells sized 5-6 µm was lower in the I-R hearts and the proportion of cells sized ≥ 8 µm 
was increased, but these findings did not reach statistical significance (p=0.068, Two-way ANOVA). 
 
A (normal heart) 
 
B (I-R heart) 
 
 
 
 
190 
Next, the retention efficiency of each cell-size subpopulation of donor BMMNC was 
assessed and compared in both normal and I-R hearts. Cells were subdivided into groups of 
the same 3 cell sizes, as described. The results are expressed as a fraction of the number of 
injected donor cells of each size (shown in Figure 4-61). In both groups, larger cells were 
more efficiency retained. In I-R hearts, cells sized ≥8 µm were retained 1.4 times more 
efficiently than similar sized cells in normal hearts (58.5 ± 2.4 vs. 42.8 ± 4.7%, p=0.01). 
There was a trend towards increased retention efficiency after I-R of cells sized 7 µm (40.5 ± 
2.8 vs. 29.3 ± 4.7%) although this did not reach statistical significance (p=0.061). I-R did not 
affect the retention of cells with a diameter of 5-6 µm. 
 
 
Figure 4-61: Proportion of cells of different diameters retained in the heart after IC injection of 
BMMNC into normal and I-R hearts. The diameters of cells retained in the heart were subdivided 
into diameters below the median (5-6 µm), the median (7 µm) and above the median (≥8 µm) for 
injection into normal (n=5) and I-R (n=6) hearts. The proportions of the original injected donor cell 
fractions for each cell size that were retained in the heart were calculated. There was a non-significant 
increase in cells sized below 7 µm retained after I-R. The proportion of cells >8 µm retained in the 
heart increased after I-R (unpaired T-tests). 
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4.6.4. Histological distribution of retained BMMNC 
Using immunohistochemical analysis, all donor BMMNC were observed inside the coronary 
vasculature up to 60 minutes post-injection in both normal and I-R hearts. This suggests that 
extravasation of donor BMMNC does not occur within this timeframe and that I-R does not 
result in a different pattern of cell retention at a microscopic level. No histological 
observation consistent with coronary embolization was seen in either normal or I-R hearts. 
The semi-quantitative counts of retained cells were compared between normal and  
I-R hearts. In normal hearts and I-R hearts 5 minutes after injection, there were respectively 
1.32 ± 0.13 and 2.93 ± 0.28 cells / mm2. After 60 minutes, there were 0.71 ± 0.04 and 2.25 ± 
0.08 cells/mm2 respectively in normal and I-R hearts. Though semi-quantitative, the 
frequency of BMMNC retention was higher in I-R hearts at each time point, supporting the 
quantitative results of BMMNC retention above (refer to 4.6.2). 
 The ventricular wall was divided into three equally-wide areas (endocardium, mid 
myocardium and epicardium) and the number of cells in each area was expressed as a 
percentage of the total retained cells for normal and I-R hearts (Figure 4-62). Interestingly, 
the intramyocardial distribution of retained BMMNC was markedly different between 
normal (n=19) and I-R (n=6) hearts (p<0.0001, Two-way ANOVA). There was no 
difference between the number of cells in the mid myocardium (31.8 ± 2.7% vs. 31.6 ± 
4.4%, normal vs. I-R, mean ± SEM, p=0.97). However, the distributions of cells in the 
endocardium and epicardium were totally reversed; the proportion of cells in the 
endocardium was 48.7 ± 2.9% vs. 19.6 ± 2.1% (normal vs. I-R, p<0.001) whereas the 
proportion of cells in the epicardium was 19.6 ± 2.1% vs. 46.0 ± 5.6% (normal vs. I-R, 
p<0.001, Bonferroni’s Multiple Comparison Test). 
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Figure 4-62: Distribution of retained BMMNC within the ventricular wall in normal and I-R 
hearts. The ventricular wall was subdivided into three equal areas; endocardium, myocardium and 
epicardium, and the numbers of cells in each area were expressed as percentages. The distributions of 
cells across the ventricular wall in the two groups were reversed. n=19 normal heart samples, n=6     
I-R injury heart samples. #=p<0.001, Bonferroni’s Multiple Comparison Test. Error bars = mean ± 
SEM. 
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4.7.   Retention of MSC after IC injection into normal hearts 
 
4.7.1. Perfusion parameters after MSC injection 
8x106 passage 4 rat bone marrow-derived MSC suspended in 3 ml PBS were injected into 
the aortic root of Langendorff-perfused rat hearts (n=14) over 20 seconds in the same 
manner as BMMNC injection. It was noted that within the 20 seconds of cell injection, all 
the hearts temporally developed asystole and dilated. Over the next few minutes, the hearts 
were seen to recommence beating. The heart rates were lower at 5 minutes post injection and 
partially recovered towards the pre-injection levels over the following 40 minutes (Figure   
4-63) One of the hearts was noted to cease beating after 20 minutes and no ECG recording 
was detectable, indicating asystole. This heart was excluded from analysis. 
Coronary effluent volume (coronary flow) was measured for the minute preceding 
cell injection, the first five minutes following the initiation of cell injection and at               
10 minutes, 20 minutes, 40 minutes and 60 minutes post cell injection (Figure 4-63). The 
mean coronary flow rate prior to injection was comparable to that obtained in other previous 
experiments (refer to Figure 4-25). However, in the minute immediately following cell 
injection, the coronary flow was seen to decrease to about one third of the pre-injection 
levels. By 5 minutes, this had partially recovered and it returned to the pre-injection levels 
by 10 minutes post injection. 
The temperature decreased by 10 minutes after cell injection, indicating reduced 
myocardial perfusion and a less stable physiological state. The mean temperature partially 
recovered approaching 40 minutes following cell injection, although greater temperature 
variability and wider confidence intervals were observed. 
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Figure 4-63: Changes in perfusion parameters before and after MSC injection into normal hearts. 
8x106 MSC were injected into normal hearts (n=13). Heart rate (A), coronary effluent flow rate        
(B) and temperature of coronary effluent exiting the heart (C) were recorded before injection and up 
to 60 minutes post injection. No heart rate or temperature measurement was recorded during the first 
5 minutes after cell injection, because coronary effluent was collected each minute. “-1” indicates the 
minute immediately prior to cell injection. Error bars = SEM. 
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4.7.2. Time course of MSC loss into coronary effluent after IC injection 
The minute-by-minute pattern of donor MSC loss into the coronary effluent was quantified 
after injection of 8x106 MSC. The baseline RBC count (2.3x104 cells / min) in the coronary 
effluent was subtracted from the observed total cell count in coronary effluent as described 
above for the BMMNC experiments (refer to 3.6.8). The mean combined cell counts for n=8 
hearts with measurements up to 20 minutes and n=5 hearts with measurements up to 5 
minutes are shown (Figure 4-64). 
It was observed that 89.8% and 7.1% of lost donor MSC passed into the coronary 
effluent within the 1st and 2nd minutes respectively. At 5 minutes after IC injection, the 
number of donor cells in the coronary effluent was calculated to be negligible.  
 
Figure 4-64: Donor cell numbers in the coronary effluent after IC injection of 8x106 MSC. The 
numbers of MSC exiting the heart after IC injection were calculated for each minute. The largest 
number of MSC exited the heart in the first minute. In the second minute, the number of cells was 
approximately 10 times fewer. MSC loss for the subsequent minutes was negligible. n=13, Error bars 
= SEM. 
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4.7.3. Absolute and relative cell retention efficiency 
The number of MSC in the coronary effluent over 5 minutes after IC injection of 8x106 MSC 
into the normal heart was calculated to be 1.80 ± 0.14 cells (n=13). Therefore, the retained 
cell efficiency was 77.5 ± 1.8%.  
 
4.7.4. Size of MSC in coronary effluent  
The diameters of MSC before injection and in the coronary effluent were compared after 
analysis with an automated cell counter. The median and mean diameter of the pre-injection 
sample were 11.5 µm and 12.2 µm, which compares to the coronary effluent sample median 
11.3 µm and mean 10.6 µm. The cell size distributions are shown in Figure 4-65. The 
distribution of cell diameters in the pre-injection and coronary effluent samples were 
compared by non-linear regression by generating second order polynomial (quadratic) best-
fit lines and were found to be significantly different (p<0.05, Sum of Squares F-test). 
Although the proportion of cells with the smallest diameter (5-7 µm) only accounted for a 
small proportion of the pre-injection population (5.9%), they represented a much larger 
population (33.6%) of the cells in the coronary effluent.  
 
Figure 4-65: Distribution of cell diameters of MSC prior to injection into normal hearts and of 
donor MSC within the coronary effluent cells. The cell size of pre-injection and coronary effluent 
MSC were compared after analysis with an automated cell counter. The cell size distributions were 
different between the groups (p<0.05, Sum of Squares F-test). 
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With the use of the absolute cell retention number and the distribution of pre-
injection coronary effluent cell diameters, the retention efficiency of MSC according to their 
diameter was calculated (Figure 4-66). Among the smaller MSC (5-9 µm), there was a 
positive relationship between cell size and retention efficiency; the retention rate for 5 µm 
was 5.2 ± 17.2%, for 6 µm was 12.3 ± 12.4%, for 7 µm was 44.1 ± 12.5%, and for 8 µm was 
70.6 ± 5.3%. At cell diameter ≥ 9 µm (larger MSC), cell retention efficiency reached a 
plateau, ranging between 80-100%. 
 
Figure 4-66: Cell retention efficiency calculated according to the size of MSC after IC injection 
into normal hearts. The coronary effluent was collected from n=8 separate Langendorff heart 
injections of 8x106 MSC. The numbers of cells retained in the heart for each cell size were calculated 
and expressed as a fraction of the number of the pre-injection MSC of each size. The smallest MSC 
had a lower retention rate but that increased with larger cell diameter. The retention efficiency for 
cells ≥ 9 µm reached a plateau. Error bars represent SEM. 
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4.7.5 Distribution and location of retained MSC in relationship to the vasculature 
At either 5 or 60 minutes after injection of 8x106 PKH67-labelled MSC into Langendorff 
perfused normal hearts, the hearts were collected, fixed, sectioned and subjected to 
immunohistochemical analysis for assessing the distribution and localisation of retained 
MSC.  
At low magnification, a countable number of retained PKH67 labelled MSC were 
found in isolation (Figure 4-67) at 5 minutes after cell injection. The frequency and pattern 
of MSC distribution at 5 minutes was found to be similar to 60 minutes after cell injection 
(Figure 4-68). Higher magnification observation clearly revealed that all retained MSC were 
within the coronary lumen at both 5 and 60 minutes after cell injection (Figures 4-69 and 4-
70). No cells were observed to have extravasated by 60 minutes post injection. 
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Figure 4-69: Retained MSC location in the heart 5 minutes after injection (high magnification). 
8x106 PKH67-labelled MSC were injected into normal hearts. All PKH67-labelled MSC (green) were 
found inside the vascular lumen. Two representative images (A and B) are presented.  
Scale bar = 30 μm.  
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Figure 4-70: Retained MSC location in the heart 60 minutes after injection (high magnification). 
8x106 PKH67-labelled MSC were injected into normal hearts. All PKH67-labelled MSC (green) were 
still found inside the vascular lumen. Two representative images (A and B) are presented.             
Scale bar: 30 μm.  
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4.8.   Comparison of retention of BMMNC and MSC in normal 
hearts 
 
In order to elucidate further the possible effect of cell-type differences on donor cell 
retention after IC injection, more detailed direct comparisons between BMMNC injection 
(4.4) and bone marrow-derived MSC injection (4.7) into normal hearts were made. Although 
there are some duplicated data, I believe that in this section direct comparisons are useful to 
highlight similarities and differences between the two cell types. 
 
4.8.1. Pre-injection donor cells 
MSC and BMMNC had different morphology, particularly regarding their cell size. Flow 
cytometric studies showed that the population of MSC was larger (determined by Forward 
Scatter) and had a greater granularity compared to BMMNC (Figure 4-71). 
 
Figure 4-71: Flow cytometric analysis of BMMNC (A) and MSC (B). The same voltage settings for 
forward scatter (FS) and side scatter (SS) were used. Median ± coefficient of variance for FS and SS 
are shown (arbitrary units). The MSC were larger and had a greater granularity as assessed by flow 
cytometry (R2 vs. R1).  
A (BMMNC)                      B (MSC) 
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The size of pre-injection BMMNC and MSC were also compared using an 
Automated Cell Counter (Figure 4-72). The distribution of cell sizes of MSC was larger with 
a mean cell diameter of 12.1 µm, compared to a mean BMMNC diameter of 7.0 µm. The 
populations of cell diameters were compared by non-linear regression by generating second 
order polynomial (quadratic) best-fit lines and were found to be significantly different 
(p<0.001: Sum of Squares F-test). 
 
Figure 4-72: Distribution of diameters of BMMNC and MSC prior to injection. The diameters of 
isolated BMMNC and cultured passage 4 MSC, prior to injection were measured. The number of cells 
with each diameter were calculated and expressed as a fraction of all the total number of cells in 
each group. The size of MSC was larger than BMMNC. 
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4.8.2. Pattern of cell loss into coronary effluent 
Donor cell loss into the coronary effluent, minute by minute, after cell 8x106 injection of 
BMMNC or MSC into normal hearts for the first 5 minutes was compared (Figure 4-73, A). 
The majority of cell loss into the coronary effluent occurred in the first minute after cell 
injection of either cell type. There was a marked difference in the number of cells lost in the 
coronary effluent within the first minute between BMMNC and MSC (5.9 ± 1.9 vs.           
1.7 ± 1.6 x 106 respectively, n=13 each group, p<0.0001; Two-way ANOVA and 
Bonferroni’s Multiple Comparison Test). There was no absolute difference in cell loss 
between the 2 groups for the subsequent 4 minutes. 
Next, donor cell loss in the effluent for each minute was expressed as a fraction of 
all of the cells lost in the coronary effluent, and compared between BMMNC and MSC              
(Figure 4-73, B). The pattern of donor MSC cell loss was similar to that after BMMNC 
injection into normal hearts (p=0.09, Two-way ANOVA).  
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Figure 4-73: Donor cell loss into the coronary effluent after IC injection of BMMNC and MSC 
into normal hearts. 8x106 freshly collected BMMNC and passage 4 MSC were IC injected into 
normal hearts (n=13 in each group) and the absolute donor cells in the coronary effluent were counted 
for the first 5 minutes (A). There was 3 times the number of BMMNC in the coronary effluent in the 
first minute compared with MSC. Error bars = SEM. *=p<0.001 (Bonferroni’s Multiple Comparison 
Test). The pattern of cell loss was also calculated minute by minute as a fraction of the total cell loss 
and expressed as a percentage (B). There was no difference in the pattern of cell loss between the two 
cell types overall (Two-way ANOVA). Error bars = SEM.   
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4.8.3. Cell retention in the normal heart 
The absolute numbers of retained cells following IC injection of BMMNC and MSC were 
compared at each minute following injection (Figure 4-74). The absolute number of donor 
cells in the heart was approximately three times higher after MSC injection at each time 
point. After 5 minutes there were a mean of 6.2x106 MSC vs. 1.7x106 BMMNC retained in 
the heart (p<0.0001, Two-way ANOVA and Bonferroni’s Multiple Comparison Test). 
In both the BMMNC and MSC injected hearts, there was a slight decrease in the 
number of cells retained in the heart over time, but this was not statistically significant 
(p=0.50, Two-way ANOVA). Therefore in both groups, the number of cells retained in the 
heart at 5 minutes was dependent on the number of cells retained within the first minute.  
 
 
Figure 4-74: Absolute cell retention numbers within the first 5 minutes after IC injection of 
BMMNC and MSC. There was a significant difference in donor cell retention (absolute number) 
between the BMMNC and MSC groups at each time point (p<0.0001, Two-way ANOVA). The 
number of cells in the heart in each group over time did not change (p=0.5, Two-way ANOVA). Error 
bars = SEM. 
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Next, the 5-minute retention of cells after injection of 8x106 BMMNC (into normal 
and I-R hearts) and 8x106 MSC (into normal hearts) were compared directly (Figure 4-75). 
The proportion of MSC retention in the normal hearts was markedly higher than BMMNC 
retention into either normal or I-R hearts (p<0.0001, One-way ANOVA with Bonferroni’s 
Multiple Comparison Test).  
 
 
Figure 4-75: Retention efficiency after first 5 minutes after IC injection of 8x106 BMMNC and 
MSC. The retention efficiency of donor cells in the heart was compared after 5 minutes following IC 
injection of 8x106 BMMNC into normal and I-R hearts and 8x106 MSC into normal hearts. The 
retention of MSC was greater than BMMNC retention in both normal and I-R hearts. Percentages are 
expressed as a proportion of the total injected cell number. n=11-13 each group, #= p<0.05, 
Bonferroni’s Multiple Comparison Test. Error bars = SEM. 
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To provide additional confirmatory evidence that there was a greater number of MSC 
retained in the heart compared to BMMNC, a semi-quantitative immunohistochemical 
analysis was performed. Representative low magnification fields were obtained from hearts 
60 minutes after injection of 8x106 BMMNC (Figure 4-76) or MSC (Figure 4-77). A greater 
number of cells was observed in the MSC hearts (19.6 ± 2.4, n=7) compared to the 
BMMNC hearts (2.6 ± 0.5, n=11; p<0.0001, unpaired T-test, Figure 4-78). This 
semi-quantitative donor cell retention result was consistent to that of the quantitative 
measurement (please see 3.6.8).  
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Figure 4-76: Representative images of hearts after injection of BMMNC (low magnification). Low 
magnification images (x10) were acquired of normal hearts 60 minutes after injection of 8x106 
BMMNC. A small number of cells could be observed in each field. Green fluorescent images only are 
shown. Scale bar 100µm. 
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Figure 4-77: Representative images of hearts after injection of MSC (low magnification). Low 
magnification images (x10) were acquired of normal hearts 60 minutes after injection of 8x106 MSC. 
Many donor cells could be observed in each field. Green fluorescent images only are shown. Scale bar 
100µm. 
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Figure 4-78: Semi-quantitative analysis of 8x106 BMMNC and MSC retained in the heart. 
Representative images at x10 magnification were obtained from immunohistochemical images taken 
of hearts 60 minutes after cell injection of 8x106 BMMNC or MSC. There were a greater number of 
donor cells in the representative images from the MSC hearts compared to the BMMNC hearts 
(p<0.0001).  
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The higher retention rate of MSC was thought to be as a consequence of their larger cell 
size, compared to BMMNC. To further investigate this aspect, the size of BMMNC and 
MSC retained in the heart were directly compared. Donor cells were subdivided into the 
following cell size categories to enable a meaningful comparison: 5-6 µm, 7 µm and ≥ 8 µm. 
This determined that MSC with a larger diameter were retained with increased efficiency 
compared to BMMNC (p<0.05, Two-way ANOVA; Figure 4-79). Post-hoc analysis 
(Bonferroni’s Multiple Comparison Test) demonstrated that the retention efficiency for the 
smallest cells (5-6 µm) was similarly low in the BMMNC and MSC groups (13.0 ± 6.2 vs. 
9.0 ± 12.6% respectively, p=0.80). There appeared to be an increase in retention of MSC 
sized 7 µm compared to similarly sized BMMNC but this finding was not statistically 
significant (p=0.39). MSC sized ≥ 8 µm were retained with double the efficiency of 
BMMNC (p<0.0001). 
 
Figure 4-79: Donor cell retention efficiency in the normal heart, according to cell size of donor 
BMMNC and MSC. Cell sizes of pre-injection donor cells and of the donor cells in the coronary 
effluent were assessed by an automated cell counter. The retention efficiency of different cell sizes of 
donor BMMNC and MSC were compared. Larger MSC were retained with increased efficiency 
compared to BMMNC (p<0.05, Two-way ANOVA). n=5 BMMNC heart samples, n=8 MSC heart 
samples, #=p<0.05, Bonferroni’s Multiple Comparison Test. Error bars = SEM. 
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4.8.4. Coronary embolism after IC injection 
Larger cells may result in higher retention rate, but in turn could have an increased risk of 
coronary embolism. This issue was investigated by direct comparison between two cell types 
with different cell sizes. The pattern of coronary effluent flow rates before and after injection 
of 8x106 BMMNC or MSC into normal hearts was compared by non-linear regression by 
generating second order polynomial (quadratic) best-fit lines and were found to be 
significantly different (p<0.0001: Sum of Squares F-test) (Figure 4-80). The coronary 
effluent flow rates decreased in the MSC-injected hearts but returned to that of the 
BMMNC-injected hearts by 10 minutes. This reduction of myocardial perfusion was 
associated with reduction of heart rate and myocardial temperature (refer to 4.7.1). In 
contrast these changes were not observed after injection of the same, or an even larger (up to 
40x106) number of BMMNC into normal hearts (refer to 4.4.1). 
 
Figure 4-80: Pattern of coronary effluent flow rate before and after IC injection of BMMNC or 
MSC into normal hearts. The coronary effluent flow rates were compared before and after IC 
injection of 8x106 BMMNC and MSC in normal hearts. Whereas coronary effluent flow rate 
remained unchanged after BMMNC injection, it decreased after MSC injection and slowly recovered 
over the subsequent 10 minutes. #=p<0.01, ×=p<0.001, n=13 each group, Bonferroni’s Multiple 
Comparison Test. Error bars indicate SEM. 
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Using immunohistochemical analysis, retained BMMNC were always seen in 
isolation (refer to 4.4.7) within the heart. However after MSC injection, although retained 
cells were also seen in isolation, they were frequently seen in clusters or in very close 
proximity, suggesting that clumping or coronary embolization had occurred (refer to Figures 
4-67, 4-68, 4-69 and 4-70). This provides further supporting evidence that reduction of 
coronary flow after MSC retention was caused by cellular coronary embolization. 
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Chapter 5 – DISCUSSION 
 
5.1.   Overview of the project 
Cell transplantation is a promising approach for the treatment of AMI and chronic heart 
failure. Meta-analyses have shown that IC injection of BMMNC has therapeutic benefits, 
but one major problem with this approach is that the number of cells that engraft in the heart 
is low. A more detailed understanding of the underlying mechanisms and fate of cells is 
required if this treatment is to enter widespread clinical practice. Initial donor cell retention 
within minutes of IC cell injection is considered to be a key factor limiting donor cell 
engraftment. This project set out to investigate the patterns and mechanisms of the initial cell 
retention in the heart after IC injection. 
 In the initial work for the project, a substantial amount of time was spent developing 
the ex-vivo Langendorff model for use with mice, but reproducible data could not be 
consistently obtained with this species. However, an original rat ex-vivo Langendorff heart 
preparation was successfully generated and utilized for quantitative measurements of initial 
donor cell retention after IC cell injection. In this model, a known number of donor cells 
were injected into the coronary arteries via the aortic root, and the coronary effluent was 
collected minute-by-minute, from which the numbers of donor cells were counted. With 
knowledge of the injected donor cell number and the number of cells in the coronary 
effluent, the number of cells retained in the heart could be quantified in a reproducible 
manner. Comparison of the pre-injection and coronary effluent cell populations enabled the 
study of whether there were cell-related factors that affected retention, such as donor cell 
size and expression of adhesion-related molecules. Fluorescent labelling of donor cells 
enabled the early fate of donor cells in the heart to be assessed using immunohistochemistry. 
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 BMMNC injection into the normal intact heart resulted in initial donor cell retention 
efficiency of approximately 20% within the first 5 minutes. Addition of 30 minutes 
ischaemia followed by 30 minutes reperfusion resulted in an increase in the initial retention 
efficiency to approximately 30%. Increasing the BMMNC dose from 1×106 to 40×106 cells 
proportionally increased the number of retained cells without inducing coronary embolism, 
while the efficiency of donor cell retention was not affected by the donor cell number 
injected. Injection of bone marrow derived MSC, a larger cell type, increased retention 
efficiency to approximately 80%, but led to coronary embolism. Furthermore, larger 
subpopulations of BMMNC and MSC were preferentially retained in the heart. Conversely, 
surface protein expression of BMMNC did not influence cell retention. 
Immunohistochemistry demonstrated that all retained donor cells - both BMMNC and MSC 
- were observed inside the coronary lumen. However, BMMNC were found in isolation 
whereas MSC were frequently found in clumps. This data therefore suggests that 
extravasation of donor cells, or incorporation into the vessel wall did not occur up to          
60 minutes after IC injection of BMMNC or MSC.  
  In summary, these findings collectively demonstrate that our original experimental 
model was reproducible and can be used to assess initial donor cell retention after IC cell 
injection in a quantitative manner in small rodents. Because cell size had a large impact on 
donor cell retention but cell surface marker expression did not, the data highly suggests that 
mechanical passive entrapment, rather than active processes via intercellular interactions 
between donor cells and coronary endothelium, is predominantly responsible for initial 
donor cell retention after IC injection of BMMNC or MSC, at least in the settings of this 
research (hearts with normal coronary arteries and after I-R injury of this duration). The 
obtained results and the translational/clinical implications of this data for future work are 
discussed below.  
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5.2.   Establishment of the model to quantitatively assess initial 
retention of donor BMMNC and MSC after IC injection in rat 
 
5.2.1. Ex-vivo Langendorff heart perfusion model 
The ex-vivo Langendorff heart perfusion model is an established and frequently used 
technique in cardiovascular research. I utilized a modified version of this model whereby a 
known number of cells were injected IC into the heart and the cells collected from the 
coronary effluent. From comparison of these two cell populations, we quantified initial 
donor cell retention and characterized subpopulations that are preferentially retained within 
the heart. To my knowledge, this is the only model to enable quantitative assessment of 
donor cell retention after IC injection in small rodents. 
First, it was confirmed that this rat ex-vivo Langendorff heart perfusion model could 
be used to achieve appropriate stable myocardial perfusion before cell injection. Perfusion 
parameters (coronary effluent, heart rate and temperature of coronary effluent exiting the 
heart) were all stable and reproducible (refer to 4.3.1). In addition, these parameters were 
comparable to those reported previously using Langendorff heart preparations in rats255,257. 
After injection of a standardized numbers of BMMNC (1×106, 8×106 and 40×106), 
Langendorff parameters were also reproducible (refer to 4.4.1 and 4.7.1). Similarly, there 
were reproducible perfusion parameters after injection of MSC. More importantly, the 
pattern of donor cell loss in the coronary effluent after injection, with both BMMNC and 
MSC, was consistent using every experimental condition studied in this project (refer to 
4.8.2). 
An unexpected finding in this model was that there was a low, but countable, level 
of endogenous cell leakage from the perfused ex-vivo hearts in the coronary effluent, even 
20-30 minutes after perfusion (refer to 4.3.3). These cells were identified to be RBC (refer to 
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4.3.3). Therefore, I adjusted the cell number in the coronary effluent by subtracting the 
baseline RBC number in my calculation of initial donor cell retention. Although this cell 
number was relatively small compared to that of donor cell loss into the coronary effluent, 
this modification enabled the highest accuracy of the measurement of donor cell retention in 
the model to be obtained (refer to 4.4.2). 
Using this model and calculation formula, it was estimated that IC BMMNC 
injection into normal hearts resulted in an initial donor cell retention efficiency of 
approximately 20% within the first 5 minutes. The clinical studies that have previously 
investigated cell retention after IC injection have found that at 1 hour, 1-10% of donor cells 
persist in the heart with further attrition at 24 hours (refer to Table 1-2). In vivo animal 
studies investigating cell retention have found similar cell retention proportions at these later 
time points after injection117,118. Doyle and colleagues examined IC-injected radiolabelled 
donor cells into a pig AMI model using cycles of balloon occlusion / reperfusion182. Using 
dynamic studies, they found that myocardial tracer activity dropped to 20% of its peak 
during the restoration of coronary flow.  
Our data obtained in rat is compatible with these previous data, validating my 
original method to measure initial donor cell retention. It was considered that the normal 
heart model would be analogous to IC injection of cells into patients with dilated 
cardiomyopathy who do not have coronary artery disease. This model would also mimic 
some aspects of post-MI chronic heart failure (ischaemic cardiomyopathy), where the 
expression of adhesion molecule-related proteins on the coronary vasculature would not be 
expected to be substantially different from that of normal hearts. 
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5.2.2. Ischaemia-reperfusion (I-R) injury model 
I-R injury may influence intercellular adhesion-related molecules in the host coronary 
endothelium, which could then affect initial donor cell retention after IC injection. To 
investigate this, 30 minutes global ischaemia followed by 30 minutes reperfusion was 
chosen as a model of I-R injury (refer to 4.3.5), which has been frequently used in previous 
studies to study myocardial I-R injury218,258,259. 
 There are several different techniques which have been previously reported to 
induce I-R injury in the heart260. Neely et al. utilised low flow global ischaemia induced 
during ex-vivo Langendorff perfusion by placing a one-way valve in the aortic outflow tract, 
which prevented retrograde perfusion of the coronary arteries during diastole and reduced 
coronary blood flow by about 60%261,262. However, I believe that our model is more relevant 
to clinical settings of AMI. In addition, careful consideration was given to utilizing the 
technique of left coronary artery ligation to induce localised I-R injury and MI. This has 
previously been reported and validated in many previous small animal studies107,208,263. The 
potential advantage of this method would be that cell injection could occur ex-vivo at various 
time points post-MI. It would then be able to assess donor cell retention serially at various 
time points post MI, which is an important and controversial question in the field of stem 
cell therapy to the heart173.  
However if this model was used, it would be likely that after global cell injection the 
injected donor cells would preferentially flow down a non-infarct coronary artery. This is 
because the non-infarct artery would have a lower flow resistance for injected cells than the 
infarct artery. The non-infarct artery would also be less likely to exhibit the no-reflow 
phenomenon which frequently occurs in an infarct artery264. Given these probable outcomes, 
our model would not have been able to assess changes in overall donor cell retention 
quantitatively. This could have been overcome by independent dual perfusion of left and 
right coronary arteries in the isolated rat hearts265 or selective injection of cells into an 
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individual coronary artery, but these models would have been extremely challenging to 
establish. 
 
5.2.3. Isolation, culture and characterization of donor cells 
BMMNC and bone marrow derived MSC were chosen as donor cells to be investigated in 
this project. Both of these cell types have been frequently examined in animal and clinical 
studies, and are among the cell types with the most potential in future clinical application of 
cell therapy to the heart. For the collection of these cells, previously reported 
isolation/culture methods were used with modifications. 
3.6×108 unselected BMMNC per adult rat with a high purity (>99.5%) and high 
viability (99.3%) were obtained (refer to 4.1). Although RBC contamination has been shown 
to affect the efficacy of BMMNC therapy in the clinical setting266, the rate in my study was 
sufficiently low (<0.05%). The expression of cell surface markers was also comparable to 
other reports in general46,100,146,150,152,174,175,267, although the majority of previous studies have 
not comprehensively reported surface markers expression on BMMNC as shown in Table   
5-1. When propagating MSC using established culture protocols, it was demonstrated that 
approximately 1×108 MSC (passage 4) could be collected from the bone marrow of each 
initial donor animal, within 17-21 days of culture. The collected MSC showed all the 
cellular properties used for identification of this cell type76 as follows. The cells were 
plastic-adherent and showed a typical morphology (fibroblast-like spindle shape). They were 
shown by flow cytometry analysis to express typical cell surface marker expression; positive 
for CD29 and CD90 and negative for CD34 and CD45. In addition, the cultured cells 
demonstrated multipotency to mesenchymal lineages, via their ability to differentiate to 
adipocytes and osteocytes. 
 Overall, these data indicate successful collection of rat BMMNC and MSC and that 
they could be used in this experimental model of cell transplantation.  
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5.2.4. Limitations of the model 
Overall, the ex-vivo Langendorff model we utilized was shown to be suitable for the 
purposes of this project, and able to provide reproducible and quantitative information 
regarding the initial retention of donor cells after IC injection. However, there are some 
limitations to this model. 
 The model was able to assess donor cell retention in the heart in a quantitative 
manner, but only within the first hour of cell injection. This was because Langendorff –
based crystalloid perfusion offers only several hours stable perfusion in rat hearts269. 
Although immunohistochemical analysis enabled the location of donor cells within the 
coronary vasculature to be determined up to 60 minutes, the longer-term fate of donor cells 
could not be investigated. In addition, because the experimental model’s duration after cell 
injection was too short, it could not be determined whether different initial donor cell 
retention has any influence on improvements in post-transplant cardiac performance. 
Similarly, due to limitations in total perfusion time, donor cells needed to be injected shortly 
(30 minutes in my study) after reperfusion in the I-R model. Differences in donor cell 
retention between normal and I-R hearts might be more striking if the cells were injected 
into I-R hearts at later time points after reperfusion. The reasons for not generating MI in 
vivo and then assessing cell retention using the ex-vivo model have been described (refer to 
5.2.2). 
 This Langendorff model provided continuous coronary flow using a crystalloid 
solution. In the heart in vivo, the coronary arteries are perfused with blood in a pulsatile 
fashion. It must be considered that other blood constituents could impact on donor cell 
retention after IC injection (please refer to 1.7.3). Furthermore, all small animal models of 
MI potentially suffer from the same limiting question: is an acute cardiac ischaemic episode 
in a previously healthy small animal without atherosclerosis comparable to an acute cardiac 
ischaemic event in a chronically-diseased human patient? 
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5.3.   Mechanisms underlying initial donor cell retention after IC 
injection - physical entrapment and/or active adhesion  
 
It was hypothesized that initial donor cell retention occurs as a result of passive, physical 
entrapment within the vasculature and/or active adhesion to the vascular endothelium via 
adhesion molecules/ligands. Therefore, the frequency, pattern and underlying mechanisms 
of retention of stem/progenitor cells would vary between donor cell-types, which have 
different cell sizes and different expression profiles of endothelial adhesion-related 
molecules.  
To determine whether donor cells are retained via active retention mechanisms, the 
proportions of cells expressing each adhesion-related cell surface molecule were 
investigated in pre-injection donor BMMNC and BMMNC in the coronary effluent. If there 
had been a reduction in the proportion of cells expressing a particular adhesion molecule or 
other protein, this would have implied that cells expressing this surface marker were 
preferentially retained within the first few minutes of injection. In this project, the surface 
proteins investigated were CD11b, CD18, CD29, CD31, CD34, CD44, CD45 and CD90. 
Because there was no agreement between the clinical studies for which markers should be 
assessed, with the exception of CD34, a number of surface proteins that could hypothetically 
be involved in donor cell–endothelial cell interactions were examined (please refer to 1.3.2).  
However, unexpectedly, there was no difference in the proportions of these donor 
cell surface markers between the pre-injection and coronary effluent BMMNC samples. This 
phenomenon was observed after injection into both normal and I-R hearts (refer to 4.4.4 and 
4.5.4). This strongly suggests that donor cell surface proteins are not critical for BMMNC 
retention. However, it is not possible to deny the possibility that other cell surface proteins - 
which were not investigated here - are actively involved in BMMNC – coronary 
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endothelium interactions. These proteins could include PSGL-1 (which could not be 
examined due to the lack of available antibodies) or other unknown molecules. 
Instead, an important observation was made regarding donor cell retention and 
donor cell size. Donor cell size had been previously been thought to be relevant for donor 
cell retention after IC injection but this had not been appropriately examined to date. For the 
quantification of retained donor cell sizes, a novel method was developed (refer to 4.4.5, 
4.5.5 and 4.7.4). The confidence intervals of the findings were narrow and were replicated 
after injection of BMMNC into normal and I-R hearts (refer to 4.4.5 and 4.5.5 respectively) 
and also after MSC injection into normal hearts (refer to 4.7.4). This demonstrates that this 
novel technique for quantifying cell retention was reproducible.  
Using this technique, for the first time, evidence has been provided that donor cell 
retention after IC injection is highly dependent on donor cell size. It was quantitatively 
demonstrated that larger BMMNC were preferentially retained after BMMNC injection into 
not only normal hearts but also I-R hearts (refer to 4.4.5 and 4.5.5). In addition, MSC 
(median passage 4 diameter 11.5 µm), much larger cells than BMMNC (median diameter 7.0 
µm), showed markedly increased donor cell retention rate when IC injected into the normal 
hearts (80% for MSC versus 20% for BMMNC; refer to 5.7). Increased donor cell retention 
of MSC was associated with the observation of coronary embolism. Furthermore, within 
MSC, the larger MSC subpopulations were also preferentially retained with an increased 
frequency, although this enhanced retention appeared to plateau with cell diameters ≥ 9 µm 
(Figure 4-66). Only 9% of injected MSC sized 5-6 µm were retained, whereas 85% of MSC 
≥ 9 µm were retained. Furthermore, the smallest MSC (5-7 µm) were retained with the same 
frequency as similar-sized BMMNC (Figure 4-79). These data are highly supportive of the 
concept that cell size is the critical factor that influences initial donor cell retention, 
independently of the cell type.  
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The diameter of coronary capillaries have been reported to be 5.6 ± 1.3 µm in 
dogs270 and 5-7 µm in humans271. Intravital microscopy work has calculated the diameter of 
rat cremasteric capillaries to be 7.2 ± 0.3 µm204. The diameter of terminal coronary arterioles 
in rat perfused Langendorff hearts has been shown to be 10.4–11.4 µm272. These data agree 
with our data of donor cell retention of BMMNC and MSC. It could be speculated that most 
of BMMNC are mechanically entrapped in coronary capillaries whereas many MSC are 
retained at the level of the coronary arteriole system. This also supports the concept that it is 
unlikely that donor cell–coronary endothelial molecular interactions are critical for donor 
cell retention, as this interaction between leukocytes and coronary endothelial cells usually 
takes place in the post-capillary venules, rather than at the level of capillaries or arterioles. 
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5.4.   Impact of the condition of recipient hearts on donor cell 
retention following IC injection  
 
It was hypothesized that the pattern and frequency of initial donor cell retention following 
IC injection would be affected by the condition of recipient hearts, including the impact of 
prior I-R injury that will alter the expression profile of adhesion molecules on endothelial 
cells. The results obtained showed that after 30 minutes of ischaemia followed by               
30 minutes of reperfusion, the retention efficiency of BMMNC was significantly enhanced. 
The retention efficiency of BMMNC in normal hearts was approximately 20% but this was 
improved to approximately 30% after I-R injury. These proportions were consistently 
observed after injection of all 3 injected cell numbers: 1×106, 8×106 and 40×106 (please refer 
to Figure 4-58). The increase in cell retention after I-R was also observed by an increase in 
the proportion of donor cells per cross-sectional area in hearts analysed by 
immunohistochemistry (see 4.3.3). Our group have previously reported donor cell retention 
in mouse hearts using the modified ex-vivo Langendorff model213. Retention efficiency after 
injection of a single dose of BMMNC into normal hearts was only 13.3%, but this increased 
to 36.5% after induction of 30 minutes ischaemia and 30 minutes of reperfusion; data 
generally comparable to that obtained in this study using rat hearts.  
The pattern of cell loss into the coronary effluent was also different between 
injection into normal and I-R hearts (refer to Figures 4-56 and 4-57). Cumulative cell loss in 
the coronary effluent was lower from I-R hearts 2 minutes after injection (1.8% vs. 4.0% 
after injection of 8×106 BMMNC). This indicates that retained donor cells within the first 
minute after injection, could be flushed out into the coronary effluent in the subsequent few 
minutes and that this occurred to a greater degree in normal hearts, compared to I-R hearts. 
It is therefore suggested that there might be a mechanism by which I-R injury increases the 
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persistency of cells retained in the initial minute. This observation could be due to increased 
passive entrapment and/or enhanced active adhesion. 
In addition, I-R injury had an effect on the retention efficiency of BMMNC 
populations of different diameters (Figure 4-59). When a comparison was made between the 
size of pre-injection cells and cells in the coronary effluent, there was a decrease in mean 
cell size between pre-injection (7.0 µm) and coronary effluent cells (6.85 µm) in normal 
hearts. This decrease was more pronounced in the donor coronary effluent cells from I-R 
hearts (mean cell size: 6.44 µm). BMMNC ≤7 µm were retained with the same efficiency 
after injection into I-R and normal hearts. However, cells ≥8 µm were retained with a greater 
efficiency after I-R injury (Figure 4-61). This suggests that I-R injury may induce a 
mechanism which prevents larger cells’ release into the coronary effluent after IC injection. 
Following I-R injury, this mechanism could be due to changes in the physical properties of 
the microvasculature such as changes in vessel diameter (due to the injury itself or 
perivascular oedema) or alternatively due to changes of unknown molecular expression in 
the vasculature.  
We confirmed that P-selectin was upregulated after 30 minutes ischaemia and        
30 minutes reperfusion in Langendorff-perfused rat hearts, but that the expression of ICAM-
1 was not detected. Expression of any of these molecules was not detected in normal hearts. 
Therefore, it would have been very useful in this project to investigate the role of PSGL-1 
(P-selectin glycoprotein ligand) on increased BMMNC retention following I-R injury. 
However, unfortunately, due to unavailability of the appropriate antibody, this assessment 
could not be undertaken. Future work should address this, either using a different model 
such as a mouse model of I-R (in which a relevant antibody is available) or a rat model of   
I-R when an appropriate antibody becomes available.   
We also tried to examine the expression of VCAM-1 in this project in normal and   
I-R hearts (data not shown). Previous studies would suggest that VCAM-1 would not have 
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been expressed after 30 minutes ischaemia, 30 minutes reperfusion (see Introduction). In an 
open-chest LAD ligation rat model, VCAM-1 was not detected by immunohistochemistry 
following ischaemia and 3 hours reperfusion, but was observed after 24 hours of 
reperfusion235. A positive control sample was generated (with the kind assistance of Dr 
Masahiro Kaneko) in the same way as described for the ICAM-1 positive control (refer to 
3.8.2), although 24 hour reperfusion was allowed following 30 minutes ischaemia in 2 rat 
hearts. A very low, variable level of VCAM-1 expression was found in the positive control 
hearts with no expression found in the normal or I-R injury hearts (data not shown). 
The effect of I-R injury to increase donor cell retention, observed in this project, 
may be only active shortly following reperfusion. Forest and colleagues118 reported that 
retention of BMMNC in pigs was unaltered between post-MI day 7 pigs and normal pigs. 
This supports the concept that day 7 is too late post MI for enhanced cell retention to be 
observed.  
These findings have important implications for clinical practice. Donor cell retention 
is affected by the types/conditions of not only donor cells but also by conditions of the host 
heart. Donor cell retention into hearts with normal coronary arteries (such as in dilated 
cardiomyopathy) should be considered differently from retention after injection into AMI 
hearts. The optimization of timing post-MI for BMMNC injection is essential to achieve the 
maximum benefits from BMMNC therapy.  
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5.5.   Optimal donor cell number for IC injection 
 
It was hypothesized that the cell number delivered would affect the frequency and pattern of 
the initial retention of donor cells after IC injection. It was thought that injection of a higher 
cell number would result in a greater retention, but administration of too many cells ran the 
risk of coronary embolism. It was anticipated that the result obtained would suggest the 
optimal donor cell number for IC injection that achieves the greatest retention without 
coronary embolization.  
The effects of BMMNC dose on relative and absolute retention were assessed in 
both the normal heart and I-R heart models using injection of 1, 8 and 40×106 cells. These 
doses in rats were weight adjusted to equate to the range of doses used in clinical studies 
(refer to 3.6.7). The results obtained here support the original hypotheses. It was found that 
increasing the initial cell dose increased the absolute numbers of cells retained in the heart 
with a linear relationship (refer to Figure 4-30). However donor cell number injected did not 
affect the relative number of these retained donor cells, as a fraction of the donor cell dose 
injected (donor cell retention efficiency). In the normal hearts after injection of the               
3 different doses, the retention efficiency of BMMNC after 5 minutes was approximately 
20% and in I-R hearts, the retention efficiency was 30%. This observation that cell dose did 
not influence retention efficiency raised the speculation that distinct sub-populations of 
donor cells are critical for cell retention in normal and I-R hearts. Such sub-populations were 
investigated further in the project (see 5.7 below). 
As regards the risk of coronary embolism, the clinically relevant range of BMMNC 
doses that were tested in this study were not deleterious to post-injection Langendorff 
parameters, suggesting that coronary embolism did not occur in this range of donor cell 
dose. In addition, immunohistochemical analysis using BMMNC labelled with PKH67 
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showed that individual cells were retained in the heart in a diffuse distribution and that no 
cell clumping was observed. This result is consistent to findings in previous studies. The 
benefits in LVEF improvement in IC BMMNC injection in clinical trials – even observed 
after injection of higher cell doses25 – suggests that significant short-term myocardial 
damage does not occur using this approach. Bhakta and colleagues have examined this 
question in greater detail using a porcine model of chronic myocardial ischaemia, induced 
by ameroid cuff placement273 around the circumflex artery.274 They administered         
15×106 BMMNC via IC injection and found no evidence of MI on gross inspection, 
histopathology or via Troponin-I levels. An upper ‘safe’ limit of BMMNC dose for IC 
injection was not found in our study following injection either into normal or I-R hearts, but 
further investigation is warranted. 
 The dose of stem cells used in clinical trials has varied widely but there is some 
evidence that increased cell dose improves outcome. Meluzin et al. randomized 60 patients 
to receive IC injection of high dose BMMNC (1×108 cells), lower dose BMMNC         
(1×107 cells) or placebo, 5-10 days after anterior STEMI162. There was an improvement in 
global measures of LV function assessed by SPECT at 3 months in the high dose group 
compared to placebo, which were maintained up to 1 year. These benefits were not seen in 
the lower dose group. Recently, a Cochrane meta-analysis of IC injection of BMMNC 
performed a heterogeneity analysis assessing the effects of cell dose27 on LVEF assessed by 
MRI. In patients who received ≤ 1×108 cells, there was no improvement in LVEF. However, 
those who received ≤ 1×109 cells had a mean LVEF improvement of 2.6% from baseline to 
the end of the study (<12 months). Furthermore, a dose of ≤ 1×1010 cells administered in      
2 studies resulted in an increase in LVEF (5.7%) from baseline. 
Our work provides the first evidence that increased BMMNC dose has a linear 
relationship with donor cell retention in the normal as well as injured hearts. Future 
protocols of clinical studies investigating IC injection of BMMNC should ensure that the 
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largest cell dose possible is used and associations should be reported between cell dose and 
clinical outcome. 
In contrast to BMMNC, IC injection of 8×106 MSC had a deleterious effect on 
Langendorff perfusion parameters in rat. Heart rate, temperature of coronary effluent exiting 
the heart and coronary effluent flow rate all decreased after injection (refer to Figures 4-25, 
4-26 and 4-63). Coronary effluent flow rates returned to pre-injection levels by 10 minutes 
post injection. Heart rate and temperature took longer to recover, but returned to pre-
injection levels after approximately 40 minutes. This indicates that injection of 8×106 MSC 
resulted in transient disruption to cardiac perfusion and overall suggests injection of this 
number of MSC induced coronary embolism.  
Assuming the weight of rats used in this project were 250g, the globally injected 
MSC dose was 32x106 cells / kg or 10.1x106 cells / body weight (kg) / artery. Vulliet and 
colleagues injected 5×105 MSC / per body weight (kg) into the left circumflex artery of        
6 healthy dogs91, (less than 1/10th of the dose in our study). During cell administration, ECG 
changes consistent with MI were noted with increasing ST segment elevation with 
progressive cell delivery in all dogs. Gross examination with histological and 
immunohistochemical analysis confirmed focal areas of microinfarction. The levels of 
Troponin I increased in the 2 dogs in which it was measured, confirming post-injection 
myocardial necrosis. IC injection of 3x105 MSC / body weight (kg) / artery has also been 
reported to result in improved LVEF and decreased infarct size (assessed by cardiac MRI) 
up to 8 weeks in a porcine model of AMI275. Again, this was a lower weight-adjusted MSC 
dose than was utilized in my project. However, the the largest reported clinical study to date 
investigating IC injection of MSC was performed by Chen and colleagues and utilized much 
higher doses of MSC than were used in this project78. Following PCI for AMI, 69 patients 
underwent a bone marrow biopsy and in-vitro culture of autologous MSC. Ten days later, 
approximately 50×109 MSC (or a dose of over 650x106 MSC / body weight (kg) /artery in an 
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average human subject) were administered into the infarct artery in half the patients and the 
other patients received an IC injection of saline. This MSC dose is over 50 times the weight-
adjusted, number-of-arteries adjusted MSC dose that I used. It was commented by the 
authors that there was a small rise in CK-MB in the MSC group compared to the PCI group 
alone, suggesting some myocardial damage post procedure. Cardiac function improved in 
both groups from baseline after 6 months, but this improvement in LVEF was enhanced in 
the MSC group. It will be important to optimise the MSC number that induces the maximum 
therapeutic effect with minimum risk of coronary embolism for future success of IC 
injection of MSC for the treatment of heart failure. 
5.6.   Different anatomical distributions of retained donor cells after 
IC injection in normal and I-R hearts.  
 
One of the novel and interesting findings obtained in my research was that the anatomical 
pattern of donor cell retention (endocardium, mid myocardium and epicardium) was 
different between IC BMMNC injection into normal and I-R hearts (refer to Figure 4-62). 
Approximately 50% of retained donor BMMNC were found in the endocardium and 20% in 
the epicardium after IC injection into the normal heart. In contrast, in I-R hearts, these 
proportions were reversed and approximately 50% of cells were found in the epicardium 
with 20% in the endocardium. The proportion of cells in the mid myocardium was not 
affected. This phenomenon has not been reported in any previous animal or clinical studies. 
This finding may be explained by previous studies that have shown that coronary 
flow is not uniform between the different layers of the ventricular wall and these areas are 
differentially affected by I-R injury / infarction. In normal subjects, in many species, 
endocardial coronary flow has been shown to exceed epicardial flow276 277,278. It is also 
known that the endocardium is the most vulnerable area of the LV to effects of 
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hypoperfusion and ischaemia279 although the reasons for these transmural differences are not 
understood280. Therefore, it is likely that the endocardium was predominantly affected 
following 30 minutes of ischaemia and 30 minutes of reperfusion, and early damage may 
include impairment to microvascular flow. Therefore, coronary flow post I-R injury may be 
relatively enhanced via the epicardial vessels, resulting in increased donor cell retention in 
the epicardium. 
 
5.7.   Subpopulations of BMMNC are preferentially retained in the 
heart after IC injection 
 
It is known that BMMNC are a heterogeneous cell population containing several distinct 
stem/progenitor cell populations, including EPC, MSC and haematopoietic stem cells, and 
non-stem cell populations. Within this mixed population, it was thought that certain 
subpopulations would show a greater ability to be retained in the heart. Identification of such 
subpopulations will be important in understanding and refining BMMNC transplantation. 
Firstly as discussed above, cell size of BMMNC subpopulations was found to be a 
critical factor for initial donor cell retention after IC injection. The cell size distribution 
graphs show that there was a tendency towards a leftward shift in the donor BMMNC in 
coronary effluent compared to the pre-injection cells in normal hearts (Figure 4-33). That is 
to say that the smaller BMMNC subpopulations were more likely to be lost in the coronary 
effluent compared to the larger subpopulations. This effect was magnified when examining 
the donor coronary effluent cells from I-R hearts (Figure 4-48). After injection of BMMNC 
into normal hearts, cells with a diameter above the median (≥8 µm) accounted for 48.5% of 
all the retained cells, despite only accounting for 29.8% of the pre-injection samples. In 
contrast, cells with a diameter below the median (5-6 µm) accounted for 42.0% of the      
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pre-injection sample but only 20.1% of the cells retained in the heart (Figure 4-34). 
Furthermore, in I-R hearts, cells ≥8 µm accounted for 58.5% of retained cells whereas cells 
with a diameter 5-6 µm accounted for 9.5% of retained cells (Figure 4-49).  
As described previously, it was thought that certain subpopulations of donor 
BMMNC expressing a specific surface protein would be preferentially retained via active 
donor cell-coronary endothelial cell interactions (refer to 5.3). However, we could not 
identify specific BMMNC subpopulations that were preferentially retained in the heart after 
IC injection according to cell surface proteins and therefore active retention involving these 
surface markers was not observed in normal heart or in I-R hearts. This all said, however, 
there were several limitations to this experiment. To fully conclude whether surface markers 
identify cells that are preferentially retained, an additional experiment would need to be 
performed whereby only cells expressing a single marker would be selected and then 
separately injected to quantify their retention. In addition, there may be other (unknown) 
molecules that distinguish the BMMNC subpopulations that are preferentially retained in the 
heart. PSGL-1 expression could not be examined due to the lack of suitable antibodies. 
Additionally, cells were only stained for single surface markers. Some reports have 
suggested that multiple surface markers are required to identify distinct functional 
populations of bone marrow stem / progenitor cells48. 
This study design does not provide any information as to whether cells with a larger 
diameter that are retained are otherwise functionally similar to small donor cells that are 
flushed out into the coronary effluent. However, it does provide an intriguing possibility for 
techniques to increase retention. In future work, larger selected BMMNC should be injected 
to quantify whether long-term engraftment is affected and whether this leads to functional 
benefits.  
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5.8.   Fate of retained donor cells after IC injection 
 
It was hypothesized that following active or passive attachment of donor cells to the 
coronary endothelium in the early phase of cell retention, they would subsequently undergo 
transendothelial migration into the myocardial interstitium or integration into the vascular 
walls. It was planned that the time scale and frequency of these events would be clarified. 
To investigate this, this project firstly assessed BMMNC retention after IC injection 
using immunohistochemistry. Donor cells were typically found within the heart in isolation 
(refer to 4.4.7) and only very rarely were the cells found in the same vessel. Furthermore, 5 
minutes after injection in normal hearts, all of the retained BMMNC observed in the heart 
were found within the lumen of the vessel. This finding was also observed 60 minutes after 
injection. This demonstrates that retained donor BMMNC remain within the coronary 
vasculature lumen but do not undergo transendothelial migration or extravasation out of the 
coronary lumen up to 60 minutes following transplantation. Ziegelhoffer et al281 have 
previously demonstrated that BMMNC do not incorporate into the vessel wall.  
MSC retention was assessed in the same way and it was found that retained MSC 
were also always localised within the lumen of the coronary vasculature, at 5 minutes and 
also at 60 minutes post injection. Retained MSC were typically found with a number of cells 
within the same field and frequently a number of MSC were seen within the same vessel as a 
cluster. The consequences of MSC retention observed here were similar to that reported by 
Toma and colleagues who utilized an intravital microscopy model to semi-quantitatively 
investigate patterns of MSC retention in the rat cremaster muscle microvasculature204. They 
utilized passage 10 rat MSC with a calculated mean diameter of 22 µm, which was much 
larger than the diameters of MSC used in this project (passage 4 cells). The authors reported 
that 92% of injected cells stopped and interrupted flow at the pre-capillary level. This is a 
similar retention efficiency seen in our study for the largest MSC. 3 days later, semi-
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quantitative assessment found that only 14% of the retained cells were still present in the 
heart. After 1 day, the cells were found spread out on the luminal side of the basement 
membrane, but by 3 days after injection, they had become incorporated into the vascular 
wall. 
Overall, extravasation from the vasculature using BMMNC and MSC did not occur 
within the timescale investigated. In contrast to 8×106 BMMNC injection into normal hearts, 
injection of the same number of MSC via the IC approach results in coronary embolism and 
disruption to coronary flow, although this was transient. Given that MSC remain within the 
intravascular space, it is not necessarily straightforward to explain why coronary flow rates 
(and the other Langendorff parameters) returned to normal. It is possible that coronary flow 
rates normalized because of shunting around the occluded coronary vasculature. Prinzmetal 
and colleagues injected glass spheres into the coronary arteries of post mortem human hearts 
and described shunts of 70 – 220 µm in diameter between the coronary arteries and both 
ventricular cavities, in addition to AV shunts into the coronary sinus of 70-170 µm.282  
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5.9.   Future directions  
 
There are a range of important implications of this work for future laboratory and clinical 
studies investigating IC stem cell administration to the heart. 
 This project found that a larger number of donor cells are lost from the heart within 
minutes of IC injection of BMMNC. The finding that approximately 80% of donor cells are 
lost within that time frame after injection into normal hearts and 70% of cells are lost after 
injection into I-R hearts means that only a small fraction of injected donor cells are able to 
exert their effects within the heart. There is an urgent need to develop techniques to enhance 
cell retention in the heart after IC injection if this approach is to enter widespread clinical 
use. No clinical study has measured retention or survival of stem cells in the heart as an 
outcome25 but retention efficiency should be routinely quantified at least in animal studies of 
IC injection. 
The major finding from this work - that larger cells are preferentially retained in the 
heart after IC injection - requires future study. The first important avenue to pursue is the 
comprehensive characterization of larger cell types within the unfractionated BMMNC 
population. These cells could be selected with mechanical filtering techniques283.  
Immunomagnetic beads may be an alternative approach to isolate larger cells from bone 
marrow in a closed system but specific markers to larger cells will need to be investigated. 
The cell surface markers of larger BMMNC should be widely investigated using a number 
of surface markers in addition to those chosen in this project. The surface markers utilized in 
this project were chosen because it was hypothesized that they might exert a ligand effect on 
active donor cell-endothelial cell interactions, but it remains possible that other surface 
marker proteins without a ligand effect could select larger cell types. In addition, this 
characterization would clarify to what extent these larger cells represent specific lineages 
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within the bone marrow (such as mesenchymal stem cells or ?granulocytes - check)  and the 
fraction of  progenitor cells (such as ?myelocytic precursors). Another feature of cells with a 
larger diameter that needs to be investigated is whether this population have a different 
cortical tension to smaller cells. This could be investigated using the bolus filtration 
method204,284. It could be hypothesized that if larger cells had a higher cortical tension, they 
would be less likely to deform whilst moving through the coronary circulation.  
 The distribution of diameters of unfractionated BMMNC was characterized in this 
project using a homogenous group of younger animals. It remains unknown whether this 
distribution is maintained in adult humans with a range of comorbidities. It could be 
hypothesized that the heterogeneity seen in response to cell therapy is partly to the 
proportion of larger autologous BMMNC administered, which itself is affected by patient 
related factors. The distribution of donor cell sizes therefore should be characterized in 
patients undergoing clinical studies; it could then be determined whether the proportion of 
larger cells correlates with subsequent clinical response. 
Following the characterization of these cells, it should then be confirmed whether 
larger cells injected in isolation have a superior retention efficiency using an ex-vivo 
Langendorff model. Subsequent to this, larger cells should be injected in vivo and it should 
be determined whether this leads to enhanced clinical benefits of cell therapy. This would be 
best performed using larger animals, because smaller animal in vivo models of cell injection 
are mostly dependent on IM injection (which may be dependent on other retention 
processes). If large animal studies were shown to derive clinical benefit, then this work 
should be translated into human studies. 
Furthermore, the longer term survival of these cells as well as potential clinical 
benefits of administration of only BMMNC with a larger diameter need to be clarified, in 
long-term cell tracking models in vivo.  
 
 
240 
Using the ex-vivo Langendorff-perfused heart model, it would be of additional 
interest to determine whether chemical treatments are able to influence donor cell retention 
after IC injection. These chemical treatments could potentially be applied either to the heart 
or the donor cells themselves prior to administration. One such potential molecule that could 
be investigated would be adenosine. It has been shown that stimulation of adenosine 
receptors increases EPC adhesion to endothelial cells, within minutes, with static and flow 
models223. Additionally, adenosine increased the retention of embryo-derived EPC (eEPC) 
after injection in a mouse Langendorff-perfused heart model. After a stabilization period, the 
hearts were perfused with fluorescein isothiocyanate (FITC) to stain the endothelial cells. 
Then cells labelled with DiI were administered, with or without adenosine perfusion. As a 
result, it was found that adenosine significantly increased the proportion of the vascular area 
occupied by eEPC. Adenosine increased the upregulation of P-selectin on endothelial cells 
and increased EPC-endothelium binding. This effect of adenosine in vitro could be partially 
blocked if EPC were pre-incubated with a PSGL-1 antibody.  
The cell dose of MSC that was used in this project suggested that a high proportion 
of donor cells were retained, but with associated damage to the heart. However, only a single 
dose of MSC was used for investigation. It is important to investigate the effects of lower 
MSC doses on cell retention and perfusion parameters in the modified ex-vivo Langendorff 
model. It could be hypothesized that lower doses would be less likely to induce cardiac 
damage but with a high relative fraction of donor cell retention. This would also provide 
additional important mechanistic information about cell embolism. It remains unclear 
whether the coronary embolism of a single MSC affects the likelihood of retention of 
another MSC. Investigation of a number of MSC cell doses will enable important 
speculation about these interactions. 
Another important question that requires investigation is the effect of repeated cell 
doses on cell retention. In the clinical setting, a number of bolus injections of lower cell 
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doses are frequently used rather than a single larger dose. It could be speculated that 
cumulative injections of lower cell doses have a beneficial effect on retention without 
inducing coronary embolism. The modified ex-vivo model is well suited to investigating this 
question and would provide further important information about the mechanisms of early 
cell retention.  
 It was demonstrated that MSC diameter increases with advancing cell passage. If 
MSC are going to enter widespread clinical practice, it is important to determine the 
optimum passage timing for cell injection. Earlier time passages may incorporate cell 
populations that are not purified MSC but later time passages may have a reduced 
differentiation potential. The modified ex-vivo model is again well suited to investigating 
the effects of different cell passages on early retention and would provide supporting 
evidence as to whether MSC retention is an entirely passive (mechanical) process, or 
whether it involves active donor cell-coronary endothelial cell interactions. 
Stem cell therapy to the heart requires further understanding if it is to enter 
widespread clinical practice. This project has demonstrated that this novel ex-vivo model 
provides a robust and reproducible quantification and characterization of donor cells after 
intracoronary injection to the heart.  This work has also provided important novel insights 
into the initial processes underpinning initial stem cell retention within the first few minutes 
of IC injection. It is to be hoped that this model will be utilized by other investigators who 
wish to embark on new IC delivery approaches to the heart, that it will lead onto further 
knowledge in this emerging field and enable the optimization of stem cell administration 
protocols in future clinical trials.  
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